<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1148" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1148/" /><meta name="ncbi_pagename" content="Prothrombin-Related Thrombophilia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Prothrombin-Related Thrombophilia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Prothrombin-Related Thrombophilia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/08/14" /><meta name="citation_author" content="Jody L Kujovich" /><meta name="citation_pmid" content="20301327" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1148/" /><meta name="citation_keywords" content="F2-Related Thrombophilia" /><meta name="citation_keywords" content="Factor II-Related Thrombophilia" /><meta name="citation_keywords" content="Prothrombin 20210G&gt;A Thrombophilia" /><meta name="citation_keywords" content="Prothrombin G20210A Thrombophilia" /><meta name="citation_keywords" content="Prothrombin Thrombophilia" /><meta name="citation_keywords" content="Prothrombin G20210A Thrombophilia" /><meta name="citation_keywords" content="F2-Related Thrombophilia" /><meta name="citation_keywords" content="Factor II-Related Thrombophilia" /><meta name="citation_keywords" content="Prothrombin 20210G&gt;A Thrombophilia" /><meta name="citation_keywords" content="Prothrombin Thrombophilia" /><meta name="citation_keywords" content="Prothrombin" /><meta name="citation_keywords" content="F2" /><meta name="citation_keywords" content="Prothrombin-Related Thrombophilia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Prothrombin-Related Thrombophilia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Jody L Kujovich" /><meta name="DC.Date" content="2014/08/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1148/" /><meta name="description" content="Prothrombin-related thrombophilia is characterized by venous thromboembolism (VTE) manifest most commonly in adults as deep-vein thrombosis (DVT) in the legs or pulmonary embolism. The clinical expression of prothrombin-related thrombophilia is variable; many individuals heterozygous or homozygous for the 20210G&gt;A (G20210A or c.*97G&gt;A) allele in F2 never develop thrombosis, and while most heterozygotes who develop thrombotic complications remain asymptomatic until adulthood, some have recurrent thromboembolism before age 30 years. The relative risk for DVT in adults heterozygous for the 20210G&gt;A allele is two- to fivefold increased; in children, the relative risk for thrombosis is three- to fourfold increased. Heterozygosity for 20210G&gt;A has at most a modest effect on recurrence risk after a first episode. Although prothrombin-related thrombophilia may increase the risk for pregnancy loss, its association with preeclampsia and other complications of pregnancy such as intrauterine growth restriction and placental abruption remains controversial. Factors that predispose to thrombosis in prothrombin-related thrombophilia include: the number of 20210G&gt;A alleles; presence of coexisting genetic abnormalities including factor V Leiden; and acquired thrombophilic disorders (e.g., antiphospholipid antibodies). Circumstantial risk factors for thrombosis include pregnancy and oral contraceptive use. Some evidence suggests that the risk for VTE in 20210G&gt;A heterozygotes increases after travel." /><meta name="og:title" content="Prothrombin-Related Thrombophilia" /><meta name="og:type" content="book" /><meta name="og:description" content="Prothrombin-related thrombophilia is characterized by venous thromboembolism (VTE) manifest most commonly in adults as deep-vein thrombosis (DVT) in the legs or pulmonary embolism. The clinical expression of prothrombin-related thrombophilia is variable; many individuals heterozygous or homozygous for the 20210G&gt;A (G20210A or c.*97G&gt;A) allele in F2 never develop thrombosis, and while most heterozygotes who develop thrombotic complications remain asymptomatic until adulthood, some have recurrent thromboembolism before age 30 years. The relative risk for DVT in adults heterozygous for the 20210G&gt;A allele is two- to fivefold increased; in children, the relative risk for thrombosis is three- to fourfold increased. Heterozygosity for 20210G&gt;A has at most a modest effect on recurrence risk after a first episode. Although prothrombin-related thrombophilia may increase the risk for pregnancy loss, its association with preeclampsia and other complications of pregnancy such as intrauterine growth restriction and placental abruption remains controversial. Factors that predispose to thrombosis in prothrombin-related thrombophilia include: the number of 20210G&gt;A alleles; presence of coexisting genetic abnormalities including factor V Leiden; and acquired thrombophilic disorders (e.g., antiphospholipid antibodies). Circumstantial risk factors for thrombosis include pregnancy and oral contraceptive use. Some evidence suggests that the risk for VTE in 20210G&gt;A heterozygotes increases after travel." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1148/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ptt/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1148/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BF05CE0418F210000000000AD0049.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1148_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1148_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/proteus/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/psach/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1148_"><span class="title" itemprop="name">Prothrombin-Related Thrombophilia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: <i>F2</i>-Related Thrombophilia, Factor II-Related Thrombophilia, Prothrombin 20210G&#x0003e;A Thrombophilia, Prothrombin G20210A Thrombophilia, Prothrombin Thrombophilia</div><p class="contrib-group"><span itemprop="author">Jody L Kujovich</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1148_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1148_ai__"><div class="contrib half_rhythm"><span itemprop="author">Jody L Kujovich</span>, MD<div class="affiliation small">Assistant Professor of Pediatrics and Medicine<br />Oregon Hemophilia Center<br />Oregon Health and Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@hcivojuk" class="oemail">ude.usho@hcivojuk</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 25, 2006</span>; Last Update: <span itemprop="dateModified">August 14, 2014</span>.</p><p><em>Estimated reading time: 1 hour, 15 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ptt.Summary" itemprop="description"><h2 id="_ptt_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Prothrombin-related thrombophilia is characterized by venous thromboembolism (VTE) manifest most commonly in adults as deep-vein thrombosis (DVT) in the legs or pulmonary embolism. The clinical expression of prothrombin-related thrombophilia is variable; many individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A (G20210A or c.*97G&#x0003e;A) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in <i>F2</i> never develop thrombosis, and while most heterozygotes who develop thrombotic complications remain asymptomatic until adulthood, some have recurrent thromboembolism before age 30 years. The relative risk for DVT in adults heterozygous for the 20210G&#x0003e;A allele is two- to fivefold increased; in children, the relative risk for thrombosis is three- to fourfold increased. Heterozygosity for 20210G&#x0003e;A has at most a modest effect on <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> after a first episode. Although prothrombin-related thrombophilia may increase the risk for pregnancy loss, its association with preeclampsia and other complications of pregnancy such as intrauterine growth restriction and placental abruption remains controversial. Factors that predispose to thrombosis in prothrombin-related thrombophilia include: the number of 20210G&#x0003e;A alleles; presence of coexisting genetic abnormalities including factor V Leiden; and acquired thrombophilic disorders (e.g., antiphospholipid antibodies). Circumstantial risk factors for thrombosis include pregnancy and oral contraceptive use. Some evidence suggests that the risk for VTE in 20210G&#x0003e;A heterozygotes increases after travel.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of prothrombin-related thrombophilia requires <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>F2</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding prothrombin, to identify the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (also known as G20210A or c.*97G&#x0003e;A).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management depends on the clinical circumstances. The first acute thrombosis is treated according to standard guidelines with a course of low molecular-weight heparin (LMWH) or fondaparinux, and concurrent oral administration of warfarin for at least five days (except in pregnancy). The international-normalized ratio (INR) is used to monitor warfarin anticoagulation. Rivaroxaban, a factor Xa inhibitor, is approved for the treatment of acute VTE and long-term prevention of recurrence. The duration of anticoagulation therapy is determined by assessment of the risks for (1) VTE recurrence and (2) anticoagulant-related bleeding. Individuals with a spontaneous thrombosis with no identifiable provoking factors and those with persistent risk factors are candidates for long-term anticoagulation therapy. Treatment for three months is recommended for individuals with transient (reversible) risk factors such as surgery. Graduated compression stockings should be worn for at least two years following an acute DVT.</p><p><i>Agents/circumstances to avoid:</i> Heterozygous and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> women with a history of VTE should avoid estrogen-containing contraception and hormone replacement therapy (HRT).</p><p><i>Evaluation of relatives at risk:</i> Because there is no clinical evidence that early diagnosis reduces morbidity or mortality, the indications for family testing are unresolved and the decision to test at-risk family members should be made on an individual basis.</p><p><i>Pregnancy management:</i> No consensus exists on the optimal management of prothrombin-related thrombophilia during pregnancy; guidelines for treatment of VTE are derived from studies in non-pregnant individuals.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Prothrombin-related thrombophilia is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner: heterozygosity for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> results in an increased risk for thrombosis; homozygosity for this allele confers a higher risk for thrombosis than heterozygosity. All individuals reported to date with prothrombin-related thrombophilia who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the 20210G&#x0003e;A allele have had an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Because of the relatively high prevalence of this allele in the general population, occasionally one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or both parents are heterozygous for this allele. If one parent of a heterozygous <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is heterozygous for the 20210G&#x0003e;A allele, the sibs of the proband are at 50% risk of being heterozygous; if one parent is homozygous, the sibs of the proband will be heterozygous. Although technically possible, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD) are rarely, if ever, performed because the 20210G&#x0003e;A allele only increases the relative risk for thrombophilia and is not predictive of a thrombotic event.</p></div></div><div id="ptt.Diagnosis"><h2 id="_ptt_Diagnosis_">Diagnosis</h2><div id="ptt.Suggestive_Findings"><h3>Suggestive Findings</h3><p>No clinical features are specific for prothrombin-related thrombophilia. The diagnosis is suspected in probands with at least one of the more specific features [<a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>, <a class="bk_pop" href="#ptt.REF.mcglennen.2002.1319">McGlennen &#x00026; Key 2002</a>, <a class="bk_pop" href="#ptt.REF.howard.2013.391">Howard &#x00026; Hughes 2013</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF12">Royal College of Obstetricians and Gynaecologists 2009</a>, <a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>, <a class="bk_pop" href="#ptt.REF245">Royal College of Obstetricians and Gynaecologists 2011a</a>, <a class="bk_pop" href="#ptt.REF.tait.2012">Tait et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>]:</p><ul><li class="half_rhythm"><div>A first unprovoked venous thromboembolism (VTE) before age 50 years</div></li><li class="half_rhythm"><div>A history of recurrent VTE</div></li><li class="half_rhythm"><div>Venous thrombosis at certain unusual sites such as the cerebral, mesenteric, portal, or hepatic veins</div></li><li class="half_rhythm"><div>VTE during pregnancy or the puerperium</div></li><li class="half_rhythm"><div>VTE associated with the use of estrogen-containing oral contraceptives or hormone replacement therapy (HRT)</div></li><li class="half_rhythm"><div>An unprovoked VTE at any age in an individual with a first-degree family member with a VTE before age 50 years</div></li></ul><p>Prothrombin-related thrombophilia may also be considered in probands who have less specific findings, including the following:</p><ul><li class="half_rhythm"><div>A history of unprovoked VTE considering discontinuation of anticoagulation [<a class="bk_pop" href="#ptt.REF10">National Clinical Guideline Centre 2012</a>]</div></li><li class="half_rhythm"><div>Selected women with unexplained second trimester fetal loss</div></li><li class="half_rhythm"><div>A first VTE related to use of tamoxifen or other selective estrogen receptor modulators (SERM)</div></li><li class="half_rhythm"><div>Age greater than 50 years with a first unprovoked VTE</div></li><li class="half_rhythm"><div>Neonates and children with non-catheter related <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> VTE or stroke</div></li></ul></div><div id="ptt.Testing_to_Confirm_the_Diagnosis"><h3>Testing to Confirm the Diagnosis</h3><p>The diagnosis of prothrombin-related thrombophilia requires molecular genetic analysis of <i>F2</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding prothrombin, to identify the common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> (see <a class="figpopup" href="/books/NBK1148/table/ptt.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpttTmoleculargenetictestingusedin" rid-ob="figobpttTmoleculargenetictestingusedin">Table 1</a>). Note that because the range of plasma concentrations of prothrombin in heterozygotes overlaps with the normal range (see <a href="#ptt.Molecular_Genetics">Molecular Genetics</a>, <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>), the plasma prothrombin concentration is not reliable for diagnosis.</p><p>The decision to test an individual suspected of having prothrombin-related thrombophilia should be based on the likelihood that test results would influence treatment [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>, <a class="bk_pop" href="#ptt.REF.de_stefano.2013.697">De Stefano &#x00026; Rossi 2013</a>].</p><p>Note: (1) Clinical guidelines from the UK and the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group stress the uncertain benefit of testing for inherited thrombophilia in several accepted circumstances, including in individuals who have some of the more specific findings [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>, <a class="bk_pop" href="#ptt.REF.tait.2012">Tait et al 2012</a>]. See <a href="#ptt.References">Published Guidelines / Policy Statements</a>. (2) American and British guidelines do not recommend routine testing for thrombophilia in adults or children with VTE [<a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>, <a class="bk_pop" href="#ptt.REF.tait.2012">Tait et al 2012</a>].</p><div id="ptt.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Prothrombin-Related Thrombophilia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1148/table/ptt.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ptt.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected</th><th id="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>F2</i></td><td headers="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2</sup></td><td headers="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> (c.*97G&#x0003e;A)&#x000a0;<sup>3</sup></td><td headers="hd_h_ptt.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ptt.TF.1.1"><p class="no_margin">See <a href="/books/NBK1148/#ptt.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#ptt.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="ptt.TF.1.2"><p class="no_margin">Targeted analysis for the <a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> (c.*97G&#x0003e;A) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is performed by a variety of comparable methods [<a class="bk_pop" href="#ptt.REF.spector.2005">Spector et al 2005</a>].</p></div></dd><dt>3. </dt><dd><div id="ptt.TF.1.3"><p class="no_margin">The official designation of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is c.*97G&#x0003e;A per guidelines at <a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>.</p></div></dd></dl></div></div></div><p><b>Interpretation of test results.</b> Molecular genetic test results are reliable in individuals on warfarin, heparin, or other antithrombotic agents and are independent of thrombotic episodes.</p><p>Test results on DNA extracted from peripheral blood leukocytes need to be interpreted with caution in the setting of liver transplantation or hematopoetic stem cell transplantation (HSCT).</p><ul><li class="half_rhythm"><div>Diagnosis of prothrombin-related thrombophilia in the setting of liver transplantation requires <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of donor liver, the site of prothrombin synthesis [<a class="bk_pop" href="#ptt.REF.mas.2003.247">Mas et al 2003</a>].</div></li><li class="half_rhythm"><div>Diagnosis of prothrombin-related thrombophilia in HSCT recipients requires molecular analysis of non-hematopoietic tissue in the recipient (e.g., buccal cells).</div></li></ul><p><b>Note: Testing for the <i>F2</i> 20210G&#x0003e;A</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is not recommended</b> for the following:</p><ul><li class="half_rhythm"><div>General population screening</div></li><li class="half_rhythm"><div>Routine initial testing prior to the use of estrogen-containing contraceptives, hormone replacement therapy (HRT), or SERMs</div></li><li class="half_rhythm"><div>Adults with VTE occurring in the setting of major transient risk factors (e.g., surgery, trauma) [<a class="bk_pop" href="#ptt.REF.hicks.2013.9">Hicks et al 2013</a>]</div></li><li class="half_rhythm"><div>Routine initial testing in adults with arterial thrombosis</div></li><li class="half_rhythm"><div>Individuals with unprovoked VTE already receiving long-term anticoagulation treatment</div></li><li class="half_rhythm"><div>Routine initial testing during pregnancy</div></li><li class="half_rhythm"><div>Routine testing in women with recurrent fetal loss, placental abruption, fetal growth restriction, or preeclampsia [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>]</div></li><li class="half_rhythm"><div>Prenatal or newborn testing</div></li><li class="half_rhythm"><div>Neonates and children with asymptomatic central venous catheter-related thrombosis</div></li><li class="half_rhythm"><div>Routine testing in asymptomatic children</div></li><li class="half_rhythm"><div>Routine testing of unselected children with a first episode of VTE [<a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>]</div></li></ul></div></div><div id="ptt.Clinical_Characteristics"><h2 id="_ptt_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ptt.Clinical_Description"><h3>Clinical Description</h3><p>The clinical expression of prothrombin-related thrombophilia is variable. Many individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>F2</i>
<a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> never develop thrombosis. While most individuals with prothrombin-related thrombophilia do not experience a first thrombotic event until adulthood, some have recurrent VTE before age 30 years.</p><div id="ptt.Venous_Thromboembolism_VTE"><h4>Venous Thromboembolism (VTE)</h4><p>The primary clinical manifestation of prothrombin-related thrombophilia is venous thromboembolism (VTE). Deep-vein thrombosis (DVT) and pulmonary embolism (PE) are the most common VTE. The most common site for deep-vein thrombosis is the legs, but upper-extremity thrombosis also occurs.</p><p><b>Risk for VTE in adults <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b></p><p>The relative risk for VTE is increased two- to fivefold in 20210G&#x0003e;A heterozygotes [<a class="bk_pop" href="#ptt.REF.lijfering.2009.5314">Lijfering et al 2009</a>, <a class="bk_pop" href="#ptt.REF.rosendaal.2009.301">Rosendaal &#x00026; Reitsma 2009</a>]. In a large meta-analysis of 79 studies, 20210G&#x0003e;A heterozygosity was associated with a threefold increased risk for VTE [<a class="bk_pop" href="#ptt.REF.gohil.2009.360">Gohil et al 2009</a>].</p><p>Among individuals with DVT, 20210G&#x0003e;A heterozygotes had a significantly higher rate of PE (32%) than those with the <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (19%) or without thrombophilia (17%). 20210G&#x0003e;A heterozygotes are also at increased risk of developing <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pulmonary emboli [<a class="bk_pop" href="#ptt.REF.martinelli.2006.2582">Martinelli et al 2006</a>] and may develop VTE at a younger age than individuals without the allele [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2006.2582">Martinelli et al 2006</a>].</p><p><b>Upper-extremity thrombosis.</b> The available evidence suggests that heterozygosity for 20210G&#x0003e;A is an independent risk factor for upper-extremity thrombosis [<a class="bk_pop" href="#ptt.REF.vay_.2003.452">Vay&#x000e1; et al 2003</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2004.566">Martinelli et al 2004</a>, <a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>, <a class="bk_pop" href="#ptt.REF.linnemann.2008a.440">Linnemann et al 2008a</a>]:</p><ul><li class="half_rhythm"><div>The 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was reported in 5%-12% of persons with upper-extremity thrombosis not related to a central venous catheter, suggesting that the allele confers a three- to sixfold increased risk for thrombosis in this location [<a class="bk_pop" href="#ptt.REF.vay_.2003.452">Vay&#x000e1; et al 2003</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2004.566">Martinelli et al 2004</a>, <a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>, <a class="bk_pop" href="#ptt.REF.linnemann.2008a.440">Linnemann et al 2008a</a>]. The prevalence of the allele is higher in those with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> (unprovoked) upper-extremity thrombosis than in those with thrombosis related to a central venous catheter [<a class="bk_pop" href="#ptt.REF.lechner.2008.1269">Lechner et al 2008</a>].</div></li><li class="half_rhythm"><div>Heterozygosity for 20210G&#x0003e;A was associated with a fivefold increased risk for <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> (unprovoked) upper-extremity thrombosis (not related to malignancy or a central venous catheter) [<a class="bk_pop" href="#ptt.REF.martinelli.2004.566">Martinelli et al 2004</a>]. Women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A who were using oral contraceptives had a nine- to 14-fold increased risk for idiopathic upper-extremity thrombosis [<a class="bk_pop" href="#ptt.REF.martinelli.2004.566">Martinelli et al 2004</a>, <a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>].</div></li></ul><p><b>Cerebral vein thrombosis</b></p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity is associated with a six- to tenfold increased risk for cerebral vein thrombosis [<a class="bk_pop" href="#ptt.REF.martinelli.1998.1793">Martinelli et al 1998</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2003a.1363">Martinelli et al 2003a</a>, <a class="bk_pop" href="#ptt.REF.dentali.2006.2766">Dentali et al 2006</a>, <a class="bk_pop" href="#ptt.REF.lauw.2013.913">Lauw et al 2013</a>].</div></li><li class="half_rhythm"><div>In two case-control studies, women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A who used oral contraceptives had an 80-fold and 150-fold increased relative risk for cerebral vein thrombosis, respectively [<a class="bk_pop" href="#ptt.REF.martinelli.1998.1793">Martinelli et al 1998</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2003a.1363">Martinelli et al 2003a</a>].</div></li></ul><p><b>Hepatic thrombosis and portal vein thrombosis</b> are other reported complications in adult 20210G&#x0003e;A heterozygotes [<a class="bk_pop" href="#ptt.REF.janssen.2000.2364">Janssen et al 2000</a>, <a class="bk_pop" href="#ptt.REF.amitrano.2004.736">Amitrano et al 2004</a>, <a class="bk_pop" href="#ptt.REF.primignani.2005.603">Primignani et al 2005</a>]. A meta-analysis concluded that 20210G&#x0003e;A heterozygosity was associated with a fourfold increased risk for both <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> and liver disease-associated portal vein thrombosis [<a class="bk_pop" href="#ptt.REF.dentali.2008a.675">Dentali et al 2008a</a>].</p><p><b>Thrombosis in unusual locations</b> in adults who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A also occurs more frequently than in the general population. However, these events are much less common than DVT or pulmonary emboli, and there is no evidence that identification of a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> should alter management [<a class="bk_pop" href="#ptt.REF.tait.2012">Tait et al 2012</a>].</p><ul><li class="half_rhythm"><div>Retinal vein thrombosis and other ocular thrombotic events are reported in 20210G&#x0003e;A heterozygotes [<a class="bk_pop" href="#ptt.REF.benami.2002.57">Ben-Ami et al 2002</a>, <a class="bk_pop" href="#ptt.REF.glueck.2009.12">Glueck &#x00026; Wang 2009</a>], although the association is much weaker than with DVT and/or PE [<a class="bk_pop" href="#ptt.REF.janssen.2005.1021">Janssen et al 2005</a>, <a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.tait.2012">Tait et al 2012</a>].</div></li><li class="half_rhythm"><div>The risk for superficial venous thrombosis was increased nearly fourfold in 20210G&#x0003e;A heterozygotes in one study [<a class="bk_pop" href="#ptt.REF.martinelli.1999a.1215">Martinelli et al 1999a</a>].</div></li></ul><p><b>Risk for VTE in family members of probands with the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b></p><p>Whereas the relative risk for a first episode of VTE in asymptomatic family members with a <a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is increased two- to fivefold, the absolute risk is low. In several retrospective family studies the absolute incidence of a first VTE was 0.19%/year to 0.41%/year in asymptomatic 20210G&#x0003e;A heterozygotes, compared to 0.05%/year to 0.18%/year in relatives without the allele [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>, <a class="bk_pop" href="#ptt.REF.lijfering.2009.5314">Lijfering et al 2009</a>].</p><ul><li class="half_rhythm"><div>A prospective study of asymptomatic relatives of probands with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and arterial or venous thromboembolism found similar annual incidences of a first VTE in relatives with (0.37%/year) and without (0.12%/year) the allele [<a class="bk_pop" href="#ptt.REF.coppens.2006.2604">Coppens et al 2006</a>].</div></li><li class="half_rhythm"><div>A large study of family members of probands with thrombophilia found no increased risk of VTE among relatives <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A [<a class="bk_pop" href="#ptt.REF.rossi.2011.646">Rossi et al 2011</a>].</div></li><li class="half_rhythm"><div>The risk for VTE is higher in asymptomatic 20210G&#x0003e;A heterozygotes from families with a strong history of VTE than in unselected individuals identified by population screening [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>, <a class="bk_pop" href="#ptt.REF.couturaud.2009.1537">Couturaud et al 2009</a>]. The increased susceptibility to VTE in thrombosis-prone families results from the coinheritance of other unidentified inherited thrombophilic disorders.</div></li><li class="half_rhythm"><div>In a single large retrospective family study, the annual incidence of a first VTE was 1.10%/year in relatives <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for 20210G&#x0003e;A [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>]. In contrast, no VTE events occurred in the small number of homozygous family members included in two other studies [<a class="bk_pop" href="#ptt.REF.coppens.2006.2604">Coppens et al 2006</a>, <a class="bk_pop" href="#ptt.REF.lijfering.2009.5314">Lijfering et al 2009</a>]. Relatives <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A in combination with other inherited thrombophilic disorders had an annual incidence of first VTEof 0.45%-0.59%/year [<a class="bk_pop" href="#ptt.REF.lijfering.2009.5314">Lijfering et al 2009</a>].</div></li></ul><p><b>Risk for VTE in children <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b></p><p>A combination of risk factors appears to be necessary to provoke thrombosis in children [<a class="bk_pop" href="#ptt.REF.revelvilk.2006.59">Revel-Vilk &#x00026; Kenet 2006</a>, <a class="bk_pop" href="#ptt.REF.raffini.2008.228">Raffini 2008</a>, <a class="bk_pop" href="#ptt.REF.tuckuviene.2011.663">Tuckuviene et al 2011</a>]. VTE in children is usually a complication of one or more medical conditions and/or a central venous catheter. The majority of children reported with VTE had other coexisting inherited and/or circumstantial risk factors [<a class="bk_pop" href="#ptt.REF.revelvilk.2003.915">Revel-Vilk et al 2003</a>, <a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>]. An increased prevalence of 20210G&#x0003e;A was found in neonates and children with VTE in some but not all studies. The variation in reported prevalence of the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> likely reflects differences in study design and clinical characteristics of the children included.</p><p>The available data summarized below suggest that asymptomatic healthy children who are heterozygotes or homozygotes for 20210G&#x0003e;A are at low risk for thrombosis except in the setting of strong circumstantial risk factors [<a class="bk_pop" href="#ptt.REF.tuckuviene.2011.663">Tuckuviene et al 2011</a>].</p><p>Studies that support an association of 20210G&#x0003e;A heterozygosity with VTE in children:</p><ul><li class="half_rhythm"><div>Several retrospective case-control studies found a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in 4%-8% of children with a first VTE compared to 1%-3% of controls, suggesting a three- to fourfold increase in relative risk [<a class="bk_pop" href="#ptt.REF.junker.1999.2568">Junker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.schobess.1999.s105">Schobess et al 1999</a>].</div></li><li class="half_rhythm"><div>In a retrospective review of 38 symptomatic children <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, additional circumstantial risk factors were present at the time in 92% of VTE events. Central venous catheters and malignancy were among the most common risk factors identified [<a class="bk_pop" href="#ptt.REF.young.2003.958">Young et al 2003</a>, <a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>].</div></li><li class="half_rhythm"><div>A meta-analysis found that 20210G&#x0003e;A heterozygosity was associated with a two- to threefold increased risk for a first VTE in children. The risk was increased more than ninefold in children with two or more inherited thrombophilic disorders [<a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>]. Other studies also found a higher risk in children doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the 20210G&#x0003e;A and <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a> alleles or with the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in combination with other inherited thrombophilic disorders [<a class="bk_pop" href="#ptt.REF.junker.1999.2568">Junker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.young.2003.958">Young et al 2003</a>].</div></li></ul><p>Studies that do not support an association of 20210G&#x0003e;A heterozygosity with VTE in children:</p><ul><li class="half_rhythm"><div>Several studies of unselected children with a history of VTE found a low prevalence of 20210G&#x0003e;A heterozygosity, similar to that in controls or in the general population [<a class="bk_pop" href="#ptt.REF.revelvilk.2003.915">Revel-Vilk et al 2003</a>, <a class="bk_pop" href="#ptt.REF.van_ommen.2003.2516">van Ommen et al 2003</a>, <a class="bk_pop" href="#ptt.REF.albisetti.2007.149">Albisetti et al 2007</a>].</div></li><li class="half_rhythm"><div>In a prospective study of family members of symptomatic probands, asymptomatic children <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for 20210G&#x0003e;A had no thrombotic complications during an average follow-up period of five years [<a class="bk_pop" href="#ptt.REF.tormene.2002.2403">Tormene et al 2002</a>].</div></li></ul><p><b>Cerebral vein thrombosis in children.</b> Although some evidence suggests that 20210G&#x0003e;A heterozygosity may predispose to central nervous system (CNS) thrombosis in children, the evidence is conflicting.</p><p>Studies that support an association of 20210G&#x0003e;A heterozygosity with cerebral vein thrombosis in children:</p><ul><li class="half_rhythm"><div>The combination of an inherited or acquired thrombophilic disorder (including 20210G&#x0003e;A heterozygosity) and an underlying medical condition conferred a fourfold increased risk for cerebral vein thrombosis, underscoring the <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a> etiology of this thrombotic complication [<a class="bk_pop" href="#ptt.REF.heller.2003.1362">Heller et al 2003</a>].</div></li><li class="half_rhythm"><div>A meta-analysis found that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was associated with a significant twofold increased risk for the combined outcome of first cerebral vein thrombosis or acute ischemic stroke in children [<a class="bk_pop" href="#ptt.REF.kenet.2010.1838">Kenet et al 2010</a>].</div></li></ul><p>Studies that do not support an association of 20210G&#x0003e;A heterozygosity with cerebral vein thrombosis in children:</p><ul><li class="half_rhythm"><div>In a small case-control study, the prevalence of 20210G&#x0003e;A heterozygosity was similar in children with cerebral vein thrombosis (2.6%) and a group of control children (3.5%) [<a class="bk_pop" href="#ptt.REF.kenet.2004.713">Kenet et al 2004</a>].</div></li><li class="half_rhythm"><div>Data from a large population-based registry suggest a low prevalence of the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>* among children and neonates with cerebral vein thrombosis [<a class="bk_pop" href="#ptt.REF.deveber.2001.417">deVeber et al 2001</a>].</div></li></ul><p>*Note: Throughout this <i>GeneReview</i>, 20210G&#x0003e;A without specification of homo- vs. heterozygosity indicates that the studies described did not specify zygosity.</p><p><b>Hepatic, portal, and retinal vein thromboses in children</b> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have also been reported.</p><p><b>Thrombosis in unusual locations (e.g., cerebral vein and hepatic vein) in children</b> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A occur less commonly than thrombosis of an extremity or pulmonary embolism.</p></div><div id="ptt.Recurrent_Thrombosis"><h4>Recurrent Thrombosis</h4><p><b>Risk for recurrent thrombosis in adult 20210G&#x0003e;A heterozygotes</b></p><p><b>Summary.</b> Current evidence suggests that 20210G&#x0003e;A heterozygosity has at most a modest effect on <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> after initial treatment of a first VTE [<a class="bk_pop" href="#ptt.REF.kyrle.2010.2032">Kyrle et al 2010</a>]. Although the data are conflicting, the majority of more recent studies found no increase in risk. An evidence review by the EGAPP concluded that 20210G&#x0003e;A heterozygosity is not predictive of VTE recurrence [<a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>]. The clinical circumstances of the first event (provoked or unprovoked), individual characteristics such as male sex, and global hemostasis tests (e.g. D-dimer) are more important determinants of recurrence. A case-control study found that testing individuals with a first VTE for thrombophilia did not reduce the incidence of recurrence [<a class="bk_pop" href="#ptt.REF.coppens.2007.1444">Coppens et al 2007</a>]. There are no randomized or controlled trials assessing the effect of thrombophilia testing on VTE recurrence risk [<a class="bk_pop" href="#ptt.REF.cohn.2012.cd007069">Cohn et al 2012</a>].</p><p>Studies that support an association of 20210G&#x0003e;A heterozygosity and increased risk for recurrent VTE in adults:</p><ul><li class="half_rhythm"><div>In a prospective long-term follow-up study of persons who stopped anticoagulation after treatment for a first VTE, a thrombophilic defect including 20210G&#x0003e;A was associated with a twofold increased <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> [<a class="bk_pop" href="#ptt.REF.prandoni.2007.199">Prandoni et al 2007</a>].</div></li><li class="half_rhythm"><div>A meta-analysis and a systematic review both concluded that 20210G&#x0003e;A heterozygosity is associated with a modest but statistically significant increased risk for recurrent VTE after a first event (OR = 1.72, OR=1.74, respectively) [<a class="bk_pop" href="#ptt.REF.ho.2006.729">Ho et al 2006</a>, <a class="bk_pop" href="#ptt.REF.marchiori.2007.1107">Marchiori et al 2007</a>].</div></li></ul><p>Studies that do not support an association of 20210G&#x0003e;A heterozygosity and increased risk for recurrent VTE in adults:</p><ul><li class="half_rhythm"><div>Multiple retrospective and prospective studies found no significant difference in the rate of recurrent VTE between 20210G&#x0003e;A heterozygotes and individuals without the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.eichinger.1999.14">Eichinger et al 1999</a>, <a class="bk_pop" href="#ptt.REF.lindmarker.1999.684">Lindmarker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.de_stefano.2001.630">De Stefano et al 2001</a>, <a class="bk_pop" href="#ptt.REF.gonz_lezporras.2006.23">Gonz&#x000e1;lez-Porras et al 2006</a>, <a class="bk_pop" href="#ptt.REF.christiansen.2005.2352">Christiansen et al 2005</a>].</div></li><li class="half_rhythm"><div>In a large family study, the incidence of recurrent VTE in relatives with 20210G&#x0003e;A heterozygosity was 7% after two years, 11% after five years, and 25% after ten years, rates similar to those reported in the general population [<a class="bk_pop" href="#ptt.REF.lijfering.2009.5314">Lijfering et al 2009</a>].</div></li><li class="half_rhythm"><div>A systematic review pooling data from nine studies found that 20210G&#x0003e;A heterozygosity is not predictive of recurrent VTE [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>].</div></li><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity is not associated with an increased risk of recurrent cerebral vein thrombosis [<a class="bk_pop" href="#ptt.REF.dentali.2012.1297">Dentali et al 2012</a>, <a class="bk_pop" href="#ptt.REF.lauw.2013.913">Lauw et al 2013</a>].</div></li><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity is not associated with a higher risk for recurrent VTE during warfarin therapy [<a class="bk_pop" href="#ptt.REF.kearon.2008.4432">Kearon et al 2008</a>]. Multiple studies showed that the reduction in risk during oral anticoagulation is similar in individuals with and without the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>].</div></li></ul><p><b>Risk for recurrent thrombosis in 20210G&#x0003e;A homozygotes and in 20210G&#x0003e;A heterozygotes with other risk factors</b></p><p><b>Summary.</b> The risk for recurrent VTE in 20210G&#x0003e;A homozygotes is not well defined, but presumed to be higher than in 20210G&#x0003e;A heterozygotes. Most studies did not include an adequate number of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> to evaluate the effect on <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>, <a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>]. The available evidence suggests that individuals with multiple thrombophilic defects have a higher risk for recurrent VTE.</p><p>Studies that support an increased risk for recurrent thrombosis in 20210G&#x0003e;A homozygotes and in 20210G&#x0003e;A heterozygotes with other risk factors:</p><ul><li class="half_rhythm"><div>Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for both the 20210G&#x0003e;A and <a href="/books/n/gene/factor-v-leiden/">factor V Leiden alleles</a> (i.e., doubly heterozygous) have a three- to ninefold higher <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> than those with neither <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, and a threefold higher risk than individuals heterozygous for the factor V Leiden allele alone [<a class="bk_pop" href="#ptt.REF.de_stefano.1999.801">De Stefano et al 1999</a>, <a class="bk_pop" href="#ptt.REF.margaglione.1999.1583">Margaglione et al 1999</a>, <a class="bk_pop" href="#ptt.REF.meinardi.2002.625">Meinardi et al 2002</a>].</div></li><li class="half_rhythm"><div>In a prospective study, the annual incidence of recurrent VTE was 12%/year in persons <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden, compared to 2.8% in those without either thrombophilia-related allele [<a class="bk_pop" href="#ptt.REF.gonz_lezporras.2006.23">Gonz&#x000e1;lez-Porras et al 2006</a>].</div></li><li class="half_rhythm"><div>A systematic review found that individuals doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden had a nearly fivefold increased risk for recurrent VTE [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>].</div></li></ul><p>Not all studies found an increased risk for recurrent thrombosis in individuals with multiple thrombophilic alleles:</p><ul><li class="half_rhythm"><div>In a family study individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden did not have an increased risk for recurrent thrombosis, even when the analysis was restricted to those with a first unprovoked VTE [<a class="bk_pop" href="#ptt.REF.lijfering.2010.1706">Lijfering et al 2010</a>].</div></li></ul><p><b>Risk for recurrent thrombosis in children</b></p><p><b>Summary.</b> The risk for recurrent VTE is likely higher in children with an initial spontaneous (unprovoked) event, a strong family history of thrombosis, and multiple thrombophilic defects [<a class="bk_pop" href="#ptt.REF.revelvilk.2006.59">Revel-Vilk &#x00026; Kenet 2006</a>, <a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>, <a class="bk_pop" href="#ptt.REF.young.2009.72">Young et al 2009</a>]. Data on the risk for recurrent VTE in children who are 20210G&#x0003e;A heterozygotes are limited and conflicting. Multiple studies were not statistically powered because of small sample size.</p><p>Studies that support an increased risk for recurrent thrombosis in children who are 20210G&#x0003e;A heterozygotes:</p><ul><li class="half_rhythm"><div>In a prospective cohort study, the incidence of recurrent VTE at a median 12 months after the initial event was 58 VTE events/1000 person-years in children with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, compared to 11.8/1000 person-years in children without thrombophilia. VTE recurred in 18% of children with 20210G&#x0003e;A compared to 7.6% of controls, suggesting a two- to threefold increase in <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> [<a class="bk_pop" href="#ptt.REF.young.2009.72">Young et al 2009</a>].</div></li><li class="half_rhythm"><div>In a meta-analysis of 12 observational studies, 20210G&#x0003e;A was associated with a twofold increased risk for recurrent VTE. The risk was increased four- to fivefold in children with multiple thrombophilic defects [<a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>].</div></li></ul><p>Studies that do not support an increased risk for recurrent thrombosis in children who are 20210G&#x0003e;A heterozygotes:</p><ul><li class="half_rhythm"><div>In a series of Dutch children with VTE, VTE recurred in 11%, none of whom had a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. The presence of one or more inherited thrombophilic disorders was not an independent risk factor for recurrent VTE [<a class="bk_pop" href="#ptt.REF.van_ommen.2003.2516">van Ommen et al 2003</a>].</div></li><li class="half_rhythm"><div>In another study 20210G&#x0003e;A heterozygosity was not found among children with recurrent thrombosis, all of whom had other acquired risk factors [<a class="bk_pop" href="#ptt.REF.revelvilk.2003.915">Revel-Vilk et al 2003</a>].</div></li></ul><p><b>Risk for recurrent thrombosis in pregnant women</b></p><p><b>Summary.</b> Women with a prior history of VTE have an increased <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> during pregnancy; recurrence rates range from 0% to 15% among published studies. The risk is higher in women with a prior unprovoked episode or an estrogen-related VTE, and in those with coexisting genetic or acquired risk factors. Note: No studies have specifically evaluated the risk for recurrent VTE in pregnant women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p><ul><li class="half_rhythm"><div>Analysis of a large in-patient database found that thrombophilia and a prior history of VTE were the strongest risk factors for pregnancy-related VTE, conferring a 52-fold and 25-fold increase in relative risk, respectively [<a class="bk_pop" href="#ptt.REF.james.2006.1311">James et al 2006</a>].</div></li><li class="half_rhythm"><div>The results of several studies suggest that women with a history of VTE provoked by oral contraceptives or related to pregnancy are at higher risk for recurrent thrombosis during a subsequent pregnancy [<a class="bk_pop" href="#ptt.REF.de_stefano.2006.386">De Stefano et al 2006</a>, <a class="bk_pop" href="#ptt.REF.white.2008.246">White et al 2008</a>].</div></li><li class="half_rhythm"><div>A prospective study evaluated the safety of withholding anticoagulation during pregnancy in women with a history of a single VTE. In subgroup analysis, women with a previous spontaneous thromboembolic event and thrombophilia had the highest recurrence rate during pregnancy (20%, odds ratio of 10) [<a class="bk_pop" href="#ptt.REF.brilledwards.2000.1439">Brill-Edwards et al 2000</a>]. Women with either inherited or acquired thrombophilia or with a prior unprovoked VTE (but not both) had recurrence rates of 13% and 7.7%, respectively.</div></li></ul></div><div id="ptt.Pregnancy_Complications"><h4>Pregnancy Complications</h4><p>It is unlikely that 20210G&#x0003e;A heterozygosity is a major factor contributing to pregnancy loss and other adverse pregnancy outcomes. Although multiple retrospective studies have suggested a modest increased risk of fetal loss, most prospective studies have not confirmed an association. The available data suggest that 20210G&#x0003e;A heterozygosity is associated with at most a two- to threefold increased relative risk for pregnancy loss.The association with preeclampsia, fetal growth restriction, and placental abruption is more controversial. A 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is at most one of multiple predisposing factors contributing to these complications. Other genetic and environmental triggers are necessary for the development of pregnancy complications in women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A allele.</p><p><b>Pregnancy loss</b></p><p><b>Summary.</b> Some (though not all) evidence suggests that 20210G&#x0003e;A heterozygosity increases the risk for fetal loss [<a class="bk_pop" href="#ptt.REF.kujovich.2004b.412">Kujovich 2004b</a>]. However, despite a modest increase in relative risk, the absolute risk for fetal loss is low and the majority of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women have normal pregnancies.</p><p>Studies that show an association between unexplained pregnancy loss and a maternal 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity was found in 4%-9% of women with recurrent pregnancy loss (the majority in the first trimester), compared with 1%-2% of those with uncomplicated pregnancies, with odds ratios ranging from two to nine [<a class="bk_pop" href="#ptt.REF.pihusch.2001.124">Pihusch et al 2001</a>, <a class="bk_pop" href="#ptt.REF.raziel.2001.65">Raziel et al 2001</a>, <a class="bk_pop" href="#ptt.REF.reznikoffeti_van.2001.1251">Reznikoff-Eti&#x000e9;van et al 2001</a>].</div></li><li class="half_rhythm"><div>Several case-control studies and three meta-analyses found an increased risk for first trimester pregnancy loss in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.rey.2003.901">Rey et al 2003</a>, <a class="bk_pop" href="#ptt.REF.kovalevsky.2004.558">Kovalevsky et al 2004</a>, <a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>, <a class="bk_pop" href="#ptt.REF.ivanov.2009.134">Ivanov et al 2009</a>, <a class="bk_pop" href="#ptt.REF.yenicesu.2010.126">Yenicesu et al 2010</a>].</div></li><li class="half_rhythm"><div>Several meta-analyses concluded that 20210G&#x0003e;A heterozygosity was associated with a two- to threefold increased risk for recurrent first trimester fetal loss and a nearly ninefold increased risk for non-recurrent second trimester loss [<a class="bk_pop" href="#ptt.REF.rey.2003.901">Rey et al 2003</a>, <a class="bk_pop" href="#ptt.REF.kovalevsky.2004.558">Kovalevsky et al 2004</a>, <a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li></ul><p>Some evidence suggests that women with prothrombin-related thrombophilia have a higher risk for pregnancy loss in the second and third trimesters. Although late fetal loss may reflect thrombosis of placental vessels, the role of thrombophilic disorders including 20210G&#x0003e;A in the complex biologic events predisposing to placental insufficiency is not well defined.</p><ul><li class="half_rhythm"><div>An observational study of women with three consecutive miscarriages before ten weeks&#x02019; gestation found that 20210G&#x0003e;A heterozygotes had a rate of recurrent early miscarriage similar to that of women without a thromboplhic disorder. However, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women had a significantly higher rate of late fetal loss during the next pregnancy (8.8% versus 2.3%) [<a class="bk_pop" href="#ptt.REF.bouvier.2014.404">Bouvier et al 2014</a>].</div></li><li class="half_rhythm"><div>Two studies found 20210G&#x0003e;A heterozygosity in 9%-13% of women with a first unexplained third-trimester loss, compared with 2%-3% of controls suggesting a two- to threefold increase in risk [<a class="bk_pop" href="#ptt.REF.martinelli.2000b.1015">Martinelli et al 2000b</a>, <a class="bk_pop" href="#ptt.REF.many.2002.684">Many et al 2002</a>].</div></li><li class="half_rhythm"><div>A meta-analysis found that 20210G&#x0003e;A heterozygosity is associated with a more than threefold higher risk for fetal loss in the second trimester compared to the first trimester. The <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was also associated with a two- to threefold increased risk for third-trimester loss and the risk increased after 24 weeks&#x02019; gestation [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li></ul><p>Studies that found no increased risk for pregnancy loss in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>Multiple observational and prospective studies found no association between 20210G&#x0003e;A and an increased risk for early or late recurrent pregnancy loss [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>, <a class="bk_pop" href="#ptt.REF.kocher.2007.68">Kocher et al 2007</a>, <a class="bk_pop" href="#ptt.REF.karakantza.2008.124">Karakantza et al 2008</a>, <a class="bk_pop" href="#ptt.REF.pasquier.2009.306">Pasquier et al 2009</a>, <a class="bk_pop" href="#ptt.REF.silver.2010.14">Silver et al 2010</a>].</div></li><li class="half_rhythm"><div>A family cohort study suggested that 20210G&#x0003e;A has no effect on the outcome of a subsequent pregnancy after a first fetal loss. The live birth rate in a second pregnancy was high and similar in women with and without the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (77% and 76%, respectively) [<a class="bk_pop" href="#ptt.REF.coppens.2007.1444">Coppens et al 2007</a>].</div></li><li class="half_rhythm"><div>In a meta-analysis of prospective cohort studies, 20210G&#x0003e;A was not associated with an increased risk for a composite outcome of placental mediated complications including pregnancy loss. However, the analysis was not powered to detect small differences in risk due to the small number of studies reviewed [<a class="bk_pop" href="#ptt.REF.rodger.2010.e1000292">Rodger et al 2010</a>].</div></li></ul><p>Limited available evidence indicates that paternal thrombophilia, including 20210G&#x0003e;A heterozygosity, is not associated with an increased risk for fetal loss [<a class="bk_pop" href="#ptt.REF.toth.2008.325">Toth et al 2008</a>, <a class="bk_pop" href="#ptt.REF.pasquier.2009.306">Pasquier et al 2009</a>, <a class="bk_pop" href="#ptt.REF.yenicesu.2010.126">Yenicesu et al 2010</a>].</p><p><b>Other obstetric complications</b></p><p>Although preeclampsia, fetal growth restriction (FGR), and placental abruption may also involve impaired placental perfusion, their association with inherited thrombophilia is controversial. The conflicting results reported in different studies may reflect the varying diagnostic and selection criteria, different ethnic groups, and small number of cases included [<a class="bk_pop" href="#ptt.REF.rodger.2008.320">Rodger et al 2008</a>, <a class="bk_pop" href="#ptt.REF.funai.2009.121">Funai 2009</a>]. The available evidence does not support an association between 20210G&#x0003e;A heterozygosity and these adverse pregnancy outcomes.</p><p><b>Preeclampsia.</b> Preeclampsia is a heterogeneous disorder and it is unlikely that a single thrombophilic variant such as 20210G&#x0003e;A plays a major causal role. The conflicting results of the following studies suggest that 20210G&#x0003e;A heterozygosity does not significantly increase the risk for preeclampsia.</p><p>Studies showing an increased risk for preeclampsia in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>Multiple case-control studies found a significantly higher prevalence of 20210G&#x0003e;A in women with preeclampsia (7%-11%) than in women with normal pregnancies (1%-4%), suggesting a two- to sevenfold increase in risk [<a class="bk_pop" href="#ptt.REF.grandone.1998.1324">Grandone et al 1998</a>, <a class="bk_pop" href="#ptt.REF.kupferminc.2000a.45">Kupferminc et al 2000a</a>, <a class="bk_pop" href="#ptt.REF.benedetto.2002.1095">Benedetto et al 2002</a>, <a class="bk_pop" href="#ptt.REF.mello.2005.1270">Mello et al 2005</a>].</div></li><li class="half_rhythm"><div>A recent prospective study found that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was associated with threefold higher risk for recurrent preeclampsia which occurred in 50% of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women [<a class="bk_pop" href="#ptt.REF.facchinetti.2009.46.e1">Facchinetti et al 2009</a>].</div></li><li class="half_rhythm"><div>A meta-analysis of eight studies found that 20210G&#x0003e;A heterozygosity was associated with a two- to threefold increased risk for preeclampsia [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li></ul><p>Studies showing no increased risk for preeclampsia in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity did not increase the risk for preeclampsia in multiple studies of unselected women screened during pregnancy [<a class="bk_pop" href="#ptt.REF.dudding.2008.1869">Dudding et al 2008</a>, <a class="bk_pop" href="#ptt.REF.karakantza.2008.124">Karakantza et al 2008</a>, <a class="bk_pop" href="#ptt.REF.kahn.2009.151.e1">Kahn et al 2009</a>, <a class="bk_pop" href="#ptt.REF.silver.2010.14">Silver et al 2010</a>]. In one study histopathologic features of placental insufficiency were found in 63% of preeclamptic women, but were not associated with 20210G&#x0003e;A heterozygosity [<a class="bk_pop" href="#ptt.REF.kahn.2009.151.e1">Kahn et al 2009</a>].</div></li><li class="half_rhythm"><div>Two meta-analyses found no significant association between a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and preeclampsia [<a class="bk_pop" href="#ptt.REF.lin.2005.182">Lin &#x00026; August 2005</a>, <a class="bk_pop" href="#ptt.REF.rodger.2010.e1000292">Rodger et al 2010</a>]. The absolute risk for preeclampsia was similar in women with and without a 20210G&#x0003e;A allele (3.5% and 3%, respectively) [<a class="bk_pop" href="#ptt.REF.rodger.2010.e1000292">Rodger et al 2010</a>].</div></li></ul><p><b>Fetal growth restriction (FGR).</b> The data on the risk for FGR associated with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are more limited and also conflicting. There is no consistent association between 20210G&#x0003e;A heterozygosity and FGR.</p><p>Studies showing an increased risk for FGR in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity was found in 7%-15% of women with pregnancies complicated by FGR, compared with 2%-4% of controls, with odds ratios ranging from four to nine [<a class="bk_pop" href="#ptt.REF.kupferminc.1999.9">Kupferminc et al 1999</a>, <a class="bk_pop" href="#ptt.REF.kupferminc.2000b.963">Kupferminc et al 2000b</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2001.428">Martinelli et al 2001</a>, <a class="bk_pop" href="#ptt.REF.kupferminc.2002.1373">Kupferminc et al 2002</a>].</div></li><li class="half_rhythm"><div>Two meta-analyses found that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was associated with a two- to threefold increased risk for FGR [<a class="bk_pop" href="#ptt.REF.howley.2005.694">Howley et al 2005</a>, <a class="bk_pop" href="#ptt.REF.kist.2008.77">Kist et al 2008</a>].</div></li></ul><p>Studies showing no increased risk for FGR in women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>:</p><ul><li class="half_rhythm"><div>A large case-control study found no significant association between maternal or fetal thrombophilia and FGR. Women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> had no increase in risk for a pregnancy complicated by FGR compared with unaffected controls [<a class="bk_pop" href="#ptt.REF.infanterivard.2002.19">Infante-Rivard et al 2002</a>].</div></li><li class="half_rhythm"><div>In several prospective studies of unselected pregnant women, a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> did not increase the risk for FGR [<a class="bk_pop" href="#ptt.REF.karakantza.2008.124">Karakantza et al 2008</a>, <a class="bk_pop" href="#ptt.REF.said.2010.5">Said et al 2010</a>, <a class="bk_pop" href="#ptt.REF.silver.2010.14">Silver et al 2010</a>].</div></li><li class="half_rhythm"><div>A large cohort study and a meta-analysis of 11 case-control studies found no association between a maternal or fetal 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (singly or in combination) and FGR [<a class="bk_pop" href="#ptt.REF.dudding.2008.1869">Dudding et al 2008</a>, <a class="bk_pop" href="#ptt.REF.facco.2009.1206">Facco et al 2009</a>].</div></li></ul><p><b>Placental abruption.</b> The data on the risk for placental abruption in women with prothrombin-related thrombophilia are limited and conflicting. A large prospective study and a meta-analysis found that 29210G&#x0003e;A heterozygosity conferred a nine- to12-fold increased risk for placental abruption [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>, <a class="bk_pop" href="#ptt.REF.said.2010.5">Said et al 2010</a>]. In contrast, other prospective studies and a meta-analysis found no association [<a class="bk_pop" href="#ptt.REF.karakantza.2008.124">Karakantza et al 2008</a>, <a class="bk_pop" href="#ptt.REF.rodger.2010.e1000292">Rodger et al 2010</a>, <a class="bk_pop" href="#ptt.REF.silver.2010.14">Silver et al 2010</a>]. There is currently no convincing evidence of an association with placental abruption.</p></div></div><div id="ptt.Factors_that_Predispose_to_Thrombosi"><h3>Factors that Predispose to Thrombosis</h3><p>The clinical expression of prothrombin thrombophilia is influenced by: the <a href="#ptt.Number_of_20210G_A_Alleles">number of 20210G&#x0003e;A alleles</a>, <a href="#ptt.Coexisting_Genetic_Abnormalities">coexisting genetic abnormalities</a>, <a href="#ptt.Acquired_Thrombophilic_Disorders">acquired thrombophilic disorders</a>, and <a href="#ptt.Circumstantial_Risk_Factors">circumstantial risk factors</a>.</p><div id="ptt.Number_of_20210G_A_Alleles"><h4>Number of 20210G&#x0003e;A Alleles</h4><p><b>20210G&#x0003e;A heterozygotes</b> have a relative risk for venous thrombosis that is approximately two- to fivefold increased [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.leroyer.1998.49">Leroyer et al 1998</a>, <a class="bk_pop" href="#ptt.REF.middeldorp.2008.321">Middeldorp &#x00026; van Hylckama Vlieg 2008</a>].</p><p><b>20210G&#x0003e;A homozygotes</b> are at higher risk, although the magnitude is not well defined. Whereas 20210G&#x0003e;A homozygotes may develop thrombosis more frequently and at a younger age, the risk is much lower than that associated with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> protein C deficiency or homozygous protein S deficiency. Numerous reports of asymptomatic 20210G&#x0003e;A homozygotes emphasize the contribution of other genetic and acquired risk factors to thrombosis [<a class="bk_pop" href="#ptt.REF.ridker.1999.999">Ridker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.souto.1999.627">Souto et al 1999</a>].</p></div><div id="ptt.Coexisting_Genetic_Abnormalities"><h4>Coexisting Genetic Abnormalities</h4><p>Another inherited thrombophilic disorder is present in 8%-14% of 20210G&#x0003e;A heterozygotes, creating supra-additive effect on overall thrombotic risk. Individuals with multiple thrombophilic disorders develop VTE at a younger age and are at higher risk for recurrent thrombosis than those with a single defect [<a class="bk_pop" href="#ptt.REF.ferraresi.1997.2418">Ferraresi et al 1997</a>, <a class="bk_pop" href="#ptt.REF.makris.1997.1426">Makris et al 1997</a>].</p><p><a href="/books/n/gene/factor-v-leiden/"><b>Factor V Leiden</b></a><b>.</b> Heterozygosity for a factor V Leiden <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> occurs in 20%-40% of symptomatic 20210G&#x0003e;A heterozygotes [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>].</p><p>Individuals doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden have an increased relative risk for VTE, although estimates of the magnitude of risk vary. In one analysis, the risk was increased 20-fold in individuals heterozygous for both alleles, suggesting a multiplicative effect on overall thrombotic risk [<a class="bk_pop" href="#ptt.REF.ehrenforth.1999.276">Ehrenforth et al 1999</a>, <a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>]. A more recent systematic review concluded that double heterozygosity for both thrombophilic alleles confers a more modest sevenfold increase in thrombotic risk [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>]. Doubly heterozygous individuals are at a three- to fourfold higher risk than those with a single thrombophilic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and are more likely to develop thrombosis in unusual locations (e.g., hepatic, mesenteric, or cerebral veins) [<a class="bk_pop" href="#ptt.REF.de_stefano.1999.801">De Stefano et al 1999</a>].</p><p><b>Anticoagulant protein deficiency.</b> In one study of families with thrombophilia, the combination of protein S deficiency and 20210G&#x0003e;A heterozygosity was associated with a nearly 13-fold increased risk for VTE, compared to a fourfold increased risk with 20210G&#x0003e;A heterozygosity alone [<a class="bk_pop" href="#ptt.REF.tirado.2001.1200">Tirado et al 2001</a>]. In contrast, coinheritance of a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> did not increase the risk for thrombosis in a large kindred with protein C deficiency [<a class="bk_pop" href="#ptt.REF.bovill.2000.366">Bovill et al 2000</a>].</p><p><b>Other genetic factors.</b> An <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may also interact with other genetic factors, such as normal sequence variants in the following two genes, which independently may not predispose to thrombosis:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b><i>F8</i>,</b> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding factor XIII. The effect of the <i>F8</i> Val34Leu variant has been extensively studied with conflicting results [<a class="bk_pop" href="#ptt.REF.undas.2009.4272">Undas et al 2009</a>, <a class="bk_pop" href="#ptt.REF.bereczky.2011.305">Bereczky &#x00026; Muszbek 2011</a>]. Two meta-analyses found a slight overall protective effect of an <i>F8</i> Val34Leu <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> against VTE [<a class="bk_pop" href="#ptt.REF.wells.2006.101">Wells et al 2006</a>, <a class="bk_pop" href="#ptt.REF.gohil.2009.360">Gohil et al 2009</a>].</div><div class="half_rhythm">Note: The <i>F8</i> variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 (<a href="/nuccore/NM_000132.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000132.3</a>:c.157G&#x0003e;T) encodes a normal protein variant officially designated <a href="/protein/NP_000123.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000123.1</a>:p.Val53Leu (commonly known as Val34Leu, which does not count the 19 amino-acid signal sequence) [<a class="bk_pop" href="#ptt.REF.kohler.1998.8">Kohler et al 1998</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>SERPINE1</i></b><i>,</i> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding PAI1 (plasminogen activator inhibitor type 1). Heterozygosity for the <i>SERPINE1</i> 4G polymorphic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in combination with 20210G&#x0003e;A heterozygosity was associated with a sixfold increased risk for venous thrombosis. Homozygosity for the <i>SERPINE1</i> 4G polymorphic allele in combination with 20210G&#x0003e;A heterozygosity was associated with a 13-fold increased risk for venous thrombosis [<a class="bk_pop" href="#ptt.REF.barcellona.2003.1061">Barcellona et al 2003</a>]. (The risk for 4G/5G was not calculated in this study.)</div><div class="half_rhythm">Note: The <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/polymorphism/">polymorphism</a> commonly referred to as 4G/5G is a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> substitution (<a href="/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NG_013213.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NG_013213.1</a>: g.4328G&#x0003e;T;rs114094261) that is -675 nucleotides from the transcription start. The missense substitution results in either four or five G nucleotides in a row; hence, the common designation of 4G or 5G alleles.</div></li></ul><p><b>Family history.</b> A family history of thrombosis affecting at least one <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> is a risk factor for VTE even after identification of an inherited thrombophilic disorder (including 20210A heterozygosity) [<a class="bk_pop" href="#ptt.REF.bezemer.2009.610">Bezemer et al 2009</a>]. A positive family history is associated with a three- to fourfold increased risk for VTE among individuals with a 20210G&#x0003e;A or factor V Leiden <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.noboa.2008.624">Noboa et al 2008</a>, <a class="bk_pop" href="#ptt.REF.rossi.2011.646">Rossi et al 2011</a>]. The risk is higher when multiple members are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and thrombosis occurs at a young age.</p></div><div id="ptt.Acquired_Thrombophilic_Disorders"><h4>Acquired Thrombophilic Disorders</h4><p><b>Hyperhomocysteinemia</b> may increase the thrombotic risk associated with 20210G&#x0003e;A heterozygosity. In one study, the combination of high plasma concentrations of homocysteine (&#x0003e;12 &#x000b5;mol/L) and 20210G&#x0003e;A heterozygosity conferred an estimated 50-fold increase in risk, suggesting a multiplicative effect on overall thrombotic risk [<a class="bk_pop" href="#ptt.REF.de_stefano.2001.630">De Stefano et al 2001</a>].</p><p><b>Antiphospholipid antibodies (APLA).</b> The effect of antiphospholipid antibodies on the thrombotic risk associated with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is not well defined. One study found that the presence of antiphospholipid antibodies was associated with a fourfold increased risk for thromboembolic events in 20210G&#x0003e;A heterozygotes (OR = 4.4) [<a class="bk_pop" href="#ptt.REF.desancho.2010.11">DeSancho et al 2010</a>].</p><p><b>Malignancy.</b> Whether inherited thrombophilia increases the risk for VTE in persons with cancer is still controversial [<a class="bk_pop" href="#ptt.REF.decousus.2007.s51">Decousus et al 2007</a>]. Malignancy is associated witha markedly increased risk for VTE, especially during the first few months after diagnosis and in those with distant metastases [<a class="bk_pop" href="#ptt.REF.blom.2005b.715">Blom et al 2005b</a>]. Because malignancy is such a strong risk factor, it may obscure the effect of mild thrombophilic disorders, including prothrombin thrombophilia. Thrombophilia status was not considered in recent guidelines for prophylaxis and treatment of VTE in patients with cancer [<a class="bk_pop" href="#ptt.REF.farge.2013.56">Farge et al 2013</a>].</p><p>A few small studies found a similar prevalence of 20210G&#x0003e;A heterozygosity in persons with cancer with and without VTE [<a class="bk_pop" href="#ptt.REF.ramacciotti.2003.171">Ramacciotti et al 2003</a>, <a class="bk_pop" href="#ptt.REF.eroglu.2007.31">Eroglu et al 2007</a>]. Other evidence suggests that the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may increase the risk for malignancy-related VTE.</p><ul><li class="half_rhythm"><div>A large population-based case-control study found that persons with cancer and 20210G&#x0003e;A heterozygosity had a 17-fold higher risk for VTE than individuals with neither risk factor, and a fourfold higher risk for VTE than those with cancer and without the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.blom.2005b.715">Blom et al 2005b</a>].</div></li><li class="half_rhythm"><div>Individuals with cancer who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for factor V Leiden or 20210G&#x0003e;A have a 20-fold higher risk for developing an upper-extremity thrombosis than individuals with cancer without either thrombophilia-related <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>].</div></li><li class="half_rhythm"><div>A meta-analysis found that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is associated with a fivefold increased risk for central venous catheter thrombosis in persons with cancer [<a class="bk_pop" href="#ptt.REF.dentali.2008b.70">Dentali et al 2008b</a>].</div></li></ul></div><div id="ptt.Circumstantial_Risk_Factors"><h4>Circumstantial Risk Factors</h4><p>Other predisposing factors include: pregnancy, oral contraceptive use, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), organ transplantation, central venous catheter use, surgery, travel, and minor injury. The 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> interacts with these environmental risk factors to increase the risk for VTE. At least 50% of thrombotic episodes in individuals with prothrombin-related thrombophilia are provoked by additional predisposing factors, with pregnancy being the most common [<a class="bk_pop" href="#ptt.REF.gerhardt.2000.374">Gerhardt et al 2000</a>].</p><p>Circumstantial risk factors play a major role in VTE in children. In several studies 62%-97% of children with VTE had coexisting circumstantial risk factors, with central venous catheters, malignancy, and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart disease among the most frequently reported [<a class="bk_pop" href="#ptt.REF.junker.1999.2568">Junker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.revelvilk.2003.915">Revel-Vilk et al 2003</a>, <a class="bk_pop" href="#ptt.REF.young.2008.1373">Young et al 2008</a>, <a class="bk_pop" href="#ptt.REF.tuckuviene.2011.663">Tuckuviene et al 2011</a>].</p><p><b>Pregnancy.</b> Women with thrombophilia are at higher risk for VTE during pregnancy [<a class="bk_pop" href="#ptt.REF.kujovich.2004a.443">Kujovich 2004a</a>, <a class="bk_pop" href="#ptt.REF.james.2006.1311">James et al 2006</a>].</p><ul><li class="half_rhythm"><div>In several studies 20210G&#x0003e;A heterozygotes had a three- to 15-fold higher risk for pregnancy-associated VTE than women without the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.gerhardt.2000.374">Gerhardt et al 2000</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2002.791">Martinelli et al 2002</a>, <a class="bk_pop" href="#ptt.REF.meglic.2003.157">Meglic et al 2003</a>].</div></li><li class="half_rhythm"><div>A population based case-control study found that 20210G&#x0003e;A heterozygotes have a 31-fold increased risk of developing VTE during pregnancy or the postpartum period compared with non-pregnant women without the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.pomp.2008.632">Pomp et al 2008</a>].</div></li><li class="half_rhythm"><div>A meta-analysis suggested that 20210G&#x0003e;A heterozygotes have a nearly sevenfold higher risk for pregnancy-related VTE than pregnant women without inherited or acquired thrombophilia [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li></ul><p>Although 20210G&#x0003e;A heterozygosity increases the relative risk for pregnancy-associated VTE, the absolute risk in asymptomatic heterozygotes is low in the absence of other predisposing factors. The highest risk occurs during the first six weeks post partum:</p><ul><li class="half_rhythm"><div>Several retrospective studies estimated the probability of VTE in the range of one in 200 to 300 pregnancies [<a class="bk_pop" href="#ptt.REF.gerhardt.2000.374">Gerhardt et al 2000</a>, <a class="bk_pop" href="#ptt.REF.gerhardt.2003.77">Gerhardt et al 2003</a>]. A population study estimated that VTE occurs in approximately one in 111 20210G&#x0003e;A heterozygotes during pregnancy [<a class="bk_pop" href="#ptt.REF.jacobsen.2010.2443">Jacobsen et al 2010</a>].</div></li><li class="half_rhythm"><div>In a retrospective family study, no VTE events occurred during pregnancy in asymptomatic 20210G&#x0003e;A heterozygotes. Postpartum VTE complicated 1.5% of pregnancies of 20210G&#x0003e;A heterozygotes compared to 0.4% of those in relatives without thrombophilia [<a class="bk_pop" href="#ptt.REF.martinelli.2008.494">Martinelli et al 2008</a>].</div></li><li class="half_rhythm"><div>In two prospective cohort studies of unselected pregnant women, no VTE events occurred during pregnancy or the postpartum period in 20210G&#x0003e;A heterozygotes [<a class="bk_pop" href="#ptt.REF.said.2010.5">Said et al 2010</a>, <a class="bk_pop" href="#ptt.REF.silver.2010.14">Silver et al 2010</a>].</div></li></ul><p>Women <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for 20210G&#x0003e;A or doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden have a higher risk for pregnancy-associated VTE:</p><ul><li class="half_rhythm"><div>The risk for pregnancy-associated VTE was increased 26-fold in 20210G&#x0003e;A homozygotes in one study [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li><li class="half_rhythm"><div>The risk for pregnancy-associated VTE was increased 15-fold in 20210G&#x0003e;A heterozygotes, ninefold in those <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a>, and greater than 100-fold in women who were doubly heterozygous for 20210G&#x0003e;A and factor V Leiden [<a class="bk_pop" href="#ptt.REF.gerhardt.2000.374">Gerhardt et al 2000</a>].</div></li><li class="half_rhythm"><div>VTE complicated 17.8% of pregnancies in women doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden, compared to 6.2% of those in women heterozygous for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> alone, suggesting that the combination confers a nearly threefold greater risk than 20210G&#x0003e;A heterozygosity alone [<a class="bk_pop" href="#ptt.REF.samama.2003.327">Samama et al 2003</a>].</div></li></ul><p>The absolute risk for pregnancy-associated VTE in 20210G&#x0003e;A homozygotes and women doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden is less well defined:</p><ul><li class="half_rhythm"><div>Women doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden have a higher risk for VTE in the range of 1/20 to 1/125 pregnancies [<a class="bk_pop" href="#ptt.REF.gerhardt.2000.374">Gerhardt et al 2000</a>, <a class="bk_pop" href="#ptt.REF.gerhardt.2003.77">Gerhardt et al 2003</a>, <a class="bk_pop" href="#ptt.REF.jacobsen.2010.2443">Jacobsen et al 2010</a>]. The estimated absolute risk in 20210G&#x0003e;A homozygotes is approximately 1/40 pregnancies [<a class="bk_pop" href="#ptt.REF.robertson.2006.171">Robertson et al 2006</a>].</div></li><li class="half_rhythm"><div>A family study found a low risk for pregnancy-associated VTE in asymptomatic doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women. No VTE events occurred during pregnancy; postpartum VTE complicated 1.8% of pregnancies [<a class="bk_pop" href="#ptt.REF.martinelli.2008.494">Martinelli et al 2008</a>].</div></li><li class="half_rhythm"><div>In a large family cohort of women who were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, doubly heterozygous or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for factor V Leiden or 20210G&#x0003e;A, the absolute risk for pregnancy associated VTE with women with no, a single, or combined defects was 0.73, 1.97, and 7.65 per 100 pregnancy years, respectively [<a class="bk_pop" href="#ptt.REF.van_vlijmen.2011.2055">van Vlijmen et al 2011</a>].</div></li></ul><p><b>Oral contraceptive use.</b> The use of oral contraceptives substantially increases the risk for VTE in women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. The risk for thrombosis is much higher during the first year of oral contraceptive use than during subsequent years [<a class="bk_pop" href="#ptt.REF.bloemenkamp.2000.49">Bloemenkamp et al 2000</a>].</p><ul><li class="half_rhythm"><div>Oral contraceptive use alone and 20210G&#x0003e;A heterozygosity alone are associated with a two- to fourfold and two- to threefold increased risk for VTE, respectively. However, the relative risk for VTE is increased 16- to 59-fold in 20210G&#x0003e;A heterozygotes who use contraceptives, indicating a supra-additive effect [<a class="bk_pop" href="#ptt.REF.martinelli.1999b.700">Martinelli et al 1999b</a>, <a class="bk_pop" href="#ptt.REF.legnani.2002.984">Legnani et al 2002</a>, <a class="bk_pop" href="#ptt.REF.wu.2005.17">Wu et al 2005</a>].</div></li><li class="half_rhythm"><div>The risk for VTE is also markedly increased in oral contraceptive users who are doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden, with reported odds ratios ranging from 17 to 110 [<a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>, <a class="bk_pop" href="#ptt.REF.legnani.2002.984">Legnani et al 2002</a>, <a class="bk_pop" href="#ptt.REF.mohllajee.2006.166">Mohllajee et al 2006</a>]. Although no studies have estimated the thrombotic risk associated with oral contraceptives in 20210G&#x0003e;A homozygotes, the risk is likely to be substantially higher than in women who are heterozygous.</div></li></ul><p>Despite the marked increase in relative risk, the absolute incidence of VTE may still be low because of the low baseline risk in young healthy women.</p><ul><li class="half_rhythm"><div>In a recent family study that assessed the risk of a first VTE during OCP use in women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, doubly heterozygous, or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for factor V Leiden or 20210G&#x0003e;A, the incidence of VTE in women with a single defect or combined defects was 0.35 and 0.94 per 100 person-years, respectively [<a class="bk_pop" href="#ptt.REF.van_vlijmen.2011.2055">van Vlijmen et al 2011</a>].</div></li><li class="half_rhythm"><div>In another family study the absolute incidence of VTE among women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> who used oral contraceptives was 0.2%/years of use [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>].</div></li><li class="half_rhythm"><div>A prospective family study found that none of the 84 asymptomatic women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> who used oral contraceptives developed VTE during a total of 84 years of use [<a class="bk_pop" href="#ptt.REF.coppens.2006.2604">Coppens et al 2006</a>].</div></li></ul><p><b>Other contraceptives.</b> The risk for VTE associated with transdermal and vaginal ring contraception is at least as high as the risk for VTE associated with oral contraceptives [<a class="bk_pop" href="#ptt.REF.cole.2007.339">Cole et al 2007</a>, <a class="bk_pop" href="#ptt.REF.jick.2007.4">Jick et al 2007</a>, <a class="bk_pop" href="#ptt.REF.dore.2010.408">Dore et al 2010</a>]. The thrombotic risk of these newer forms of contraception in 20210G&#x0003e;A heterozygotes has not been studied, but is likely to be higher than in women without thrombophilia. Unopposed progestin contraception is associated with a much lower risk for thrombosis than estrogen-containing contraception. A retrospective study found that oral progestin alone did not increase the risk for VTE in high-risk women with a history of thrombosis and/or thrombophilia including a small group of 20210G&#x0003e;A heterozygotes and women doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden [<a class="bk_pop" href="#ptt.REF.conard.2004.437">Conard et al 2004</a>]. However, no prospective studies confirm the safety of progestin-alone contraception in 20210G&#x0003e;A heterozygotes.</p><p><b>Hormone replacement therapy (HRT).</b> Oral HRT is associated with a two- to fourfold increase in relative risk for VTE in healthy postmenopausal users of HRT compared to non-users [<a class="bk_pop" href="#ptt.REF.grady.2000.689">Grady et al 2000</a>, <a class="bk_pop" href="#ptt.REF.rossouw.2002.321">Rossouw et al 2002</a>, <a class="bk_pop" href="#ptt.REF.canonico.2007.840">Canonico et al 2007</a>, <a class="bk_pop" href="#ptt.REF.renoux.2010.979">Renoux et al 2010</a>]. The risk increases with higher estrogen doses and may differ with the particular estrogen and progestin components [<a class="bk_pop" href="#ptt.REF.smith.2006.2807">Smith et al 2006</a>, <a class="bk_pop" href="#ptt.REF.canonico.2010.340">Canonico et al 2010</a>, <a class="bk_pop" href="#ptt.REF.renoux.2010.979">Renoux et al 2010</a>, <a class="bk_pop" href="#ptt.REF.canonico.2011.354">Canonico et al 2011</a>].</p><p>Limited data suggest that women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a 20210G&#x0003e; <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> who use HRT have a significantly increased thrombotic risk:</p><ul><li class="half_rhythm"><div>A case-control study found that women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or a factor V Leiden allele who used oral estrogen replacement had a 25-fold increased risk for VTE compared with non-users without either thrombophilic allele [<a class="bk_pop" href="#ptt.REF.straczek.2005.3495">Straczek et al 2005</a>].</div></li><li class="half_rhythm"><div>The risk of VTE in postmenopausal HRT users with either a 20210G&#x0003e;A or a factor V Leiden <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was threefold higher than the risk in HRT users without thrombophilia [<a class="bk_pop" href="#ptt.REF.roach.2013.124">Roach et al 2013</a>].</div></li><li class="half_rhythm"><div>The risk for VTE may differ with the type of hormonal content. In one study, the risk for VTE was fivefold higher with conjugated equine estrogen use than with esterified estrogen use among women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or factor V Leiden allele [<a class="bk_pop" href="#ptt.REF.smith.2006.2807">Smith et al 2006</a>].</div></li><li class="half_rhythm"><div>A meta-analysis found that women with either a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or a factor V Leiden allele who used oral estrogen had an eightfold increased venous thrombotic risk [<a class="bk_pop" href="#ptt.REF.canonico.2008.1227">Canonico et al 2008</a>].</div></li></ul><p><b>Transdermal hormone replacement therapy.</b> The available evidence suggests that transdermally administered estrogen has minimal or no effect on thrombotic risk [<a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013a.887">American College of Obstetricians and Gynecologists 2013a</a>].</p><ul><li class="half_rhythm"><div>Multiple retrospective studies and a meta-analysis found that current use of low- or high-dose transdermal estrogen replacement with or without a progestin did not increase the risk for VTE. In contrast, oral HRT was associated with a two- to fourfold increase in thrombotic risk [<a class="bk_pop" href="#ptt.REF.canonico.2007.840">Canonico et al 2007</a>, <a class="bk_pop" href="#ptt.REF.canonico.2008.1227">Canonico et al 2008</a>, <a class="bk_pop" href="#ptt.REF.canonico.2010.340">Canonico et al 2010</a>, <a class="bk_pop" href="#ptt.REF.renoux.2010.979">Renoux et al 2010</a>, <a class="bk_pop" href="#ptt.REF.lalibert_.2011.1052">Lalibert&#x000e9; et al 2011</a>].</div></li><li class="half_rhythm"><div>There is also evidence that transdermal estrogen is associated with a lower thrombotic risk than oral estrogen in women with inherited thrombophilic disorders such as prothrombin-related thrombophilia [<a class="bk_pop" href="#ptt.REF.canonico.2007.840">Canonico et al 2007</a>, <a class="bk_pop" href="#ptt.REF.canonico.2010.340">Canonico et al 2010</a>].</div></li><li class="half_rhythm"><div>Women with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> using transdermal estrogen had a risk similar to that of non-users with the allele. Among women with a 20210G&#x0003e;A allele the use of oral estrogen was associated with a fourfold higher risk for VTE than transdermal estrogen [<a class="bk_pop" href="#ptt.REF.straczek.2005.3495">Straczek et al 2005</a>]. However, no prospective randomized trials have confirmed the safety of transdermal HRT in women with inherited or acquired thrombophilia and/or prior VTE.</div></li></ul><p><b>Selective estrogen receptor modulators (SERMs).</b> Limited data suggest that SERMs such as tamoxifen and raloxifene are associated with a twofold increased risk for VTE, similar to the risk for HRT [<a class="bk_pop" href="#ptt.REF.cummings.1999.2189">Cummings et al 1999</a>, <a class="bk_pop" href="#ptt.REF.duggan.2003.3588">Duggan et al 2003</a>, <a class="bk_pop" href="#ptt.REF.abramson.2006.904">Abramson et al 2006</a>, <a class="bk_pop" href="#ptt.REF.barrettconnor.2006.125">Barrett-Connor et al 2006</a>]. The thrombotic risk associated with tamoxifen was higher than raloxifene in trials for primary prevention of breast cancer [<a class="bk_pop" href="#ptt.REF.nelson.2013.604">Nelson et al 2013</a>]. 20210G&#x0003e;A heterozygosity did not increase the risk for arterial or venous thromboembolism in high-risk healthy women using tamoxifen for breast cancer prevention [<a class="bk_pop" href="#ptt.REF.duggan.2003.3588">Duggan et al 2003</a>, <a class="bk_pop" href="#ptt.REF.abramson.2006.904">Abramson et al 2006</a>]. However, both studies were limited by the small number of cases included. The risk for VTE in women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> who use SERMs is uncertain but likely higher than that associated with SERM use alone.</p><p><b>Obesity.</b> Obesity (BMI&#x0003e;30 kg/m<sup>2</sup>) is associated with a two- to threefold increased risk for VTE. Obese women with a 20210 G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have a nearly sevenfold higher risk for VTE than women with neither risk factor. Overweight women (BMI &#x02265;25 and &#x0003c;30 kg/m<sup>2</sup>) with the allele have a fivefold increased thrombotic risk [<a class="bk_pop" href="#ptt.REF.pomp.2007.289">Pomp et al 2007</a>].</p><p><b>Organ transplantation</b>. It is unclear whether 20210G&#x0003e;A heterozygosity contributes to thrombotic and other complications after organ transplantation [<a class="bk_pop" href="#ptt.REF.pherwani.2003.603">Pherwani et al 2003</a>, <a class="bk_pop" href="#ptt.REF.kujovich.2004c.959">Kujovich 2004c</a>].</p><ul><li class="half_rhythm"><div>A 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was associated with a trend toward a threefold increased risk for thromboembolic complications after renal transplantation which did not reach statistical significance due to the small number of recipients with the allele [<a class="bk_pop" href="#ptt.REF.ghisdal.2010.99">Ghisdal et al 2010</a>].</div></li><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity was identified in 14% of liver allografts complicated by hepatic artery thrombosis, but not in recipient peripheral blood leukocytes [<a class="bk_pop" href="#ptt.REF.mas.2003.247">Mas et al 2003</a>]. However, a recent study found no association with hepatic vascular thrombosis after liver transplantation [<a class="bk_pop" href="#ptt.REF.pereboom.2011.587">Pereboom et al 2011</a>]</div></li></ul><p><b>Central venous catheters.</b> An indwelling central venous catheter is the strongest risk factor for upper-extremity thrombosis, contributing to up to one third of occurrences [<a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>]. The data on the contribution of a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> to catheter-related thrombosis are conflicting:</p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygotes had a two- to threefold increased risk for central venous catheter-related thrombosis [<a class="bk_pop" href="#ptt.REF.van_rooden.2004.201">Van Rooden et al 2004</a>].</div></li><li class="half_rhythm"><div>Two other studies reported a low prevalence of the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in persons with catheter-related thrombosis, similar to controls or the general population [<a class="bk_pop" href="#ptt.REF.vay_.2003.452">Vay&#x000e1; et al 2003</a>, <a class="bk_pop" href="#ptt.REF.linnemann.2008a.440">Linnemann et al 2008a</a>].</div></li></ul><p><b>Surgery.</b> It is still unclear to what extent the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> adds to the overall thrombotic risk in individuals undergoing surgery. Any excess risk conferred by 20210G&#x0003e;A heterozygosity is likely small in comparison to the thrombotic risk associated with surgery:</p><ul><li class="half_rhythm"><div>Individuals with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or a factor V leiden allele undergoing surgery had a nearly 13-fold increased risk for upper-extremity DVT during a postoperative period of up to three months [<a class="bk_pop" href="#ptt.REF.blom.2005a.2471">Blom et al 2005a</a>].</div></li><li class="half_rhythm"><div>In a large prospective trial, a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was a risk factor for symptomatic VTE after total hip or knee arthroplasty, conferring a tenfold increase in risk. The allele was associated with a sixfold increased risk for symptomatic postoperative pulmonary embolism [<a class="bk_pop" href="#ptt.REF.w_hlander.2002.580">W&#x000e5;hlander et al 2002</a>].</div></li><li class="half_rhythm"><div>In contrast, several other studies found no association between a 20210 G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and the risk for VTE after orthopedic surgery [<a class="bk_pop" href="#ptt.REF.joseph.2005.87">Joseph et al 2005</a>, <a class="bk_pop" href="#ptt.REF.ringwald.2009.1507">Ringwald et al 2009</a>].</div></li></ul><p><b>Travel.</b> Some evidence suggests that 20210G&#x0003e;A heterozygotes are more likely to develop VTE after travel. One study found that air travel was a mild risk factor for a first VTE (OR = 2). However, the combination of air travel and any type of thrombophilia (including 20210G&#x0003e;A heterozygosity) was associated with a 17-fold increase in risk, indicating a multiplicative interaction between the two risk factors [<a class="bk_pop" href="#ptt.REF.martinelli.2003b.2771">Martinelli et al 2003b</a>].</p><p><b>Minor injury</b>. Minor leg injuries are associated with a fivefold increased risk for VTE. The risk is particularly high after muscle or ligament rupture. Individuals with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a minor leg injury had a nine- to 30-fold higher thrombotic risk than those without these risk factors [<a class="bk_pop" href="#ptt.REF.van_stralen.2008.21">van Stralen et al 2008</a>].</p></div></div><div id="ptt.Thrombosis_NOT_Convincingly_Associat"><h3>Thrombosis NOT Convincingly Associated with Prothrombin-Related Thrombophilia</h3><p><b>Arterial thrombosis in adults.</b> The role of prothrombin-related thrombophilia in arterial disease is controversial, with conflicting results from different studies. The available evidence indicates that the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is not a major risk factor for arterial thrombosis. The majority of myocardial infarctions (MIs) and strokes occur in the presence of established cardiovascular risk factors including hypertension, hyperlipidemia, diabetes mellitus, and smoking. The contribution of a single thrombophilic allele to these complex diseases is likely small.</p><p>Most studies of unselected or elderly adult populations found no significant association between the presence of one or two 20210G&#x0003e;A alleles and myocardial infarction or stroke [<a class="bk_pop" href="#ptt.REF.ridker.1999.999">Ridker et al 1999</a>, <a class="bk_pop" href="#ptt.REF.smiles.2002.614">Smiles et al 2002</a>, <a class="bk_pop" href="#ptt.REF.linnemann.2008b.743">Linnemann et al 2008b</a>].</p><p>Other studies also found no increase in the annual incidence of stroke, transient ischemic attack (TIA), or MI associated with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.bank.2004.1932">Bank et al 2004</a>, <a class="bk_pop" href="#ptt.REF.slooter.2005.1213">Slooter et al 2005</a>, <a class="bk_pop" href="#ptt.REF.bolaman.2009.11">Bolaman et al 2009</a>]. In a prospective study the annual incidence of a first arterial cardiovascular event was 0.56% in family members with the allele compared to 0.73% in those without the allele [<a class="bk_pop" href="#ptt.REF.coppens.2006.2604">Coppens et al 2006</a>]. The annual incidence of ischemic stroke or TIA was also similar in family members with and without the allele (0.33% and 0.23%, respectively).</p><p>The results of several meta-analyses suggest at most a weak association with ischemic stroke (pooled OR = 1.4) [<a class="bk_pop" href="#ptt.REF.casas.2004.1652">Casas et al 2004</a>], and myocardial infarction (per <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> relative risk = 1.31) [<a class="bk_pop" href="#ptt.REF.ye.2006.651">Ye et al 2006</a>].</p><p>The risk for arterial thrombosis in 20210G&#x0003e;A homozygotes is unknown, as very few <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> individuals have been included in published studies.</p><p><b>Myocardial infarction (MI).</b> Although a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is not a major risk factor for ischemic heart disease, it may contribute to the risk for MI in selected populations. 20210G&#x0003e;A heterozygosity increased the risk for MI 43-fold in women younger than age 50 years with traditional cardiovascular risk factors, particularly smoking [<a class="bk_pop" href="#ptt.REF.rosendaal.1997.1747">Rosendaal et al 1997</a>]. The risk may also be increased in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> postmenopausal women who use HRT [<a class="bk_pop" href="#ptt.REF.psaty.2001.906">Psaty et al 2001</a>, <a class="bk_pop" href="#ptt.REF.hindorff.2006.600">Hindorff et al 2006</a>].</p><p><b>Stroke in adults.</b> Although 20210G&#x0003e;A is not a general risk factor for stroke, it may contribute to the risk for stroke in selected populations: In two case-control studies, 20210G&#x0003e;A heterozygosity conferred a fourfold increased risk for ischemic stroke in individuals younger than age 50 years without established cardiovascular risk factors [<a class="bk_pop" href="#ptt.REF.de_stefano.1998.3562">De Stefano et al 1998</a>, <a class="bk_pop" href="#ptt.REF.aznar.2004.1031">Aznar et al 2004</a>].</p><p>Arterial thromboembolism may also occur "paradoxically" through a patent foramen ovale (PFO) in the heart of individuals with venous thrombosis. A meta-analysis concluded that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was significantly associated with PFO-related stroke in comparison with controls (OR = 3.85) and persons with non-PFO associated stroke (OR = 2.31) [<a class="bk_pop" href="#ptt.REF.pezzini.2009.813">Pezzini et al 2009</a>].</p><p><b>Stroke in children.</b> Arterial ischemic stroke in children usually occurs in the setting of multiple predisposing factors [<a class="bk_pop" href="#ptt.REF.barnes.2006.67">Barnes &#x00026; Deveber 2006</a>]. Data on the association of thrombophilia with ischemic stroke are conflicting and mostly limited to small case series and case-control studies. Stroke accounted for 21% of thrombotic events in a highly selected group of symptomatic children with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Children younger than age two years had a significantly higher rate of arterial thrombosis than older children in whom venous thrombosis was far more common [<a class="bk_pop" href="#ptt.REF.young.2003.958">Young et al 2003</a>]. A meta-analysis of 13 studies found that children with a 20210G&#x0003e;A allele had a twofold increased risk for a first stroke. The risk was increased nearly 19-fold in children with multiple thrombophilic defects [<a class="bk_pop" href="#ptt.REF.kenet.2010.1838">Kenet et al 2010</a>]. However, several other small studies and a smaller meta-analysis found no significant association between 20210G&#x0003e;A heterozygostiy and first ischemic stroke in children [<a class="bk_pop" href="#ptt.REF.zenz.1998.763">Zenz et al 1998</a>, <a class="bk_pop" href="#ptt.REF.kenet.2000.1283">Kenet et al 2000</a>, <a class="bk_pop" href="#ptt.REF.bonduel.2003.81">Bonduel et al 2003</a>, <a class="bk_pop" href="#ptt.REF.haywood.2005.402">Haywood et al 2005</a>].</p></div><div id="ptt.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Homozygotes for the <a class="figpopup" href="/books/NBK1148/table/ptt.T.selected_f2_variants_of_uncertain/?report=objectonly" target="object" rid-figpopup="figpttTselectedf2variantsofuncertain" rid-ob="figobpttTselectedf2variantsofuncertain">20210G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have a greater risk for thrombosis than do heterozygotes for the 20210G&#x0003e;A allele, although the magnitude of risk is not well defined.</p><p>The clinical course of an acute thrombotic episode is not more severe or resistant to anticoagulation in 20210G&#x0003e;A homozygotes than in 20210G&#x0003e;A heterozygotes.</p></div><div id="ptt.Prevalence"><h3>Prevalence</h3><p><i>F2</i>
<a class="figpopup" href="/books/NBK1148/table/ptt.T.selected_f2_variants_of_uncertain/?report=objectonly" target="object" rid-figpopup="figpttTselectedf2variantsofuncertain" rid-ob="figobpttTselectedf2variantsofuncertain">20210G&#x0003e;A</a> heterozygosity is the second most common inherited thrombophilia after <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a>. The prevalence of 20210G&#x0003e;A heterozygosity varies by population.</p><ul><li class="half_rhythm"><div>20210G&#x0003e;A heterozygosity occurs in 1.7%-3% of the general US and European populations. The highest heterozygosity rate is found in Europe; the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is extremely rare in Asian, African, and Native American populations. Within Europe the prevalence varies from 3% in southern Europe to 1.7% in northern countries [<a class="bk_pop" href="#ptt.REF.rosendaal.1998.706">Rosendaal et al 1998</a>].</div></li><li class="half_rhythm"><div>In the US, the prevalence of 20210G&#x0003e;A heterozygosity is 2%-5% in whites, 2.2% in Hispanic whites, and 0%- 0.6% in African Americans, reflecting the world distribution of the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#ptt.REF.dilley.1998.452">Dilley et al 1998</a>, <a class="bk_pop" href="#ptt.REF.dowling.2003.80">Dowling et al 2003</a>, <a class="bk_pop" href="#ptt.REF.chang.2009.54">Chang et al 2009</a>].</div></li><li class="half_rhythm"><div>A study of a multiracial American population found 20210G&#x0003e;A heterozygosity in 8.2% of white and 1.1% of African American persons with VTE. The <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was not detected in the African American control population [<a class="bk_pop" href="#ptt.REF.dowling.2003.80">Dowling et al 2003</a>].</div></li></ul><p>Among adults with VTE, 20210G&#x0003e;A heterozygosity is present in 6%-14% of those with a first VTE, and 18%-21% of those with a personal or family history of recurrent VTE [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.margaglione.1998.89">Margaglione et al 1998</a>, <a class="bk_pop" href="#ptt.REF.tosetto.1999.1395">Tosetto et al 1999</a>]. A prospective study identified 20210G&#x0003e;A heterozygosity in 3.7% of children with a first spontaneous VTE [<a class="bk_pop" href="#ptt.REF.nowakg_ttl.2001.858">Nowak-G&#x000f6;ttl et al 2001</a>].</p><p>The prevalence of 20210G&#x0003e;A homozygosity is approximately one in 10,000. 20210G&#x0003e;A homozygosity is found in 1.8%-4.5% of individuals with a history of VTE [<a class="bk_pop" href="#ptt.REF.margaglione.1999.1583">Margaglione et al 1999</a>, <a class="bk_pop" href="#ptt.REF.barcellona.2003.1061">Barcellona et al 2003</a>].</p><p>Double heterozygosity for the 20210G&#x0003e;A and factor V Leiden alleles occurs in approximately one in 1000 individuals in the general population and is found in 1%-5% of persons with VTE [<a class="bk_pop" href="#ptt.REF.margaglione.1999.1583">Margaglione et al 1999</a>, <a class="bk_pop" href="#ptt.REF.salomon.1999.511">Salomon et al 1999</a>, <a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>, <a class="bk_pop" href="#ptt.REF.simioni.2000.3329">Simioni et al 2000</a>].</p></div></div><div id="ptt.Genetically_Related_Allelic_Disorder"><h2 id="_ptt_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>Prothrombin deficiency, including hypoprothrombinemia and dysprothrombinemia, results from pathogenic <i>F2</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants and deletions that inactivate or decrease prothrombin levels.</p></div><div id="ptt.Differential_Diagnosis"><h2 id="_ptt_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of venous thromboembolism (VTE) includes several other inherited and acquired thrombophilic disorders. Because these disorders are not clinically distinguishable, laboratory testing is required for diagnosis in each case. (See also Management, <a href="#ptt.Evaluations_Following_Initial_Diagno">Evaluations Following Initial Diagnosis</a>.)</p><div id="ptt.Inherited"><h3>Inherited</h3><p><a href="/books/n/gene/factor-v-leiden/"><b>Factor V Leiden</b></a> refers to the specific G-to-A substitution in <i>F5</i> that predicts a single amino-acid replacement (Arg506Gln) that destroys a cleavage site for activated protein C. The resulting impaired anticoagulant response to activated protein C results in increased thrombin generation and a prothrombotic state [<a class="bk_pop" href="#ptt.REF.kujovich.2011.1">Kujovich 2011</a>]. Factor V Leiden heterozygosity is found in 3%-8% of the general population and 15%-20% of individuals with a first VTE. Factor V Leiden heterozygosity is identified in 20%-40% of symptomatic 20210G&#x0003e;A heterozygotes with VTE [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>].</p><p><b>A specific single nucleotide variant (SNV) (677C&#x0003e;T) in <i>MTHFR</i></b>, encoding methylenetetrahydrofolate reductase, results in a variant thermolabile enzyme with reduced activity for the remethylation of homocysteine. Homozygosity for 677C&#x0003e;T (also known as C677T) occurs in 10%-20% of the general population and predisposes to mild hyperhomocysteinemia in the setting of suboptimal folate stores. The <i>MTHFR</i> variant does not confer an increased risk for VTE [<a class="bk_pop" href="#ptt.REF.bezemer.2007.497">Bezemer et al 2007</a>]. The official designation for this <i>MTHFR</i> variant is <a href="/nuccore/NM_005957.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005957.4</a>:c.665C&#x0003e;T, <a href="/protein/NP_005948.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_005948.3</a>:p.Ala222Val, or <a href="/snp?term=rs1801133" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs1801133</a>.</p><p><b>Inherited deficiencies of the natural anticoagulant proteins C, S, and antithrombin</b> are approximately tenfold less common than <i>F2</i> 20210G&#x0003e;A heterozygosity with a combined prevalence of less than 1% of the population. Anticoagulant protein deficiencies are found in 1%-3% of individuals with a first VTE.</p><p><b>Elevated levels of lipoprotein(a)</b> are associated with premature atherosclerosis and may also be a risk factor for venous thrombosis.</p><p><b>Hereditary dysfibrinogenemias</b> are rare and infrequently cause thrombophilia and thrombosis.</p><p>See <a href="http://www.omim.org/phenotypicSeries/PS188050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thrombophilia: OMIM Phenotypic Series</a>, to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="ptt.Acquired"><h3>Acquired</h3><p><b>High plasma concentration of homocysteine</b> is present in 10% of individuals with a first VTE. In early studies a high plasma concentration of homocysteine was associated with a twofold increased relative risk for VTE; however, more recent data indicate that a high homocysteine level is a much weaker risk factor for VTE than previously reported [<a class="bk_pop" href="#ptt.REF.den_heijer.2005.292">Den Heijer et al 2005</a>]. It was not associated with an increased thrombotic risk in children [<a class="bk_pop" href="#ptt.REF.joachim.2013.170">Joachim et al 2013</a>]. The plasma concentration of homocysteine reflects genetic as well as environmental factors.</p><p><b>Antiphospholipid antibodies</b> comprise a heterogeneous group of autoantibodies directed against proteins bound to phospholipid. Anticardiolipin antibodies and the related anti-beta2 glycoprotein 1 antibodies are detected by solid phase immunoassays. Lupus inhibitors are autoantibodies that interfere with phospholipid-dependent clotting assays. Persistent high titer lupus inhibitors are more strongly associated with arterial and venous thromboembolism than other antiphospholipid antibodies [<a class="bk_pop" href="#ptt.REF.galli.2003.1827">Galli et al 2003</a>]. Recent evidence indicates that "triple positivity" for all three types of antiphospholipid antibodies confers the highest risk of thrombosis and pregnancy complications [<a class="bk_pop" href="#ptt.REF.pengo.2010.237">Pengo et al 2010</a>].</p><p><b>An elevated factor VIII level greater than 150%</b> of normal is associated with a four- to fivefold increased risk for a first VTE [<a class="bk_pop" href="#ptt.REF.koster.1995.152">Koster et al 1995</a>, <a class="bk_pop" href="#ptt.REF.bank.2005.79">Bank et al 2005</a>] and also significantly increases the risk for recurrent thrombosis [<a class="bk_pop" href="#ptt.REF.kyrle.2000.457">Kyrle et al 2000</a>]. Familial clustering of high factor VIII levels occurs although the relative contribution from genetic factors to persistently elevated levels is still unknown. No specific <i>F8</i> benign variants have been associated with elevaled plasma factor VIII levels [<a class="bk_pop" href="#ptt.REF.jenkins.2012.653">Jenkins et al 2012</a>].</p><p><b>An elevated plasma level of factor IX and factor XI</b> is each associated with a twofold increased risk for VTE [<a class="bk_pop" href="#ptt.REF.van_hylckama_vlieg.2000.3678">van Hylckama Vlieg et al 2000</a>, <a class="bk_pop" href="#ptt.REF.cushman.2009.2878">Cushman et al 2009</a>].</p><p><b>Elevated plasma levels of both factor VIII and factor IX</b> are associated with an eightfold increased risk for VTE [<a class="bk_pop" href="#ptt.REF.meijers.2000.696">Meijers et al 2000</a>, <a class="bk_pop" href="#ptt.REF.van_hylckama_vlieg.2000.3678">van Hylckama Vlieg et al 2000</a>].</p><p><b>An elevated plasma prothrombin level greater than 110% -115% of normal</b> is associated with a twofold increased risk for VTE in the absence of <i>F2</i> 20210G&#x0003e;A [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.legnani.2003.112">Legnani et al 2003</a>]. The combination of oral contraceptives and high levels of prothrombin and factor V or factor XI had a supra-additive effect on thrombotic risk, with odds ratios ranging from ten to 13 [<a class="bk_pop" href="#ptt.REF.van_hylckama_vlieg.2003.2186">van Hylckama Vlieg &#x00026; Rosendaal 2003</a>].</p></div><div id="ptt.Other"><h3>Other</h3><p>Although thrombosis has been reported in association with defects or deficiencies of other coagulation and fibrinolytic proteins, including heparin cofactor II, PAI-1, tissue factor pathway inhibitor, thrombin activatable fibrinolysis inhibitor (TAFI), and protein Z, a causal association has not been established [<a class="bk_pop" href="#ptt.REF.meltzer.2010.113">Meltzer et al 2010</a>].</p><p>Other genetic risk factors for thrombosis under investigation include a fibrinogen gamma chain variant (10034T), genetic variants in the protein C <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>, and several single-nucleotide polymorphisms (SNPs) in coagulation proteins [<a class="bk_pop" href="#ptt.REF.smith.2007.489">Smith et al 2007</a>, <a class="bk_pop" href="#ptt.REF.bezemer.2008.1306">Bezemer et al 2008</a>]. Genome-wide association analysis has also been used to identify novel susceptibility genes for venous thrombosis [<a class="bk_pop" href="#ptt.REF.germain.2011.e25581">Germain et al 2011</a>].</p><p>Several global markers of coagulation such as measurement of thrombin generation show promise in identifying individuals at high risk for thrombosis [<a class="bk_pop" href="#ptt.REF.eichinger.2009.291">Eichinger &#x00026; Kyrle 2009</a>, <a class="bk_pop" href="#ptt.REF.kyrle.2010.2032">Kyrle et al 2010</a>].</p><p>Testing for these potential risk factors is not routinely recommended and in many cases, assays are not commercially available.</p></div></div><div id="ptt.Management"><h2 id="_ptt_Management_">Management</h2><div id="ptt.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>Because of the increased incidence of a second thrombophilic defect among symptomatic individuals with inherited thrombophilia [<a class="bk_pop" href="#ptt.REF.emmerich.2001.809">Emmerich et al 2001</a>], individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>F2</i>
<a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> should be tested for other inherited and acquired thrombophilic disorders in order to evaluate the risk for thrombosis. Testing should include:</p><ul><li class="half_rhythm"><div class="half_rhythm">An activated protein C resistance or DNA assay for <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a>;</div></li><li class="half_rhythm"><div class="half_rhythm">Serologic assays for anticardiolipin antibodies and anti-beta 2 glycoprotein 1 antibodies;</div></li><li class="half_rhythm"><div class="half_rhythm">Multiple phospholipid-dependent coagulation assays for a lupus inhibitor.</div><div class="half_rhythm">Note: Testing for antiphospholipid antibodies should include assays for all three antibodies (anticardiolipin antibodies, anti-beta2 glycoprotein 1 antibodies, and lupus inhibitors) since only 50% of individuals with the antiphospholipid antibody syndrome have more than one type of antibody.</div></li></ul><p>Evaluation of high-risk individuals (i.e., those with a history of recurrent VTE especially at a young age, or those with strong family history of VTE at a young age), should also include assays of:</p><ul><li class="half_rhythm"><div>Protein C activity;</div></li><li class="half_rhythm"><div>Antithrombin activity;</div></li><li class="half_rhythm"><div>Protein S activity or free protein S antigen.</div></li></ul><p>Note: In an evaluation for thrombophilia: (1) Measurement of plasma concentration of homocysteine is no longer recommended because no data support the use of vitamin supplementation or modification of the duration of anticoagulation in individuals with hyperhomocysteinemia and a history of VTE [<a class="bk_pop" href="#ptt.REF.den_heijer.2007.139">den Heijer et al 2007</a>]; (2) there is no clinical rationale for DNA testing for <i>MTHFR</i> variants; and (3) routine measurement of factor VIII and other clotting factor levels is not recommended; however, such testing may be useful in certain instances [<a class="bk_pop" href="#ptt.REF.bauer.2010.210">Bauer 2010</a>, <a class="bk_pop" href="#ptt.REF.jenkins.2012.653">Jenkins et al 2012</a>]</p></div><div id="ptt.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The management of thrombosis in individuals with prothrombin-related thrombophilia depends on the clinical circumstances.</p><p><b>The first acute thrombosis</b> should be treated according to standard guidelines with a course of low molecular-weight heparin (LMWH) or fondaparinux (a pentasaccharide) [<a class="bk_pop" href="#ptt.REF.kearon.2012">Kearon et al 2012</a>]. Low molecular-weight heparins and fondaparinux have largely replaced unfractionated heparin because of their many advantages [<a class="bk_pop" href="#ptt.REF.garcia.2012">Garcia et al 2012</a>].</p><p>Oral administration of warfarin is started concurrently with LMWH or fondaparinux (except during pregnancy) and monitored with the international-normalized ratio (INR). A target INR of 2.5 (therapeutic range: 2.0-3.0) provides effective anticoagulation, even in <i>F2</i> 20210G&#x0003e;A homozygotes.</p><p>Rivaroxaban, a direct factor Xa inhibitor, is also approved for the treatment of acute DVT and PE and secondary prevention of recurrent VTE.</p><p>Note: LMWH and warfarin are both safe in women who are breast-feeding. Rivaroxaban is contraindicated during pregnancy and breast-feeding because animal studies showed reproductive toxicity, and evidence that the drug crosses the placenta and is secreted in milk [<a class="bk_pop" href="#ptt.REF.ageno.2012">Ageno et al 2012</a>].</p><p><b>The duration of oral anticoagulation therapy</b> should be based on an individualized assessment of the risks of VTE recurrence and anticoagulant-related bleeding. Approximately 30% of individuals with VTE experience recurrent thrombosis within the subsequent five years [<a class="bk_pop" href="#ptt.REF.prandoni.2007.199">Prandoni et al 2007</a>]. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors (see Clinical Description, <a href="#ptt.Recurrent_Thrombosis">Recurrent Thrombosis</a>, <b>Risk for recurrent thrombosis in adult 20210G&#x0003e;A heterozygotes</b>.</p><p>20210G&#x0003e;A heterozygosity is generally not an indication for long-term anticoagulation in the absence of other risk factors. The presence of a hereditary thrombophilia was not a factor determining the duration of anticoagulation in the 2012 American College of Chest Physicians Guidelines on Antithrombotic Therapy and Prevention of Thrombosis based on evidence that inherited thrombophilic disorders are not major determinants of VTE <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> [<a class="bk_pop" href="#ptt.REF.kearon.2012">Kearon et al 2012</a>] (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). Other clinical guidelines and expert opinion also conclude that identification of 20210G&#x0003e;A heterozygosity should not affect clinical decision making [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bauer.2010.210">Bauer 2010</a>, <a class="bk_pop" href="#ptt.REF.kyrle.2010.2032">Kyrle et al 2010</a>, <a class="bk_pop" href="#ptt.REF.heleen_van_ommen.2011.794">Heleen van Ommen &#x00026; Middeldorp 2011</a>, <a class="bk_pop" href="#ptt.REF.monagle.2012">Monagle et al 2012</a>, <a class="bk_pop" href="#ptt.REF10">National Clinical Guideline Centre 2012</a>]. See <a href="#ptt.References">Published Guidelines / Consensus Statements</a>.</p><p>Anticoagulation for at least three months is recommended for persons with DVT and/or PE associated with a transient (reversible) risk factor [<a class="bk_pop" href="#ptt.REF.kearon.2012">Kearon et al 2012</a>].</p><p><b>Long-term oral anticoagulation</b> is recommended for individuals with a first or recurrent unprovoked (i.e., <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a>) VTE and no risk factors for bleeding with good anticoagulation monitoring [<a class="bk_pop" href="#ptt.REF.kearon.2012">Kearon et al 2012</a>]. The decision should be based on an assessment of potential risks and benefits regardless of 20210G&#x0003e;A status [<a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>]. Long-term anticoagulation is considered in selected individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or with multiple inherited or acquired thrombophilic disorders [<a class="bk_pop" href="#ptt.REF.de_stefano.2013.697">De Stefano &#x00026; Rossi 2013</a>]. In these individuals at higher risk for recurrence, the potential benefits of long-term anticoagulation may outweigh the bleeding risks.</p><p>LMWH, fondaparinux, warfarin, and rivaroxaban are the primary antithrombotic agents used for the acute and long-term treatment of VTE. Several direct thrombin inhibitors (lepirudin, argatroban, and dabigatran), and apixaban, a direct factor Xa inhibitor, are approved for use in specific circumstances [<a class="bk_pop" href="#ptt.REF.schulman.2014.1">Schulman 2014</a>].</p><p><b>Graduated compression stockings</b> should be worn for at least two years following an acute DVT.</p><p><b>Treatment of thrombosis in children.</b> Treatment recommendations for children with VTE are largely adapted from studies in adults. There is no evidence that a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> should influence decisions about the intensity or duration of anticoagulation in children [<a class="bk_pop" href="#ptt.REF.monagle.2012">Monagle et al 2012</a>, <a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>, <a class="bk_pop" href="#ptt.REF.heleen_van_ommen.2011.794">Heleen van Ommen &#x00026; Middeldorp 2011</a>, <a class="bk_pop" href="#ptt.REF.monagle.2012">Monagle et al 2012</a>]. British guidelines for antithrombotic therapy in children do not consider inherited thrombophilia as a determinant of either the intensity or duration of therapy.</p><p>Children with a first VTE should receive initial treatment with either unfractionated heparin (UFH) or LMWH for at least five days. LMWH is favored over warfarin for continued therapy, especially in very young children and those with complex medical problems. Recommendations on the duration of antithrombotic therapy are based on the nature of the thrombotic event (e.g., spontaneous or provoked) [<a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>, <a class="bk_pop" href="#ptt.REF.monagle.2012">Monagle et al 2012</a>, <a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>] (see <a href="#ptt.References">Published Guidelines / Consensus Statements</a>).</p><p>Anticoagulation is recommended:</p><ul><li class="half_rhythm"><div>For at least three months after a VTE provoked by a clinical risk factor that has resolved.</div></li><li class="half_rhythm"><div>Beyond three months until the risk factor has resolved in children with ongoing but potentially reversible risk factors.</div></li><li class="half_rhythm"><div>For six to 12 months after a first <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> (unprovoked) VTE.</div></li><li class="half_rhythm"><div>Indefinitely for those with recurrent <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> VTE</div></li></ul><p>Expert opinion emphasizes the importance of a careful risk/benefit assessment in each individual [<a class="bk_pop" href="#ptt.REF.raffini.2009.277">Raffini &#x00026; Thornburg 2009</a>, <a class="bk_pop" href="#ptt.REF.heleen_van_ommen.2011.794">Heleen van Ommen &#x00026; Middeldorp 2011</a>].</p><p>Consensus guidelines are also available for management of stroke in infants and children [<a class="bk_pop" href="#ptt.REF.monagle.2012">Monagle et al 2012</a>] (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278066/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p></div><div id="ptt.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>In the absence of a history of thrombosis, long-term anticoagulation is not recommended for asymptomatic 20210G&#x0003e;A heterozygotes, since the 1%-3% yearly risk for major bleeding from warfarin is greater than the estimated (&#x0003c;1%) yearly risk for thrombosis [<a class="bk_pop" href="#ptt.REF.martinelli.2000a.1223">Martinelli et al 2000a</a>, <a class="bk_pop" href="#ptt.REF.middeldorp.2008.321">Middeldorp &#x00026; van Hylckama Vlieg 2008</a>, <a class="bk_pop" href="#ptt.REF.berg.2011.67">Berg et al 2011</a>].</p><p>Prophylactic anticoagulation may be considered in high-risk clinical settings such as surgery, pregnancy, or prolonged immobilization, although currently no evidence confirms the benefit of primary prophylaxis for asymptomatic 20210G&#x0003e;A heterozygotes. Factors that may influence decisions about the indication for and duration of anticoagulation include age, family history, and other coexisting risk factors. Recommendations for prophylaxis at the time of surgery and other high-risk situations are available in the 2012 American College of Chest Physicians consensus guidelines [<a class="bk_pop" href="#ptt.REF.guyatt.2012">Guyatt et al 2012</a>] (<a href="/pmc/articles/PMC3278060/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p></div><div id="ptt.Surveillance"><h3>Surveillance</h3><p>Individuals receiving long-term anticoagulation require periodic reevaluation to confirm that the benefits of anticoagulation continue to outweigh the bleeding risk.</p><p>Selected 20210G&#x0003e;A heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy. (See <a href="#ptt.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>.)</p></div><div id="ptt.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><i>F2</i> 20210G&#x0003e;A heterozygotes:</p><ul><li class="half_rhythm"><div>With a history of VTE should avoid estrogen contraception and HRT; asymptomatic women should be counseled on the risks of estrogen-containing contraception and HRT and should consider alternative forms of contraception and strategies for control of menopausal symptoms.</div></li><li class="half_rhythm"><div>Who are asymptomatic and elect to use oral contraceptives should avoid formulations with third-generation and other progestins with a higher thrombotic risk;</div></li><li class="half_rhythm"><div>Who elect short-term hormone replacement therapy for severe menopausal symptoms should use low-dose transdermal preparations, which have a lower thrombotic risk than oral formulations [<a class="bk_pop" href="#ptt.REF.straczek.2005.3495">Straczek et al 2005</a>, <a class="bk_pop" href="#ptt.REF.canonico.2007.840">Canonico et al 2007</a>, <a class="bk_pop" href="#ptt.REF.renoux.2010.979">Renoux et al 2010</a>].</div></li></ul><p><i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> women with or without prior VTE should avoid estrogen-containing contraception and HRT.</p></div><div id="ptt.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>The genetic status of asymptomatic at-risk family members can be established using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. However, as there is no clinical evidence that early diagnosis reduces morbidity or mortality, the indications for family testing are unresolved and the decision to test at-risk family members should be made on an individual basis [<a class="bk_pop" href="#ptt.REF.segal.2009.2472">Segal et al 2009</a>].</p><p>Clarification of 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> status may be useful in:</p><ul><li class="half_rhythm"><div>Asymptomatic adult family members of probands with one or two known 20210G&#x0003e;A alleles, especially those with a strong family history of VTE at a young age;</div></li><li class="half_rhythm"><div>Asymptomatic female family members of probands with known prothrombin-related thrombophilia who are pregnant or considering estrogen contraception or pregnancy.</div></li></ul><p>There is no clinical evidence to support testing asymptomatic children with a family history of thrombosis and/or inherited thrombophilia. Guidelines suggest delaying testing until children are able to understand the implications of the results and (optimally) can give informed consent for testing [<a class="bk_pop" href="#ptt.REF.chalmers.2011">Chalmers et al 2011</a>].</p><p>See <a href="#ptt.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ptt.Pregnancy_Management"><h3>Pregnancy Management</h3><p>No consensus exists on the optimal management of prothrombin thrombophilia during pregnancy; guidelines are derived from studies in non-pregnant individuals [<a class="bk_pop" href="#ptt.REF.kujovich.2004a.443">Kujovich 2004a</a>, <a class="bk_pop" href="#ptt.REF12">Royal College of Obstetricians and Gynaecologists 2009</a>, <a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>]; see <a href="#ptt.References">Published Guidelines / Consensus Statements</a>. LMWH is the preferred antithrombotic agent for prophylaxis during pregnancy. All women with inherited thrombophilia should undergo individualized risk assessment. Decisions about anticoagulation should be based on the number and type of thrombophilic defects, coexisting risk factors, and personal and family history of thrombosis [<a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</p><p><b>Prophylactic anticoagulation</b> during pregnancy:</p><ul><li class="half_rhythm"><div>Is recommended for all women:</div><ul><li class="half_rhythm"><div>With a history of unprovoked VTE, including those <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A. LMWH should be given during pregnancy followed by six weeks of postpartum anticoagulation [<a class="bk_pop" href="#ptt.REF12">Royal College of Obstetricians and Gynaecologists 2009</a>, <a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</div></li><li class="half_rhythm"><div>Heterozygous for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with a prior pregnancy or estrogen-related thrombosis who are also at an increased risk for recurrence [<a class="bk_pop" href="#ptt.REF.pabinger.2005.949">Pabinger et al 2005</a>, <a class="bk_pop" href="#ptt.REF.de_stefano.2006.386">De Stefano et al 2006</a>, <a class="bk_pop" href="#ptt.REF12">Royal College of Obstetricians and Gynaecologists 2009</a>, <a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</div></li></ul></li><li class="half_rhythm"><div>Should be considered for:</div><ul><li class="half_rhythm"><div>Asymptomatic women doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A and factor V Leiden, especially those with coexisting circumstantial risk factors (obesity, immobilization, multiple gestation) [<a class="bk_pop" href="#ptt.REF12">Royal College of Obstetricians and Gynaecologists 2009</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>];</div></li><li class="half_rhythm"><div>Asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> women with a family history of thrombosis [<a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</div></li></ul></li><li class="half_rhythm"><div>Is not routinely recommended in asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women with no history of thrombosis or other risk factors. These women should be counseled about potential thrombotic complications during pregnancy and the postpartum period [<a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</div><ul><li class="half_rhythm"><div>In two large prospective studies, low-risk asymptomatic women with thrombophilia (including 20210G&#x0003e;A heterozygosity) did not receive LMWH during pregnancy in the absence of additional risk factors. All women received a course of postpartum anticoagulation. The low incidence of antepartum VTE in both studies (0% and 0.34%) suggested that anticoagulation may be safely withheld during pregnancy in low-risk 20210G&#x0003e;A heterozygotes who do not have other risk factors [<a class="bk_pop" href="#ptt.REF.bauersachs.2007.1237">Bauersachs et al 2007</a>, <a class="bk_pop" href="#ptt.REF.dargaud.2009.825">Dargaud et al 2009</a>].</div></li></ul></li></ul><p><b>A six-week course of postpartum prophylactic anticoagulation</b> is recommended for:</p><ul><li class="half_rhythm"><div>Heterozygous women with a positive family history of VTE or other additional risk factors;</div></li><li class="half_rhythm"><div>All asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> women;</div></li><li class="half_rhythm"><div>All women with a prior history of VTE [<a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</div></li></ul><p><b>Prevention of pregnancy loss.</b> It is still unkown if prophylactic antithrombotic therapy improves pregnancy outcome in women with inherited thrombophilia and recurrent pregnancy loss. The available evidence consists of predominantly uncontrolled trials, observational studies, and a few randomized trials with important methodologic limitations. There are no prospective randomized trials that include an untreated control group that confirms the benefit of LMWH for preventing pregnancy loss in women with inherited thrombophilia. Of note, the ALIFE2 study, a multicenter randomized trial of LMWH versus standard surveillance in women with inherited thrombophilia and a history of recurrent miscarriage, began recruitment in December 2012 (<a href="http://www.trialregister.nl" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.trialregister.nl</a>, NTR 3361).</p><p>Current consensus <a href="#ptt.References">guidelines</a> and expert opinion recommend against the use of antithrombotic therapy in women with inherited thrombophilia and unexplained recurrent pregnancy loss outside of clinical trials because of the absence of high quality evidence confirming benefit [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF245">Royal College of Obstetricians and Gynaecologists 2011a</a>, <a class="bk_pop" href="#ptt.REF247">Royal College of Obstetricians and Gynaecologists 2011b</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>, <a class="bk_pop" href="#ptt.REF.middeldorp.2013.180">Middeldorp 2013</a>].</p><p>Studies suggesting that prophylactic anticoagulation improves pregnancy outcome:</p><ul><li class="half_rhythm"><div>The results of several observational studies suggested that prophylactic antithrombotic therapy may improve pregnancy outcome in women with inherited thrombophilia and recurrent pregnancy loss [<a class="bk_pop" href="#ptt.REF.brenner.2000.693">Brenner et al 2000</a>, <a class="bk_pop" href="#ptt.REF.carp.2003.433">Carp et al 2003</a>].</div></li><li class="half_rhythm"><div>A recent study of women with a history of unexplained pregnancy loss compared the frequency of obstetric complications in women with factor V Leiden or 20210G&#x0003e;A alleles and women without thrombophilia. Women with a thrombophilic disorder with a prior fetal loss after ten weeks&#x02019; gestation who received enoxaparin during their next pregnancy had a significantly lower rate of fetal loss and severe preeclampsia and a higher rate of live births compared to women without a thrombophilic disorder with the same obstetric history who did not receive prophylaxis [<a class="bk_pop" href="#ptt.REF.bouvier.2014.404">Bouvier et al 2014</a>].</div></li><li class="half_rhythm"><div>A prospective randomized trial compared prophylactic-dose enoxaparin and low-dose aspirin in women <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for 20210G&#x0003e;A, factor V Leiden, or protein S deficiency, and a history of a single unexplained fetal loss after ten weeks&#x02019; gestation. Enoxaparin prophylaxis was associated with a significantly higher live birth rate of 86% compared to 29% with aspirin. However, there were methodologic problems with this study and the results have not been confirmed in other trials.</div></li></ul><p>Studies suggesting that prophylactic anticoagulation does not improve pregnancy outcome:</p><ul><li class="half_rhythm"><div>Several studies found no benefit with LMWH on pregnancy outcome in women with inherited thrombophilia [<a class="bk_pop" href="#ptt.REF.laskin.2009.279">Laskin et al 2009</a>, <a class="bk_pop" href="#ptt.REF.warren.2009.281.e1">Warren et al 2009</a>, <a class="bk_pop" href="#ptt.REF.visser.2011.295">Visser et al 2011</a>].</div></li><li class="half_rhythm"><div>Two recent randomized trials compared the efficacy of LMWH and aspirin to no antithrombotic therapy or placebo in women with unexplained recurrent pregnancy loss. Combined LMWH and low-dose aspirin did not increase the live birth rate in either study [<a class="bk_pop" href="#ptt.REF.clark.2010.4162">Clark et al 2010</a>, <a class="bk_pop" href="#ptt.REF.kaandorp.2010.1586">Kaandorp et al 2010</a>]. Because only a small proportion of the study populations had inherited thrombophilia (3.5% and 15.7%), subgroup analyses were insufficiently powered to assess the effect of antithrombotic therapy.</div></li><li class="half_rhythm"><div>In the recent Thrombophilia in Pregnancy Prophylaxis Study (TIPPS) multinational randomized trial, antepartum prophylactic LMWH did not reduce the incidence of pregnancy loss or placenta-mediated complications in pregnant women with thrombophilia (22% with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) who are at high risk for these complications [<a class="bk_pop" href="#ptt.REF.rodger.2014.1673">Rodger et al 2014</a>].</div></li></ul><p><b>Other pregnancy complications.</b> Data supporting the benefit of antithrombotic therapy in women with inherited thrombophilia and other pregnancy complications are considerably more limited and also conflicting [<a class="bk_pop" href="#ptt.REF.gris.2011.1053">Gris et al 2011</a>, <a class="bk_pop" href="#ptt.REF.de_vries.2012.64">de Vries et al 2012</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2012.3269">Martinelli et al 2012</a>]. There is insufficient evidence that LMWH (with or without aspirin) reduces the risk for preeclampsia, placental abruption, or other obstetric complications in women with or without inherited thrombophilia. Current <a href="#ptt.References">guidelines</a> recommend against antithrombotic prophylaxis for women with inherited thrombophilia and a history of pregnancy complications [<a class="bk_pop" href="#ptt.REF.baglin.2010">Baglin et al 2010</a>, <a class="bk_pop" href="#ptt.REF.bates.2012">Bates et al 2012</a>, <a class="bk_pop" href="#ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists 2013b</a>].</p></div><div id="ptt.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several new oral anticoagulants (which have not been specifically studied in individuals with inherited thrombophilia) are alternatives to warfarin in specific clinical settings.</p><p>Dabigatran (a direct thrombin inhibitor) and rivaroxaban and apixaban (two new factor Xa inhibitors) are approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation [<a class="bk_pop" href="#ptt.REF.weitz.2012">Weitz et al 2012</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ptt.Genetic_Counseling"><h2 id="_ptt_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ptt.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Prothrombin-related thrombophilia and an associated risk for thrombosis are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Individuals with one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> will have thrombophilia (a disorder of blood clottiing that predisposes to thrombosis) and an increased risk for thrombosis. Individuals with two mutated alleles will have thrombophilia and a higher risk of thrombosis than heterozygotes.</p></div><div id="ptt.Risk_to_Family_Members__Proband_Hete"><h3>Risk to Family Members &#x02013; Proband Heterozygous for the <i>F2</i> 20210G&#x0003e;A Allele</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>All individuals reported to date with prothrombin-related thrombophilia have had a parent who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>F2</i>
<a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Prothrombin-related thrombophilia as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been reported.</div></li><li class="half_rhythm"><div>Because of the relatively high prevalence of the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the general population, occasionally one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for this allele.</div></li></ul><p>Note: Although most individuals diagnosed with prothrombin-related thrombophilia have a parent who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If one parent of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is heterozygous, each sib of the proband has a 50% chance of being heterozygous for a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>If one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a>, all sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> will be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>If both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, a 50% chance of being heterozygous, and a 25% chance of inheriting both normal <i>F2</i> alleles.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has a 50% chance of inheriting the allele.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s reproductive partner is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, each offspring has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the 20210G&#x0003e;A allele, a 50% chance of being heterozygous for the 20210G&#x0003e;A allele, and a 25% chance of inheriting both normal <i>F2</i> alleles.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: the family members of a person who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are at risk.</p></div><div id="ptt.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the <i>F2</i> 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, possible non-medical explanations include <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption.</p><p><b>Testing of at-risk asymptomatic adults.</b> The presence of one or two 20210G&#x0003e;A alleles can be identified in asymptomatic at-risk family members using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. However, the indications for testing at-risk family members are unresolved (see <a href="#ptt.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>).</p><p><b>Testing of at-risk individuals during childhood.</b> Asymptomatic at-risk individuals younger than age 18 years are not usually tested because thrombosis rarely occurs before young adulthood, even in <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> individuals.</p><p>See also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p></div><div id="ptt.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>F2</i> 20210G&#x0003e;A variant has been identified in a family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>However, prenatal testing for the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is rarely (if ever) requested, as the disorder may never cause thrombosis and effective treatment is available. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ptt.Resources"><h2 id="_ptt_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Blood Clot Alliance</b></div><div>120 White Plains Road</div><div>Suite 100</div><div>Tarrytown NY 10591</div><div><b>Phone:</b> 877-466-2568 (toll-free); 914-220-5040</div><div><b>Email:</b> info@stoptheclot.org</div><div><a href="http://www.stoptheclot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.stoptheclot.org</a></div></li><li class="half_rhythm"><div><b>Thrombosis UK</b></div><div>PO Box 58</div><div>Llanwrda SA190AD</div><div>United Kingdom</div><div><b>Phone:</b> 0300 772 9603</div><div><b>Email:</b> admin@thrombosisuk.org</div><div><a href="https://www.thrombosisuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thrombosisuk.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Inherited%20thrombophilia&#x00026;parent=Disease%20Risk&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Inherited thrombophilia</a></div></li></ul></div><div id="ptt.Molecular_Genetics"><h2 id="_ptt_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ptt.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Prothrombin-Related Thrombophilia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1148/table/ptt.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ptt.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ptt.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ptt.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ptt.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ptt.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ptt.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ptt.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ptt.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2147" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>F2</i></a></td><td headers="hd_b_ptt.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2147" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ptt.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P00734" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Prothrombin</a></td><td headers="hd_b_ptt.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/F2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">F2 database</a></td><td headers="hd_b_ptt.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=F2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">F2</a></td><td headers="hd_b_ptt.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=F2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">F2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ptt.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ptt.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Prothrombin-Related Thrombophilia (<a href="/omim/176930,188050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1148/table/ptt.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ptt.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176930" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176930</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COAGULATION FACTOR II; F2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/188050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">188050</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>F2</i> has 14 exons (<a href="/nuccore/169808403" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000506.3</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1148/#ptt.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>.</b> Three allelic variants have uncertain clinical significance. Larger studies are needed to determine if they increase the risk for thrombosis in individuals with and without inherited thrombophilic disorders. Genetic testing for these variants is not routinely recommended.</p><ul><li class="half_rhythm"><div>19911A&#x0003e;G in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 13 is a mild independent risk factor for VTE. Data on the extent to which this variant increases the thrombotic risk in individuals with a 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are conflicting [<a class="bk_pop" href="#ptt.REF.p_rezceballos.2002.610">P&#x000e9;rez-Ceballos et al 2002</a>, <a class="bk_pop" href="#ptt.REF.chinthammitr.2006.2587">Chinthammitr et al 2006</a>, <a class="bk_pop" href="#ptt.REF.martinelli.2006.2582">Martinelli et al 2006</a>, <a class="bk_pop" href="#ptt.REF.gohil.2009.360">Gohil et al 2009</a>].</div></li><li class="half_rhythm"><div>20209C&#x0003e;T in the 3&#x02019; untranslated region of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is a rare variant of unclear significance reported primarily in individuals of African descent with a history of thrombosis or obstetric complications. Data as to whether this variant is an independent risk factor for thrombosis are conflicting [<a class="bk_pop" href="#ptt.REF.warshawsky.2002.152">Warshawsky et al 2002</a>, <a class="bk_pop" href="#ptt.REF.arya.2005.179">Arya 2005</a>, <a class="bk_pop" href="#ptt.REF.itakura.2005.2357">Itakura et al 2005</a>, <a class="bk_pop" href="#ptt.REF.danckwardt.2006.1078">Danckwardt et al 2006</a>, <a class="bk_pop" href="#ptt.REF.hooper.2006.767">Hooper et al 2006</a>, <a class="bk_pop" href="#ptt.REF.warshawsky.2009.1585">Warshawsky et al 2009</a>].</div></li><li class="half_rhythm"><div>1787G&#x0003e;T, a novel <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> muttion in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 14 results in a variant prothrombin (prothrombin Yukuhashi) with resistance to antithrombin and a resulting prothrombotic state. Prothrombin Yukuhashi (Arg596Leu) was identified in a thrombophilic Japanese family in which five members developed thrombosis at a very young age [<a class="bk_pop" href="#ptt.REF.miyawaki.2012.2390">Miyawaki et al 2012</a>].</div></li></ul><div id="ptt.T.selected_f2_variants_of_uncertain" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>F2</i> Variants of Uncertain Significance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1148/table/ptt.T.selected_f2_variants_of_uncertain/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ptt.T.selected_f2_variants_of_uncertain_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_2" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_3" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr><tr><th headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1" id="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alias&#x000a0;<sup>1</sup></th><th headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1" id="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard Nomenclature</th></tr></thead><tbody><tr><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1787G&#x0003e;T</td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg596Leu</td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/169808403" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000506<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/4503635" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000497<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20209C&#x0003e;T</td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.*96C&#x0003e;T&#x000a0;<sup>2</sup></td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td></tr><tr><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19911A&#x0003e;G</td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_1 hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1726-59G&#x0003e;A</td><td headers="hd_h_ptt.T.selected_f2_variants_of_uncertain_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ptt.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="ptt.TF.2.2"><p class="no_margin">* indicates that the variant is in the 3&#x02019; untranslated region of <i>F2</i>; 96 indicates that the variant is the 96th nucleotide 3&#x02019; of the translation stop codon. (Nucleotides are numbered *1, *2, etc.)</p></div></dd></dl></div></div></div><p><b>Pathogenic variant.</b> The 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is located in the 3' untranslated region of <i>F2</i> where it increases the efficiency and accuracy of processing of the 3' end of the <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (see <b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>).</p><p>Haplotype analysis of <i>F2</i> strongly suggests that the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was a single event that occurred 20,000 to 30,000 years ago, after the evolutionary separation of whites from Asians and Africans [<a class="bk_pop" href="#ptt.REF.zivelin.1998.1119">Zivelin et al 1998</a>]. A more recent analysis of single nucleotide polymorphisms (SNPs) and microsatellites flanking <i>F2</i> suggests that the variant arose 21,000-24,000 years ago in whites toward the end of the last glaciation [<a class="bk_pop" href="#ptt.REF.zivelin.2006.4666">Zivelin et al 2006</a>].</p><p>Although the high prevalence of the 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> among whites suggests a balanced nucleotide variant with some type of survival advantage associated with the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state, no such advantage has been confirmed. Some investigators speculate that the mild hypercoagulable state conferred by the allele may have had a beneficial effect in reducing mortality from bleeding associated with childbirth or trauma in premodern times [<a class="bk_pop" href="#ptt.REF.corral.2001.2979">Corral et al 2001</a>, <a class="bk_pop" href="#ptt.REF.mcglennen.2002.1319">McGlennen &#x00026; Key 2002</a>, <a class="bk_pop" href="#ptt.REF.zivelin.2006.4666">Zivelin et al 2006</a>].</p><div id="ptt.T.f2_pathogenic_variants_discussed_i" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>F2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ptt.T.f2_pathogenic_variants_discussed_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_3" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr><tr><th headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_1" id="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alias&#x000a0;<sup>1</sup></th><th headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_1" id="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard Nomenclature</th></tr></thead><tbody><tr><td headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_1 hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20210G&#x0003e;A or G20210A</td><td headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_1 hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.*97G&#x0003e;A&#x000a0;<sup>2</sup></td><td headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_ptt.T.f2_pathogenic_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/169808403" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000506<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/4503635" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000497<wbr style="display:inline-block"></wbr>​.1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ptt.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="ptt.TF.3.2"><p class="no_margin">* indicates that the variant is in the 3&#x02019; untranslated region of <i>F2</i>; 97 indicates that the variant is the 97th nucleotide 3&#x02019; of the translation stop codon. (Nucleotides are numbered *1, *2, etc.)</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Coagulation factor II (prothrombin) has 622 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The 20210G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is associated with elevated plasma levels of prothrombin [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.kyrle.1998.1287">Kyrle et al 1998</a>, <a class="bk_pop" href="#ptt.REF.simioni.1998.1045">Simioni et al 1998</a>, <a class="bk_pop" href="#ptt.REF.soria.2000.2780">Soria et al 2000</a>]. Experimental evidence suggests that the G&#x0003e;A transition increases the efficiency and accuracy of processing of the 3' end of the <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>, resulting in an accumulation of mRNA and increased synthesis of the protein prothrombin. The observation that elevated prothrombin levels independently increase the risk for thrombosis suggests that the allele may act through this mechanism [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.legnani.2003.112">Legnani et al 2003</a>]. The results of several experimental and clinical studies suggest that elevated prothrombin levels contribute to increased thrombin generation and a prothrombotic state, although other mechanisms may also be involved [<a class="bk_pop" href="#ptt.REF.kyrle.1998.1287">Kyrle et al 1998</a>, <a class="bk_pop" href="#ptt.REF.butenas.1999.2169">Butenas et al 1999</a>, <a class="bk_pop" href="#ptt.REF.lavignelissalde.2010.942">Lavigne-Lissalde et al 2010</a>].</p><p>Most <a class="figpopup" href="/books/NBK1148/table/ptt.T.f2_pathogenic_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figpttTf2pathogenicvariantsdiscussedi" rid-ob="figobpttTf2pathogenicvariantsdiscussedi">20210G&#x0003e;A</a> heterozygotes have a mildly elevated plasma concentration of prothrombin that is approximately 30% higher than healthy controls [<a class="bk_pop" href="#ptt.REF.poort.1996.3698">Poort et al 1996</a>, <a class="bk_pop" href="#ptt.REF.soria.2000.2780">Soria et al 2000</a>]. However, because the range of prothrombin concentrations in heterozygotes varies widely and overlaps significantly with the normal range, the plasma concentration of prothrombin is not reliable for diagnosis of prothrombin-related thrombophilia.</p><p>Individuals with one or two 20210G&#x0003e;A alleles often have elevated plasma levels of the prothrombin fragment F1+2, and other coagulation activation markers, reflecting the resulting mild hypercoagulable state [<a class="bk_pop" href="#ptt.REF.eikelboom.1999.1">Eikelboom et al 1999</a>, <a class="bk_pop" href="#ptt.REF.franco.1999.50">Franco et al 1999</a>, <a class="bk_pop" href="#ptt.REF.gouinthibault.2002.7">Gouin-Thibault et al 2002</a>].</p></div><div id="ptt.References"><h2 id="_ptt_References_">References</h2><div id="ptt.Published_Guidelines__Consensus_Stat"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.american_college_of_obstetricians_and_gynecologists_womens_health_care_physicians.2013.706">American College of Obstetricians and Gynecologists Women's Health Care Physicians.  Practice Bulletin No.138: Inherited thrombophilias in pregnancy. <span><span class="ref-journal">Obstet Gynecol. </span>2013;<span class="ref-vol">122</span>:706–17.</span> [<a href="/pubmed/23963422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23963422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.baglin.2010">Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Available <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.08022.x/pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 7-2-19. [<a href="/pubmed/20128794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20128794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bates.2012">Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012. [<a href="/pmc/articles/PMC3278054/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278054</span></a>] [<a href="/pubmed/22315276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.chalmers.2011">Chalmers E, Ganesen V, Liesner R, Maroo S, Nokes T, Saunders D, Williams M; British Committee for Standards in Haematology. Guideline on the investigation, management and prevention of venous thrombosis in children. Available <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08543.x/full" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 7-2-19. [<a href="/pubmed/21595646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21595646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF5">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 7-2-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF6">Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G&#x0003e;A) mutations in adults with a history of idiopathic VTE and their adult family members. Available <a href="http://www.nature.com/gim/journal/v13/n1/full/gim9201111a.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 7-2-19. [<a href="/pubmed/21150787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21150787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.guyatt.2012">Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu&#x000fc;nemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012. [<a href="/pmc/articles/PMC3278060/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278060</span></a>] [<a href="/pubmed/22315257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kearon.2012">Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9 ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012. [<a href="/pmc/articles/PMC3278049/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278049</span></a>] [<a href="/pubmed/22315268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.monagle.2012">Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-G&#x000f6;ttl U, Vesely SK; American College of Chest Physicians. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e737S-801S. [<a href="/pmc/articles/PMC3278066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278066</span></a>] [<a href="/pubmed/22315277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF10">National Clinical Guideline Centre. Venous Thromboembolic Diseases: Diagnosis, Management, and Thrombophilia Testing. National Institute for Health and Care Excellence Clinical Guidelines. Available <a href="https://www.nice.org.uk/guidance/cg144?unlid=72439559020161319738" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF11">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF12">Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline 37a. Available <a href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2009. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.spector.2005">Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G&#x0003e;A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. 2005;7:444-53. [<a href="/pubmed/16024978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16024978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tait.2012">Tait C, Baglin T, Watson H, Laffan M, Makris M, Perry D, Keeling D; British Committee for Standards in Haematology. Guidelines on the investigation and management of venous thrombosis at unusual sites. Available <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09249.x/full" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 7-2-19. [<a href="/pubmed/22881455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22881455</span></a>]</div></li></ul></div><div id="ptt.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.abramson.2006.904">Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of Factor V Leiden and prothrombin G20210--&#x0003e;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. <span><span class="ref-journal">J Natl Cancer Inst. </span>2006;<span class="ref-vol">98</span>:904–10.</span> [<a href="/pubmed/16818854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16818854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ageno.2012">Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-88S. [<a href="/pmc/articles/PMC3278051/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278051</span></a>] [<a href="/pubmed/22315269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.albisetti.2007.149">Albisetti M, Moeller A, Waldvogel K, Bernet-Buettiker V, Cannizzaro V, Anagnostopoulos A, Balmer C, Schmugge M. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. <span><span class="ref-journal">Acta Haematol. </span>2007;<span class="ref-vol">117</span>:149–55.</span> [<a href="/pubmed/17159337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17159337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.american_college_of_obstetricians_and_gynecologists.2013a.887">American College of Obstetricians and Gynecologists.  ACOG Committee Opinion No. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <span><span class="ref-journal">Obstet Gynecol. </span>2013a;<span class="ref-vol">121</span>:887–90.</span> [<a href="/pubmed/23635705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23635705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.american_college_of_obstetricians_and_gynecologists.2013b.706">American College of Obstetricians and Gynecologists.  Women's Health Care Physicians Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. <span><span class="ref-journal">Obstet Gynecol. </span>2013b;<span class="ref-vol">122</span>:706–17.</span> [<a href="/pubmed/23963422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23963422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.amitrano.2004.736">Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. <span><span class="ref-journal">J Hepatol. </span>2004;<span class="ref-vol">40</span>:736–41.</span> [<a href="/pubmed/15094219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15094219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.arya.2005.179">Arya R. Detection of prothrombin gene polymorphism at position 20209 (PT20209C/T): pilot study in a black population in the United Kingdom. <span><span class="ref-journal">Thromb Haemost. </span>2005;<span class="ref-vol">93</span>:179–80.</span> [<a href="/pubmed/15630510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15630510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.aznar.2004.1031">Aznar J, Mira Y, Vay&#x000e1; A, Corella D, Ferrando F, Villa P, Estell&#x000e9;s A. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. <span><span class="ref-journal">Thromb Haemost. </span>2004;<span class="ref-vol">91</span>:1031–4.</span> [<a href="/pubmed/15116266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15116266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.baglin.2010.209">Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H, et al.  Clinical guidelines for testing for heritable thrombophilia. British Committee for Standards in Haematology. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">149</span>:209–20.</span> [<a href="/pubmed/20128794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20128794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bank.2005.79">Bank I, Libourel EJ, Middeldorp S, Hamuly&#x000e1;k K, van Pampus EC, Koopman MM, Prins MH, van der Meer J, B&#x000fc;ller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. <span><span class="ref-journal">J Thromb Haemost. </span>2005;<span class="ref-vol">3</span>:79–84.</span> [<a href="/pubmed/15634269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15634269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bank.2004.1932">Bank I, Libourel EJ, Middeldorp S, Van Pampus EC, Koopman MM, Hamuly&#x000e1;k K, Prins MH, Van Der Meer J, B&#x000fc;ller HR. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. <span><span class="ref-journal">Arch Intern Med. </span>2004;<span class="ref-vol">164</span>:1932–7.</span> [<a href="/pubmed/15451770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15451770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.barcellona.2003.1061">Barcellona D, Fenu L, Cauli C, Pisu G, Marongiu F. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. <span><span class="ref-journal">Thromb Haemost. </span>2003;<span class="ref-vol">90</span>:1061–4.</span> [<a href="/pubmed/14652637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14652637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.barnes.2006.67">Barnes C, Deveber G. Prothrombotic abnormalities in childhood ischaemic stroke. <span><span class="ref-journal">Thromb Res. </span>2006;<span class="ref-vol">118</span>:67–74.</span> [<a href="/pubmed/16039697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16039697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.barrettconnor.2006.125">Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK., Raloxifene Use for The Heart (RUTH) Trial Investigators.  Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">355</span>:125–37.</span> [<a href="/pubmed/16837676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16837676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bates.2012_1">Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S-736S. [<a href="/pmc/articles/PMC3278054/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278054</span></a>] [<a href="/pubmed/22315276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bauer.2010.210">Bauer KA. Duration of anticoagulation: applying the guidelines and beyond. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2010:210–5.</span> [<a href="/pubmed/21239796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21239796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bauersachs.2007.1237">Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ, et al.  Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. <span><span class="ref-journal">Thromb Haemost. </span>2007;<span class="ref-vol">98</span>:1237–45.</span> [<a href="/pubmed/18064320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18064320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.benami.2002.57">Ben-Ami R, Zeltser D, Leibowitz I, Berliner SA. Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>2002;<span class="ref-vol">13</span>:57–9.</span> [<a href="/pubmed/11994569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11994569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.benedetto.2002.1095">Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. <span><span class="ref-journal">Acta Obstet Gynecol Scand. </span>2002;<span class="ref-vol">81</span>:1095–100.</span> [<a href="/pubmed/12519104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12519104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bereczky.2011.305">Bereczky Z, Muszbek L. Factor XIII and venous thromboembolism. <span><span class="ref-journal">Semin Thromb Hemost. </span>2011;<span class="ref-vol">37</span>:305–14.</span> [<a href="/pubmed/21455864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21455864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.berg.2011.67">Berg AO, Botkin J, Calonge N, Campos-Outcalt D, Haddow JE, Hayes M, Kaye C, Klein RD, Offit K, Pauker SG, Piper M, Richards CS, Scott JA, Strickland OL, Teutsch S, Veenstra DL, et al.  Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G&#x0003e;A) mutations in adults with a history of idiopathic VTE and their adult family members. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:67–76.</span> [<a href="/pubmed/21150787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21150787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bezemer.2008.1306">Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. <span><span class="ref-journal">JAMA. </span>2008;<span class="ref-vol">299</span>:1306–14.</span> [<a href="/pubmed/18349091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18349091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bezemer.2007.497">Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C-&#x0003e;T polymorphism and venous thrombosis: results from the MEGA study. <span><span class="ref-journal">Arch Intern Med. </span>2007;<span class="ref-vol">167</span>:497–501.</span> [<a href="/pubmed/17353498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17353498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bezemer.2009.610">Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. <span><span class="ref-journal">Arch Intern Med. </span>2009;<span class="ref-vol">169</span>:610–5.</span> [<a href="/pubmed/19307525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19307525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bloemenkamp.2000.49">Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. <span><span class="ref-journal">Arch Intern Med. </span>2000;<span class="ref-vol">160</span>:49–52.</span> [<a href="/pubmed/10632304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10632304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.blom.2005a.2471">Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. <span><span class="ref-journal">J Thromb Haemost. </span>2005a;<span class="ref-vol">3</span>:2471–8.</span> [<a href="/pubmed/16241945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16241945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.blom.2005b.715">Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. <span><span class="ref-journal">JAMA. </span>2005b;<span class="ref-vol">293</span>:715–22.</span> [<a href="/pubmed/15701913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15701913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bolaman.2009.11">Bolaman Z, Ozkul A, Kiylioglu N, Kadikoylu G, Erturk A, Batun S, Akyol A. Hereditary thrombophilic factors in stroke due to cerebral infarct. <span><span class="ref-journal">Am J Med Sci. </span>2009;<span class="ref-vol">337</span>:11–3.</span> [<a href="/pubmed/19263510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19263510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bonduel.2003.81">Bonduel M, Sciuccati G, Hepner M, Pieroni G, Torres AF, Mardaraz C, Frontroth JP. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. <span><span class="ref-journal">Am J Hematol. </span>2003;<span class="ref-vol">73</span>:81–6.</span> [<a href="/pubmed/12749008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12749008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bouvier.2014.404">Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP, Mar&#x000e8;s P, Gris JC. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:404–13.</span> [<a href="/pubmed/24200687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24200687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.bovill.2000.366">Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. <span><span class="ref-journal">Thromb Haemost. </span>2000;<span class="ref-vol">83</span>:366–70.</span> [<a href="/pubmed/10744139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10744139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.brenner.2000.693">Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. <span><span class="ref-journal">Thromb Haemost. </span>2000;<span class="ref-vol">83</span>:693–7.</span> [<a href="/pubmed/10823264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10823264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.brilledwards.2000.1439">Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">343</span>:1439–44.</span> [<a href="/pubmed/11078768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11078768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.butenas.1999.2169">Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. <span><span class="ref-journal">Blood. </span>1999;<span class="ref-vol">94</span>:2169–78.</span> [<a href="/pubmed/10498586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10498586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.canonico.2010.340">Canonico M, Fournier A, Carcaillon L, Oli&#x000e9; V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>2010;<span class="ref-vol">30</span>:340–5.</span> [<a href="/pubmed/19834106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19834106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.canonico.2007.840">Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, L&#x000e9;vesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, et al.  Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. <span><span class="ref-journal">Circulation. </span>2007;<span class="ref-vol">115</span>:840–5.</span> [<a href="/pubmed/17309934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17309934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.canonico.2008.1227">Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. <span><span class="ref-journal">BMJ. </span>2008;<span class="ref-vol">336</span>:1227–31.</span> [<a href="/pmc/articles/PMC2405857/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2405857</span></a>] [<a href="/pubmed/18495631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18495631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.canonico.2011.354">Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. <span><span class="ref-journal">Maturitas. </span>2011;<span class="ref-vol">70</span>:354–60.</span> [<a href="/pubmed/22024394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22024394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.carp.2003.433">Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:433–8.</span> [<a href="/pubmed/12871446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.casas.2004.1652">Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1652–61.</span> [<a href="/pubmed/15534175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15534175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.chalmers.2011.196">Chalmers E, Ganesen V, Liesner R, Maroo S, Nokes T, Saunders D, Williams M, et al.  Guideline on the investigation, management and prevention of venous thrombosis in children. British Committee for Standards in Haematology. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">154</span>:196–207.</span> [<a href="/pubmed/21595646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21595646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.chang.2009.54">Chang MH, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, Moonesinghe R, Moore CA, Ned RM, Reichler MR, Sanders CL, Welch R, Yesupriya A, Khoury MJ, et al.  Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. <span><span class="ref-journal">Am J Epidemiol. </span>2009;<span class="ref-vol">169</span>:54–66.</span> [<a href="/pmc/articles/PMC2638878/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2638878</span></a>] [<a href="/pubmed/18936436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18936436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.chinthammitr.2006.2587">Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJ. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. <span><span class="ref-journal">J Thromb Haemost. </span>2006;<span class="ref-vol">4</span>:2587–92.</span> [<a href="/pubmed/17059428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17059428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.christiansen.2005.2352">Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. <span><span class="ref-journal">JAMA. </span>2005;<span class="ref-vol">293</span>:2352–61.</span> [<a href="/pubmed/15900005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15900005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.clark.2010.4162">Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, Greer IA, et al.  SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:4162–7.</span> [<a href="/pubmed/20237316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20237316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.cohn.2012.cd007069">Cohn DM, Vansenne F, de Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2012;<span class="ref-vol">12</span>:CD007069.</span> [<a href="/pubmed/23235639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23235639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.cole.2007.339">Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. <span><span class="ref-journal">Obstet Gynecol. </span>2007;<span class="ref-vol">109</span>:339–46.</span> [<a href="/pubmed/17267834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17267834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.conard.2004.437">Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. <span><span class="ref-journal">Contraception. </span>2004;<span class="ref-vol">70</span>:437–41.</span> [<a href="/pubmed/15541404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15541404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.coppens.2007.1444">Coppens M, Folkeringa N, Teune MJ, Hamuly&#x000e1;k K, van der Meer J, Prins MH, B&#x000fc;ller HR, Middeldorp S. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. <span><span class="ref-journal">J Thromb Haemost. </span>2007;<span class="ref-vol">5</span>:1444–8.</span> [<a href="/pubmed/17439630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17439630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.coppens.2006.2604">Coppens M, van de Poel MH, Bank I, Hamulyak K, van der Meer J, Veeger NJ, Prins MH, Buller HR, Middeldorp S. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">108</span>:2604–7.</span> [<a href="/pubmed/16778142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16778142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.corral.2001.2979">Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:2979–82.</span> [<a href="/pubmed/11342420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11342420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.couturaud.2009.1537">Couturaud F, Leroyer C, Julian JA, Kahn SR, Ginsberg JS, Wells PS, Douketis JD, Mottier D, Kearon C. Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. <span><span class="ref-journal">Chest. </span>2009;<span class="ref-vol">136</span>:1537–45.</span> [<a href="/pubmed/19592474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19592474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.cummings.1999.2189">Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. <span><span class="ref-journal">JAMA. </span>1999;<span class="ref-vol">281</span>:2189–97.</span> [<a href="/pubmed/10376571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10376571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.cushman.2009.2878">Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>:2878–83.</span> [<a href="/pmc/articles/PMC2756198/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756198</span></a>] [<a href="/pubmed/19617576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19617576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.danckwardt.2006.1078">Danckwardt S, Hartmann K, Katz B, Hentze MW, Levy Y, Eichele R, Deutsch V, Kulozik AE, Ben-Tal O. The prothrombin 20209 C--&#x0003e;T mutation in Jewish-Moroccan Caucasians: molecular analysis of gain-of-function of 3' end processing. <span><span class="ref-journal">J Thromb Haemost. </span>2006;<span class="ref-vol">4</span>:1078–85.</span> [<a href="/pubmed/16689762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16689762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dargaud.2009.825">Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C, Bestion A, Desmurs-Clavel H, Ninet J, Gaucherand P, Rudigoz RC, Berland M, Champion F, Trzeciak MC. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">145</span>:825–35.</span> [<a href="/pubmed/19388925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19388925</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_stefano.1998.3562">De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. <span><span class="ref-journal">Blood. </span>1998;<span class="ref-vol">91</span>:3562–5.</span> [<a href="/pubmed/9572989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9572989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_stefano.1999.801">De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. <span><span class="ref-journal">N Engl J Med. </span>1999;<span class="ref-vol">341</span>:801–6.</span> [<a href="/pubmed/10477778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10477778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_stefano.2001.630">De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Rossi E, Chiusolo P, Casorelli I, Leone G. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. <span><span class="ref-journal">Br J Haematol. </span>2001;<span class="ref-vol">113</span>:630–5.</span> [<a href="/pubmed/11380448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11380448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_stefano.2006.386">De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio Mannucci P, Leone G. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. <span><span class="ref-journal">Br J Haematol. </span>2006;<span class="ref-vol">135</span>:386–91.</span> [<a href="/pubmed/16984390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16984390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_stefano.2013.697">De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. <span><span class="ref-journal">Thromb Haemost. </span>2013;<span class="ref-vol">110</span>:697–705.</span> [<a href="/pubmed/23846575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23846575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.de_vries.2012.64">de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH. FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. <span><span class="ref-journal">J Thromb Haemost. </span>2012;<span class="ref-vol">10</span>:64–72.</span> [<a href="/pubmed/22118560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22118560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.decousus.2007.s51">Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S, Mismetti P. Thrombophilia and risk of venous thrombosis in patients with cancer. <span><span class="ref-journal">Thromb Res. </span>2007;<span class="ref-vol">120</span> Suppl 2:S51–61.</span> [<a href="/pubmed/18023713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18023713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.den_heijer.2005.292">Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. <span><span class="ref-journal">J Thromb Haemost. </span>2005;<span class="ref-vol">3</span>:292–9.</span> [<a href="/pubmed/15670035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15670035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.den_heijer.2007.139">den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:139–44.</span> [<a href="/pubmed/16960155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16960155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dentali.2006.2766">Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:2766–73.</span> [<a href="/pubmed/16397131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16397131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dentali.2008a.675">Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. <span><span class="ref-journal">Thromb Haemost. </span>2008a;<span class="ref-vol">99</span>:675–82.</span> [<a href="/pubmed/18392325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18392325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dentali.2008b.70">Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. <span><span class="ref-journal">J Thromb Haemost. </span>2008b;<span class="ref-vol">6</span>:70–5.</span> [<a href="/pubmed/17988232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17988232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dentali.2012.1297">Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, Vedovati MC, Ageno W, Falanga A, Lerede T, Bianchi M, Testa S, Witt D, McCool K, Bucherini E, Grifoni E, Coalizzo D, Benedetti R, Marietta M, Sessa M, Guaschino C, di Minno G, Tufano A, Barbar S, Malato A, Pini M, Castellini P, Barco S, Barone M, Paciaroni M, Alberti A, Agnelli G, Pierfranceschi MG, Dulicek P, Silingardi M, Federica L, Ghirarduzzi A, Tiraferri E, di Lazzaro V, Rossi E, Ciminello A, Pasca S, Barillari G, Rezoagli E, Galli M, Squizzato A, Tosetto A, et al.  Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <span><span class="ref-journal">J Thromb Haemost. </span>2012;<span class="ref-vol">10</span>:1297–302.</span> [<a href="/pubmed/22578023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22578023</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.desancho.2010.11">DeSancho MT, Berlus N, Christos PJ, Rand J. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>2010;<span class="ref-vol">21</span>:11–5.</span> [<a href="/pubmed/19474699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19474699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.deveber.2001.417">deVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ, Camfield CS, David M, Humphreys P, Langevin P, MacDonald EA, Gillett J, Meaney B, Shevell M, Sinclair DB, Yager J., Canadian Pediatric Ischemic Stroke Study Group.  Cerebral sinovenous thrombosis in children. <span><span class="ref-journal">N Engl J Med. </span>2001;<span class="ref-vol">345</span>:417–23.</span> [<a href="/pubmed/11496852" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11496852</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dilley.1998.452">Dilley A, Austin H, Hooper WC, El-Jamil M, Whitsett C, Wenger NK, Benson J, Evatt B. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. <span><span class="ref-journal">J Lab Clin Med. </span>1998;<span class="ref-vol">132</span>:452–5.</span> [<a href="/pubmed/9851733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9851733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dore.2010.408">Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. <span><span class="ref-journal">Contraception. </span>2010;<span class="ref-vol">81</span>:408–13.</span> [<a href="/pubmed/20399947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20399947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dowling.2003.80">Dowling NF, Austin H, Dilley A, Whitsett C, Evatt BL, Hooper WC. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:80–7.</span> [<a href="/pubmed/12871543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.dudding.2008.1869">Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, Ring SM, Attia J, Scott RJ. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. <span><span class="ref-journal">J Thromb Haemost. </span>2008;<span class="ref-vol">6</span>:1869–75.</span> [<a href="/pubmed/18752569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18752569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.duggan.2003.3588">Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. <span><span class="ref-journal">J Clin Oncol. </span>2003;<span class="ref-vol">21</span>:3588–93.</span> [<a href="/pubmed/14512389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14512389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ehrenforth.1999.276">Ehrenforth S, von Depka Prondsinski M, Aygoren-Pursun E, Nowak-Gottl U, Scharrer I, Ganser A. Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1999;<span class="ref-vol">19</span>:276–80.</span> [<a href="/pubmed/9974407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9974407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.eichinger.2009.291">Eichinger S, Kyrle PA. Duration of anticoagulation after initial idiopathic venous thrombosis--the swinging pendulum: risk assessment to predict recurrence. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span> Suppl 1:291–5.</span> [<a href="/pubmed/19630819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19630819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.eichinger.1999.14">Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stumpflen A, Schneider B, Lechner K, Kyrle PA. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. <span><span class="ref-journal">Thromb Haemost. </span>1999;<span class="ref-vol">81</span>:14–7.</span> [<a href="/pubmed/10348706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10348706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.eikelboom.1999.1">Eikelboom JW, Ivey L, Ivey J, Baker RI. Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>1999;<span class="ref-vol">10</span>:1–5.</span> [<a href="/pubmed/10070829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10070829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.emmerich.2001.809">Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. <span><span class="ref-journal">Thromb Haemost. </span>2001;<span class="ref-vol">86</span>:809–16.</span> [<a href="/pubmed/11583312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11583312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.eroglu.2007.31">Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. <span><span class="ref-journal">J Thromb Thrombolysis. </span>2007;<span class="ref-vol">23</span>:31–4.</span> [<a href="/pubmed/17106650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17106650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.facchinetti.2009.46.e1">Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, Zatti S, Benedetto C. Maternal thrombophilia and the risk of recurrence of preeclampsia. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2009;<span class="ref-vol">200</span>:46.e1–5.</span> [<a href="/pubmed/18845284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18845284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.facco.2009.1206">Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. <span><span class="ref-journal">Obstet Gynecol. </span>2009;<span class="ref-vol">113</span>:1206–16.</span> [<a href="/pubmed/19461414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19461414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.farge.2013.56">Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, B&#x000fc;ller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <span><span class="ref-journal">J Thromb Haemost. </span>2013;<span class="ref-vol">11</span>:56–70.</span> [<a href="/pubmed/23217107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23217107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ferraresi.1997.2418">Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1997;<span class="ref-vol">17</span>:2418–22.</span> [<a href="/pubmed/9409210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9409210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.franco.1999.50">Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. The 20210 G--&#x0003e;A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. <span><span class="ref-journal">Br J Haematol. </span>1999;<span class="ref-vol">104</span>:50–4.</span> [<a href="/pubmed/10027711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10027711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.funai.2009.121">Funai EF. Inherited thrombophilia and preeclampsia: is the evidence beginning to congeal? <span><span class="ref-journal">Am J Obstet Gynecol. </span>2009;<span class="ref-vol">200</span>:121–2.</span> [<a href="/pubmed/19185098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19185098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.galli.2003.1827">Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:1827–32.</span> [<a href="/pubmed/12393574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12393574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.garcia.2012">Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S-43S. [<a href="/pmc/articles/PMC3278070/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278070</span></a>] [<a href="/pubmed/22315264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gerhardt.2000.374">Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:374–80.</span> [<a href="/pubmed/10666427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10666427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gerhardt.2003.77">Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. <span><span class="ref-journal">Thromb Haemost. </span>2003;<span class="ref-vol">90</span>:77–85.</span> [<a href="/pubmed/12876629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12876629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.germain.2011.e25581">Germain M, Saut N, Greliche N, Dina C, Lambert JC, Perret C, Cohen W, Oudot-Mellakh T, Antoni G, Alessi MC, Zelenika D, Cambien F, Tiret L, Bertrand M, Dupuy AM, Letenneur L, Lathrop M, Emmerich J, Amouyel P, Tr&#x000e9;gou&#x000eb;t DA, Morange PE. Genetics of venous thrombosis: insights from a new genome wide association study. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e25581.</span> [<a href="/pmc/articles/PMC3181335/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3181335</span></a>] [<a href="/pubmed/21980494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21980494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ghisdal.2010.99">Ghisdal L, Broeders N, Wissing KM, Saidi A, Bensalem T, Mbaba Mena J, Lemy A, Wijns W, Pradier O, Hoang AD, Mikhalski D, Donckier V, Cochaux P, El Housni H, Abramowicz M, Vereerstraeten P, Abramowicz D. Thrombophilic factors do not predict outcomes in renal transplant recipients under prophylactic acetylsalicylic acid. <span><span class="ref-journal">Am J Transplant. </span>2010;<span class="ref-vol">10</span>:99–105.</span> [<a href="/pubmed/19845577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19845577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.glueck.2009.12">Glueck CJ, Wang P. Ocular vascular thrombotic events: a diagnostic window to familial thrombophilia (compound factor V Leiden and prothrombin gene heterozygosity) and thrombosis. <span><span class="ref-journal">Clin Appl Thromb Hemost. </span>2009;<span class="ref-vol">15</span>:12–8.</span> [<a href="/pubmed/18796459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18796459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gohil.2009.360">Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. <span><span class="ref-journal">Thromb Haemost. </span>2009;<span class="ref-vol">102</span>:360–70.</span> [<a href="/pubmed/19652888" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19652888</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gonz_lezporras.2006.23">Gonz&#x000e1;lez-Porras JR, Garc&#x000ed;a-Sanz R, Alberca I, L&#x000f3;pez ML, Balanzategui A, Gutierrez O, Lozano F, San Miguel J. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>2006;<span class="ref-vol">17</span>:23–8.</span> [<a href="/pubmed/16607075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16607075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gouinthibault.2002.7">Gouin-Thibault I, Arkam R, Nassiri S, de la Tourette A, Conard J, Horellou MH, Elalamy I, Samama MM. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. <span><span class="ref-journal">Thromb Res. </span>2002;<span class="ref-vol">107</span>:7–11.</span> [<a href="/pubmed/12413582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12413582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.grady.2000.689">Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. <span><span class="ref-journal">Ann Intern Med. </span>2000;<span class="ref-vol">132</span>:689–96.</span> [<a href="/pubmed/10787361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10787361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.grandone.1998.1324">Grandone E, Margaglione M, Colaizzo D, D'Andrea G, Cappucci G, Brancaccio V, Di Minno G. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. <span><span class="ref-journal">Am J Obstet Gynecol. </span>1998;<span class="ref-vol">179</span>:1324–8.</span> [<a href="/pubmed/9822524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9822524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.gris.2011.1053">Gris JC, Chauleur C, Molinari N, Mar&#x000e8;s P, Fabbro-Peray P, Qu&#x000e9;r&#x000e9; I, Lefrant JY, Haddad B, Dauzat M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. <span><span class="ref-journal">Thromb Haemost. </span>2011;<span class="ref-vol">106</span>:1053–61.</span> [<a href="/pubmed/21946915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21946915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.guyatt.2012_1">Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu&#x000fc;nemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S. [<a href="/pmc/articles/PMC3278060/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278060</span></a>] [<a href="/pubmed/22315257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.haywood.2005.402">Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. <span><span class="ref-journal">Arch Dis Child. </span>2005;<span class="ref-vol">90</span>:402–5.</span> [<a href="/pmc/articles/PMC1720343/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1720343</span></a>] [<a href="/pubmed/15781933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15781933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.heleen_van_ommen.2011.794">Heleen van Ommen C, Middeldorp S. Thrombophilia in childhood: to test or not to test. <span><span class="ref-journal">Semin Thromb Hemost. </span>2011;<span class="ref-vol">37</span>:794–801.</span> [<a href="/pubmed/22187402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22187402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.heller.2003.1362">Heller C, Heinecke A, Junker R, Knofler R, Kosch A, Kurnik K, Schobess R, von Eckardstein A, Strater R, Zieger B, Nowak-Gottl U. Cerebral venous thrombosis in children: a multifactorial origin. <span><span class="ref-journal">Circulation. </span>2003;<span class="ref-vol">108</span>:1362–7.</span> [<a href="/pubmed/12939214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12939214</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.hicks.2013.9">Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA. The ASH Choosing Wisely&#x000ae; campaign: five hematologic tests and treatments to question. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2013;<span class="ref-vol">2013</span>:9–14.</span> [<a href="/pubmed/24319155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24319155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.hindorff.2006.600">Hindorff LA, Psaty BM, Carlson CS, Heckbert SR, Lumley T, Smith NL, Lemaitre RN, Rieder MJ, Nickerson DA, Reiner AP. Common genetic variation in the prothrombin gene, hormone therapy, and incident nonfatal myocardial infarction in postmenopausal women. <span><span class="ref-journal">Am J Epidemiol. </span>2006;<span class="ref-vol">163</span>:600–7.</span> [<a href="/pubmed/16467413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16467413</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ho.2006.729">Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. <span><span class="ref-journal">Arch Intern Med. </span>2006;<span class="ref-vol">166</span>:729–36.</span> [<a href="/pubmed/16606808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16606808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.hooper.2006.767">Hooper WC, Roberts S, Dowling N, Austin H, Lally C, Whitsett C. The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venous thromboembolism. <span><span class="ref-journal">Thromb Res. </span>2006;<span class="ref-vol">118</span>:767–8.</span> [<a href="/pubmed/16469364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16469364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.howard.2013.391">Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. <span><span class="ref-journal">Thorax. </span>2013;<span class="ref-vol">68</span>:391–3.</span> [<a href="/pubmed/23234857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23234857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.howley.2005.694">Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2005;<span class="ref-vol">192</span>:694–708.</span> [<a href="/pubmed/15746660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15746660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.infanterivard.2002.19">Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca JC. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">347</span>:19–25.</span> [<a href="/pubmed/12097536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12097536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.itakura.2005.2357">Itakura H, Telen MJ, Hoppe CC, White DA, Zehnder JL. Characterization of a novel prothrombin variant, Prothrombin C20209T, as a modifier of thrombotic risk among African-Americans. <span><span class="ref-journal">J Thromb Haemost. </span>2005;<span class="ref-vol">3</span>:2357–9.</span> [<a href="/pubmed/16194213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16194213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ivanov.2009.134">Ivanov PD, Komsa-Penkova RS, Konova EI, Kovacheva KS, Simeonova MN, Popov JD. Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>2009;<span class="ref-vol">20</span>:134–40.</span> [<a href="/pubmed/19786941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19786941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.jacobsen.2010.2443">Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. <span><span class="ref-journal">J Thromb Haemost. </span>2010;<span class="ref-vol">8</span>:2443–9.</span> [<a href="/pubmed/20735725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20735725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.james.2006.1311">James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2006;<span class="ref-vol">194</span>:1311–5.</span> [<a href="/pubmed/16647915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16647915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.janssen.2000.2364">Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">96</span>:2364–8.</span> [<a href="/pubmed/11001884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11001884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.janssen.2005.1021">Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. <span><span class="ref-journal">Thromb Haemost. </span>2005;<span class="ref-vol">93</span>:1021–6.</span> [<a href="/pubmed/15968383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15968383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.jenkins.2012.653">Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. <span><span class="ref-journal">Br J Haematol. </span>2012;<span class="ref-vol">157</span>:653–63.</span> [<a href="/pubmed/22530883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22530883</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.jick.2007.4">Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. <span><span class="ref-journal">Contraception. </span>2007;<span class="ref-vol">76</span>:4–7.</span> [<a href="/pubmed/17586129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17586129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.joachim.2013.170">Joachim E, Goldenberg NA, Bernard TJ, Armstrong-Wells J, Stabler S, Manco-Johnson MJ. The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C&#x0003e;T) and elevated plasma homocysteine levels in a U.S. pediatric population with incident thromboembolism. <span><span class="ref-journal">Thromb Res. </span>2013;<span class="ref-vol">132</span>:170–4.</span> [<a href="/pmc/articles/PMC4115647/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4115647</span></a>] [<a href="/pubmed/23866722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23866722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.joseph.2005.87">Joseph JE, Low J, Courtenay B, Neil MJ, McGrath M, Ma D. A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. <span><span class="ref-journal">Br J Haematol. </span>2005;<span class="ref-vol">129</span>:87–92.</span> [<a href="/pubmed/15801960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15801960</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.junker.1999.2568">Junker R, Koch HG, Auberger K, Munchow N, Ehrenforth S, Nowak-Gottl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1999;<span class="ref-vol">19</span>:2568–72.</span> [<a href="/pubmed/10521389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10521389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kaandorp.2010.1586">Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamuly&#x000e1;k K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, B&#x000fc;ller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">362</span>:1586–96.</span> [<a href="/pubmed/20335572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20335572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kahn.2009.151.e1">Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, Goulet L, Lydon J, Seguin L, Dassa C, Masse A, Asselin G, Benjamin A, Miner L, Ghanem A, Kramer MS. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2009;<span class="ref-vol">200</span>(2):151.e1–9.</span> [<a href="/pubmed/19070828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19070828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.karakantza.2008.124">Karakantza M, Androutsopoulos G, Mougiou A, Sakellaropoulos G, Kourounis G, Decavalas G. Inheritance and perinatal consequences of inherited thrombophilia in Greece. <span><span class="ref-journal">Int J Gynaecol Obstet. </span>2008;<span class="ref-vol">100</span>:124–9.</span> [<a href="/pubmed/17963764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17963764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kearon.2012_1">Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S-94S. [<a href="/pmc/articles/PMC3278049/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278049</span></a>] [<a href="/pubmed/22315268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kearon.2008.4432">Kearon C, Julian JA, Kovacs MJ, Anderson DR, Wells P, Mackinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, Ginsberg JS. ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">112</span>:4432–6.</span> [<a href="/pubmed/18791166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18791166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kenet.2010.1838">Kenet G, L&#x000fc;tkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, G&#x000fc;nther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rost&#x000e1;sy K, Simioni P, Str&#x000e4;ter RD, Young G, Nowak-G&#x000f6;ttl U. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. <span><span class="ref-journal">Circulation. </span>2010;<span class="ref-vol">121</span>:1838–47.</span> [<a href="/pubmed/20385928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20385928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kenet.2000.1283">Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. <span><span class="ref-journal">Stroke. </span>2000;<span class="ref-vol">31</span>:1283–8.</span> [<a href="/pubmed/10835445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10835445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kenet.2004.713">Kenet G, Waldman D, Lubetsky A, Kornbrut N, Khalil A, Koren A, Wolach B, Fattal A, Kapelushnik J, Tamary H, Yacobovitch J, Raveh E, Revel-Vilk S, Toren A, Brenner B. Paediatric cerebral sinus vein thrombosis. A multi-center, case-controlled study. <span><span class="ref-journal">Thromb Haemost. </span>2004;<span class="ref-vol">92</span>:713–8.</span> [<a href="/pubmed/15467900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15467900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kist.2008.77">Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JI. Thrombophilias and adverse pregnancy outcome - A confounded problem! <span><span class="ref-journal">Thromb Haemost. </span>2008;<span class="ref-vol">99</span>:77–85.</span> [<a href="/pubmed/18217138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18217138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kocher.2007.68">Kocher O, Cirovic C, Malynn E, Rowland CM, Bare LA, Young BA, Henslee JG, Laffler TG, Huff JB, Kruskall MS, Wong G, Bauer KA. Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. <span><span class="ref-journal">Am J Clin Pathol. </span>2007;<span class="ref-vol">127</span>:68–75.</span> [<a href="/pubmed/17145624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17145624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kohler.1998.8">Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. <span><span class="ref-journal">Thromb Haemost. </span>1998;<span class="ref-vol">79</span>:8–13.</span> [<a href="/pubmed/9459313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9459313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.koster.1995.152">Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. <span><span class="ref-journal">Lancet. </span>1995;<span class="ref-vol">345</span>:152–5.</span> [<a href="/pubmed/7823669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7823669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kovalevsky.2004.558">Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. <span><span class="ref-journal">Arch Intern Med. </span>2004;<span class="ref-vol">164</span>:558–63.</span> [<a href="/pubmed/15006834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15006834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kujovich.2004a.443">Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. <span><span class="ref-journal">Br J Haematol. </span>2004a;<span class="ref-vol">126</span>:443–54.</span> [<a href="/pubmed/15287937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15287937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kujovich.2004b.412">Kujovich JL. Thrombophilia and pregnancy complications. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2004b;<span class="ref-vol">191</span>:412–24.</span> [<a href="/pubmed/15343215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15343215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kujovich.2004c.959">Kujovich JL. Thrombophilia and thrombotic problems in renal transplant patients. <span><span class="ref-journal">Transplantation. </span>2004c;<span class="ref-vol">77</span>:959–64.</span> [<a href="/pubmed/15087754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15087754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kujovich.2011.1">Kujovich JL. Factor V Leiden thrombophilia. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:1–16.</span> [<a href="/pubmed/21116184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21116184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kupferminc.1999.9">Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. <span><span class="ref-journal">N Engl J Med. </span>1999;<span class="ref-vol">340</span>:9–13.</span> [<a href="/pubmed/9878639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9878639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kupferminc.2000a.45">Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. <span><span class="ref-journal">Obstet Gynecol. </span>2000a;<span class="ref-vol">96</span>:45–9.</span> [<a href="/pubmed/10862840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10862840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kupferminc.2002.1373">Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. <span><span class="ref-journal">BJOG. </span>2002;<span class="ref-vol">109</span>:1373–6.</span> [<a href="/pubmed/12504973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12504973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kupferminc.2000b.963">Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. <span><span class="ref-journal">Acta Obstet Gynecol Scand. </span>2000b;<span class="ref-vol">79</span>:963–7.</span> [<a href="/pubmed/11081681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11081681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kyrle.1998.1287">Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1998;<span class="ref-vol">18</span>:1287–91.</span> [<a href="/pubmed/9714136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9714136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kyrle.2000.457">Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">343</span>:457–62.</span> [<a href="/pubmed/10950667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10950667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.kyrle.2010.2032">Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">376</span>:2032–9.</span> [<a href="/pubmed/21131039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21131039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lalibert_.2011.1052">Lalibert&#x000e9; F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. <span><span class="ref-journal">Menopause. </span>2011;<span class="ref-vol">18</span>:1052–9.</span> [<a href="/pubmed/21775912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21775912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.laskin.2009.279">Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. <span><span class="ref-journal">J Rheumatol. </span>2009;<span class="ref-vol">36</span>:279–87.</span> [<a href="/pubmed/19208560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19208560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lauw.2013.913">Lauw MN, Barco S, Coutinho JM, Middeldorp S. Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis. <span><span class="ref-journal">Semin Thromb Hemost. </span>2013;<span class="ref-vol">39</span>:913–27.</span> [<a href="/pubmed/24129682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24129682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lavignelissalde.2010.942">Lavigne-Lissalde G, Sanchez C, Castelli C, Alonso S, Mazoyer E, Bal Dit Sollier C, Drouet L, Juhan-Vague I, Gris JC, Alessi MC, Morange PE. Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. <span><span class="ref-journal">J Thromb Haemost. </span>2010;<span class="ref-vol">8</span>:942–9.</span> [<a href="/pubmed/20096005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20096005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lechner.2008.1269">Lechner D, Wiener C, Weltermann A, Eischer L, Eichinger S, Kyrle PA. Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. <span><span class="ref-journal">J Thromb Haemost. </span>2008;<span class="ref-vol">6</span>:1269–74.</span> [<a href="/pubmed/18445117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18445117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.legnani.2003.112">Legnani C, Cosmi B, Valdr&#x000e8; L, Boggian O, Bernardi F, Coccheri S, Palareti G. Venous thromboembolism, oral contraceptives and high prothrombin levels. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:112–7.</span> [<a href="/pubmed/12871547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.legnani.2002.984">Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, Coccheri S. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. <span><span class="ref-journal">Eur Heart J. </span>2002;<span class="ref-vol">23</span>:984–90.</span> [<a href="/pubmed/12069454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12069454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.leroyer.1998.49">Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. <span><span class="ref-journal">Thromb Haemost. </span>1998;<span class="ref-vol">80</span>:49–51.</span> [<a href="/pubmed/9684784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9684784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lijfering.2009.5314">Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamuly&#x000e1;k K, Prins MH, B&#x000fc;ller HR, van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">113</span>:5314–22.</span> [<a href="/pubmed/19139080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19139080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lijfering.2010.1706">Lijfering WM, Middeldorp S, Veeger NJ, Hamuly&#x000e1;k K, Prins MH, B&#x000fc;ller HR, van der Meer J. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. <span><span class="ref-journal">Circulation. </span>2010;<span class="ref-vol">121</span>:1706–12.</span> [<a href="/pubmed/20368522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20368522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lin.2005.182">Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. <span><span class="ref-journal">Obstet Gynecol. </span>2005;<span class="ref-vol">105</span>:182–92.</span> [<a href="/pubmed/15625161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15625161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.lindmarker.1999.684">Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. <span><span class="ref-journal">Thromb Haemost. </span>1999;<span class="ref-vol">81</span>:684–9.</span> [<a href="/pubmed/10365737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10365737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.linnemann.2008a.440">Linnemann B, Meister F, Schwonberg J, Schindewolf M, Zgouras D, Lindhoff-Last E, et al.  Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. <span><span class="ref-journal">Thromb Haemost. </span>2008a;<span class="ref-vol">100</span>:440–6.</span> [<a href="/pubmed/18766260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18766260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.linnemann.2008b.743">Linnemann B, Schindewolf M, Zgouras D, Erbe M, Jarosch-Preusche M, Lindhoff-Last E. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis? <span><span class="ref-journal">Thromb Res. </span>2008b;<span class="ref-vol">121</span>:743–50.</span> [<a href="/pubmed/17804043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17804043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.makris.1997.1426">Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. <span><span class="ref-journal">Thromb Haemost. </span>1997;<span class="ref-vol">78</span>:1426–9.</span> [<a href="/pubmed/9423788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9423788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.many.2002.684">Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. <span><span class="ref-journal">Obstet Gynecol. </span>2002;<span class="ref-vol">99</span>:684–7.</span> [<a href="/pubmed/11978272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11978272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.marchiori.2007.1107">Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. <span><span class="ref-journal">Haematologica. </span>2007;<span class="ref-vol">92</span>:1107–14.</span> [<a href="/pubmed/17650440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17650440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.margaglione.1998.89">Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G. Increased risk for venous thrombosis in carriers of the prothrombin G--&#x0003e;A20210 gene variant. <span><span class="ref-journal">Ann Intern Med. </span>1998;<span class="ref-vol">129</span>:89–93.</span> [<a href="/pubmed/9669991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9669991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.margaglione.1999.1583">Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, del Popolo A, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. <span><span class="ref-journal">Thromb Haemost. </span>1999;<span class="ref-vol">82</span>:1583–7.</span> [<a href="/pubmed/10613638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10613638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2004.566">Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. <span><span class="ref-journal">Circulation. </span>2004;<span class="ref-vol">110</span>:566–70.</span> [<a href="/pubmed/15262837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15262837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2008.494">Martinelli I, Battaglioli T, De Stefano V, Tormene D, Valdr&#x000e8; L, Grandone E, Tosetto A, Mannucci PM, et al.  The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. <span><span class="ref-journal">J Thromb Haemost. </span>2008;<span class="ref-vol">6</span>:494–8.</span> [<a href="/pubmed/18182035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18182035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2003a.1363">Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. <span><span class="ref-journal">Blood. </span>2003a;<span class="ref-vol">102</span>:1363–6.</span> [<a href="/pubmed/12714502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12714502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2006.2582">Martinelli I, Battaglioli T, Tosetto A, Legnani C, Sottile L, Ghiotto R, Mannucci PM. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. <span><span class="ref-journal">J Thromb Haemost. </span>2006;<span class="ref-vol">4</span>:2582–6.</span> [<a href="/pubmed/16981886" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16981886</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2000a.1223">Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. <span><span class="ref-journal">Br J Haematol. </span>2000a;<span class="ref-vol">111</span>:1223–9.</span> [<a href="/pubmed/11167765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11167765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.1999a.1215">Martinelli I, Cattaneo M, Taioli E, De Stefano V, Chiusolo P, Mannucci PM. Genetic risk factors for superficial vein thrombosis. <span><span class="ref-journal">Thromb Haemost. </span>1999a;<span class="ref-vol">82</span>:1215–7.</span> [<a href="/pubmed/10544900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10544900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2002.791">Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. <span><span class="ref-journal">Thromb Haemost. </span>2002;<span class="ref-vol">87</span>:791–5.</span> [<a href="/pubmed/12038778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12038778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2012.3269">Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM., HAPPY Study Group.  Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>:3269–75.</span> [<a href="/pmc/articles/PMC3321853/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3321853</span></a>] [<a href="/pubmed/22289887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22289887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.1998.1793">Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">338</span>:1793–7.</span> [<a href="/pubmed/9632445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9632445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2003b.2771">Martinelli I, Taioli E, Battaglioli T, Podda GM, Passamonti SM, Pedotti P, Mannucci PM. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. <span><span class="ref-journal">Arch Intern Med. </span>2003b;<span class="ref-vol">163</span>:2771–4.</span> [<a href="/pubmed/14662632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14662632</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.1999b.700">Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1999b;<span class="ref-vol">19</span>:700–3.</span> [<a href="/pubmed/10073976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10073976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2000b.1015">Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. <span><span class="ref-journal">N Engl J Med. </span>2000b;<span class="ref-vol">343</span>:1015–8.</span> [<a href="/pubmed/11018168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11018168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.martinelli.2001.428">Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, Di Minno G. Familial thrombophilia and the occurrence of fetal growth restriction. <span><span class="ref-journal">Haematologica. </span>2001;<span class="ref-vol">86</span>:428–31.</span> [<a href="/pubmed/11325651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11325651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.mas.2003.247">Mas VR, Fisher RA, Maluf DG, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A. Hepatic artery thrombosis after liver transplantation and genetic factors: prothrombin G20210A polymorphism. <span><span class="ref-journal">Transplantation. </span>2003;<span class="ref-vol">76</span>:247–9.</span> [<a href="/pubmed/12865818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12865818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.mcglennen.2002.1319">McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. <span><span class="ref-journal">Arch Pathol Lab Med. </span>2002;<span class="ref-vol">126</span>:1319–25.</span> [<a href="/pubmed/12421139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12421139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.meglic.2003.157">Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P, Novak-Antolic Z. Factor V Leiden, prothrombin 20210G --&#x0003e; A, methylenetetrahydrofolate reductase 677C --&#x0003e; T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. <span><span class="ref-journal">Eur J Obstet Gynecol Reprod Biol. </span>2003;<span class="ref-vol">111</span>:157–63.</span> [<a href="/pubmed/14597244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14597244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.meijers.2000.696">Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:696–701.</span> [<a href="/pubmed/10706899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10706899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.meinardi.2002.625">Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K, Prins MH, Buller HR, van der Meer J. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">116</span>:625–31.</span> [<a href="/pubmed/11849222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11849222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.mello.2005.1270">Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T, Facchinetti F, Benedetto C. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. <span><span class="ref-journal">Hypertension. </span>2005;<span class="ref-vol">46</span>:1270–4.</span> [<a href="/pubmed/16246971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16246971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.meltzer.2010.113">Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:113–21.</span> [<a href="/pubmed/20385790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20385790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.middeldorp.2008.321">Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">143</span>:321–35.</span> [<a href="/pubmed/18710381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18710381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.middeldorp.2013.180">Middeldorp S. Thrombosis in women: what are the knowledge gaps in 2013? <span><span class="ref-journal">J Thromb Haemost. </span>2013 Jun;<span class="ref-vol">11</span> Suppl 1:180–91.</span> [<a href="/pubmed/23809122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23809122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.miyawaki.2012.2390">Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T. Thrombosis from a prothrombin mutation conveying antithrombin resistance. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">366</span>:2390–6.</span> [<a href="/pubmed/22716977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22716977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.mohllajee.2006.166">Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. <span><span class="ref-journal">Contraception. </span>2006;<span class="ref-vol">73</span>:166–78.</span> [<a href="/pubmed/16413847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16413847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.monagle.2012_1">Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-G&#x000f6;ttl U, Vesely SK; American College of Chest Physicians. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S-801S. [<a href="/pmc/articles/PMC3278066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278066</span></a>] [<a href="/pubmed/22315277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF206">National Clinical Guideline Centre. Venous Thromboembolic Diseases: Diagnosis, Management, and Thrombophilia Testing. National Institute for Health and Care Excellence Clinical Guidelines. No. 144. London, UK: Royal College of Physicians; 2012.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.nelson.2013.604">Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. <span><span class="ref-journal">Ann Intern Med. </span>2013;<span class="ref-vol">158</span>:604–14.</span> [<a href="/pubmed/23588749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23588749</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.noboa.2008.624">Noboa S, Le Gal G, Lacut K, Mercier B, Leroyer C, Nowak E, Mottier D, Oger E, et al. EDITH Collaborative Study Group.  Family history as a risk factor for venous thromboembolism. <span><span class="ref-journal">Thromb Res. </span>2008;<span class="ref-vol">122</span>:624–9.</span> [<a href="/pubmed/18281082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18281082</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.nowakg_ttl.2001.858">Nowak-G&#x000f6;ttl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N, Schobess R, Ehrenforth S. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:858–62.</span> [<a href="/pubmed/11159508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11159508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pabinger.2005.949">Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. <span><span class="ref-journal">J Thromb Haemost. </span>2005;<span class="ref-vol">3</span>:949–54.</span> [<a href="/pubmed/15869590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15869590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pasquier.2009.306">Pasquier E, Bohec C, Mottier D, Jaffuel S, Mercier B, F&#x000e9;rec C, Collet M, De Saint Martin L. Inherited thrombophilias and unexplained pregnancy loss: an incident case-control study. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span>:306–11.</span> [<a href="/pubmed/19036071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19036071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pengo.2010.237">Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. <span><span class="ref-journal">J Thromb Haemost. </span>2010;<span class="ref-vol">8</span>:237–42.</span> [<a href="/pubmed/19874470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19874470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pereboom.2011.587">Pereboom IT, Adelmeijer J, van der Steege G, van den Berg AP, Lisman T, Porte RJ. Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation. <span><span class="ref-journal">Transplantation. </span>2011;<span class="ref-vol">92</span>:587–93.</span> [<a href="/pubmed/21836539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21836539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.p_rezceballos.2002.610">P&#x000e9;rez-Ceballos E, Corral J, Alberca I, Vay&#x000e1; A, Llamas P, Montes R, Gonz&#x000e1;lez-Conejero R, Vicente V. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">118</span>:610–4.</span> [<a href="/pubmed/12139755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12139755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pezzini.2009.813">Pezzini A, Grassi M, Zotto ED, Giossi A, Volonghi I, Costa P, Grau A, Magoni M, Padovani A, Lichy C. Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis. <span><span class="ref-journal">Thromb Haemost. </span>2009;<span class="ref-vol">101</span>:813–7.</span> [<a href="/pubmed/19404532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19404532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pherwani.2003.603">Pherwani AD, Winter PC, McNamee PT, Patterson CC, Hill CM, Connolly JK, Maxwell AP. Is screening for factor V Leiden and prothrombin G20210A mutations in renal transplantation worthwhile? Results of a large single-center U.K. study. <span><span class="ref-journal">Transplantation. </span>2003;<span class="ref-vol">76</span>:603–5.</span> [<a href="/pubmed/12923451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12923451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pihusch.2001.124">Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler CJ. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. <span><span class="ref-journal">Am J Reprod Immunol. </span>2001;<span class="ref-vol">46</span>:124–31.</span> [<a href="/pubmed/11506076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11506076</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pomp.2007.289">Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. <span><span class="ref-journal">Br J Haematol. </span>2007;<span class="ref-vol">139</span>:289–96.</span> [<a href="/pubmed/17897305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17897305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.pomp.2008.632">Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. <span><span class="ref-journal">J Thromb Haemost. </span>2008;<span class="ref-vol">6</span>:632–7.</span> [<a href="/pubmed/18248600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18248600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.poort.1996.3698">Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">88</span>:3698–703.</span> [<a href="/pubmed/8916933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8916933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.prandoni.2007.199">Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <span><span class="ref-journal">Haematologica. </span>2007;<span class="ref-vol">92</span>:199–205.</span> [<a href="/pubmed/17296569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17296569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.primignani.2005.603">Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM. Risk factors for thrombophilia in estrahepatic portal vein obstruction. <span><span class="ref-journal">Hepatology. </span>2005;<span class="ref-vol">41</span>:603–8.</span> [<a href="/pubmed/15726653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15726653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.psaty.2001.906">Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. <span><span class="ref-journal">JAMA. </span>2001;<span class="ref-vol">285</span>:906–13.</span> [<a href="/pubmed/11180734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11180734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.raffini.2008.228">Raffini L. Thrombophilia in children: who to test, how, when, and why? <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2008:228–35.</span> [<a href="/pubmed/19074088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19074088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.raffini.2009.277">Raffini L, Thornburg C. Testing children for inherited thrombophilia: more questions than answers. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">147</span>:277–88.</span> [<a href="/pubmed/19656153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19656153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ramacciotti.2003.171">Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A, Franco RF. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. <span><span class="ref-journal">Thromb Res. </span>2003;<span class="ref-vol">109</span>:171–4.</span> [<a href="/pubmed/12757770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12757770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.raziel.2001.65">Raziel A, Kornberg Y, Friedler S, Schachter M, Sela BA, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. <span><span class="ref-journal">Am J Reprod Immunol. </span>2001;<span class="ref-vol">45</span>:65–71.</span> [<a href="/pubmed/11216876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11216876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.renoux.2010.979">Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. <span><span class="ref-journal">J Thromb Haemost. </span>2010;<span class="ref-vol">8</span>:979–86.</span> [<a href="/pubmed/20230416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20230416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.revelvilk.2003.915">Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:915–21.</span> [<a href="/pubmed/12871356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.revelvilk.2006.59">Revel-Vilk S, Kenet G. Thrombophilia in children with venous thromboembolic disease. <span><span class="ref-journal">Thromb Res. </span>2006;<span class="ref-vol">118</span>:59–65.</span> [<a href="/pubmed/15993476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15993476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rey.2003.901">Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">361</span>:901–8.</span> [<a href="/pubmed/12648968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12648968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.reznikoffeti_van.2001.1251">Reznikoff-Eti&#x000e9;van MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. <span><span class="ref-journal">BJOG. </span>2001;<span class="ref-vol">108</span>:1251–4.</span> [<a href="/pubmed/11843387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11843387</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ridker.1999.999">Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. <span><span class="ref-journal">Circulation. </span>1999;<span class="ref-vol">99</span>:999–1004.</span> [<a href="/pubmed/10051291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10051291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ringwald.2009.1507">Ringwald J, Berger A, Adler W, Kraus C, Pitto RP. Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study. <span><span class="ref-journal">Clin Orthop Relat Res. </span>2009;<span class="ref-vol">467</span>:1507–15.</span> [<a href="/pmc/articles/PMC2674155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2674155</span></a>] [<a href="/pubmed/18800213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18800213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.roach.2013.124">Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. <span><span class="ref-journal">J Thromb Haemost. </span>2013;<span class="ref-vol">11</span>:124–31.</span> [<a href="/pubmed/23136837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23136837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.robertson.2006.171">Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, Greer IA, et al.  Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study: Thrombophilia in pregnancy: a systematic review. <span><span class="ref-journal">Br J Haematol. </span>2006;<span class="ref-vol">132</span>:171–96.</span> [<a href="/pubmed/16398652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16398652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rodger.2010.e1000292">Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. <span><span class="ref-journal">PLoS Med. </span>2010;<span class="ref-vol">7</span>:e1000292.</span> [<a href="/pmc/articles/PMC2885985/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2885985</span></a>] [<a href="/pubmed/20563311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20563311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rodger.2014.1673">Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said J, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead-Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS, et al.  Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. <span><span class="ref-journal">Lancet. </span>2014;<span class="ref-vol">384</span>:1673–83.</span> [<a href="/pubmed/25066248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25066248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rodger.2008.320">Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I. Inherited thrombophilia and pregnancy complications revisited. <span><span class="ref-journal">Obstet Gynecol. </span>2008;<span class="ref-vol">112</span>:320–4.</span> [<a href="/pubmed/18669729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18669729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rosendaal.1998.706">Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. <span><span class="ref-journal">Thromb Haemost. </span>1998;<span class="ref-vol">79</span>:706–8.</span> [<a href="/pubmed/9569177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9569177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rosendaal.2009.301">Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span> Suppl 1:301–4.</span> [<a href="/pubmed/19630821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19630821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rosendaal.1997.1747">Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. <span><span class="ref-journal">Blood. </span>1997;<span class="ref-vol">90</span>:1747–50.</span> [<a href="/pubmed/9292507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9292507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rossi.2011.646">Rossi E, Ciminello A, Za T, Betti S, Leone G, De Stefano V. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. <span><span class="ref-journal">Thromb Haemost. </span>2011;<span class="ref-vol">106</span>:646–54.</span> [<a href="/pubmed/21833444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21833444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.rossouw.2002.321">Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. <span><span class="ref-journal">JAMA. </span>2002;<span class="ref-vol">288</span>:321–33.</span> [<a href="/pubmed/12117397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12117397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF245">Royal College of Obstetricians and Gynaecologists. Recurrent miscarriage, investigation and treatment of couples. Green-top Guideline 17. Available <a href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg17/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011a. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF246">Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline 37a. Available <a href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2009. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF247">Royal College of Obstetricians and Gynaecologists. The use of antithrombotics in the prevention of recurrent pregnancy loss. Scientific Impact Paper 26. Available <a href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/sip26/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011b. Accessed 7-2-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.said.2010.5">Said JM, Higgins JR, Moses EK, Walker SP, Borg AJ, Monagle PT, Brennecke SP. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. <span><span class="ref-journal">Obstet Gynecol. </span>2010;<span class="ref-vol">115</span>:5–13.</span> [<a href="/pubmed/20027027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20027027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.salomon.1999.511">Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>1999;<span class="ref-vol">19</span>:511–8.</span> [<a href="/pubmed/10073951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10073951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.samama.2003.327">Samama MM, Rached RA, Horellou MH, Aquilanti S, Mathieux VG, Plu-Bureau G, Elalamy I, Conard J. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. <span><span class="ref-journal">Br J Haematol. </span>2003;<span class="ref-vol">123</span>:327–34.</span> [<a href="/pubmed/14531916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14531916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.schobess.1999.s105">Schobess R, Junker R, Auberger K, Munchow N, Burdach S, Nowak-Gottl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis--evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. <span><span class="ref-journal">Eur J Pediatr. </span>1999;<span class="ref-vol">158</span> Suppl 3:S105–8.</span> [<a href="/pubmed/10650846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10650846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.schulman.2014.1">Schulman S. Advantages and limitations of the new anticoagulants. <span><span class="ref-journal">J Intern Med. </span>2014;<span class="ref-vol">275</span>:1–11.</span> [<a href="/pubmed/24112453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24112453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.segal.2009.2472">Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">301</span>:2472–85.</span> [<a href="/pubmed/19531787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19531787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.silver.2010.14">Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ, et al.  Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (NICHD MFMU) Network: Prothrombin gene G20210A mutation and obstetric complications. <span><span class="ref-journal">Obstet Gynecol. </span>2010;<span class="ref-vol">115</span>:14–20.</span> [<a href="/pmc/articles/PMC2981703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2981703</span></a>] [<a href="/pubmed/20027028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20027028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.simioni.2000.3329">Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M, Girolami A. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">96</span>:3329–33.</span> [<a href="/pubmed/11071624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11071624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.simioni.1998.1045">Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. <span><span class="ref-journal">Br J Haematol. </span>1998;<span class="ref-vol">103</span>:1045–50.</span> [<a href="/pubmed/9886317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9886317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.slooter.2005.1213">Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. <span><span class="ref-journal">J Thromb Haemost. </span>2005;<span class="ref-vol">3</span>:1213–7.</span> [<a href="/pubmed/15946211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15946211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.smiles.2002.614">Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. <span><span class="ref-journal">Thromb Haemost. </span>2002;<span class="ref-vol">87</span>:614–21.</span> [<a href="/pubmed/12008943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12008943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.smith.2006.2807">Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Rosendaal FR, Psaty BM. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>2006;<span class="ref-vol">26</span>:2807–12.</span> [<a href="/pubmed/16973976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16973976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.smith.2007.489">Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, Lumley T, Bis JC, Wiggins KL, Rosendaal FR, Psaty BM. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. <span><span class="ref-journal">JAMA. </span>2007;<span class="ref-vol">297</span>:489–98.</span> [<a href="/pubmed/17284699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17284699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.soria.2000.2780">Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J, Fontcuberta J. Linkage analisis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">95</span>:2780–5.</span> [<a href="/pubmed/10779421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10779421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.souto.1999.627">Souto JC, Mateo J, Soria JM, Llobet D, Coll I, Borrell M, Fontcuberta J. Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism. <span><span class="ref-journal">Haematologica. </span>1999;<span class="ref-vol">84</span>:627–32.</span> [<a href="/pubmed/10406905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10406905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.spector.2005.444">Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G&#x0003e;A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. <span><span class="ref-journal">Genet Med. </span>2005;<span class="ref-vol">7</span>:444–53.</span> [<a href="/pubmed/16024978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16024978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.straczek.2005.3495">Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, L&#x000e9;vesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, et al.  Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. <span><span class="ref-journal">Circulation. </span>2005;<span class="ref-vol">112</span>:3495–500.</span> [<a href="/pubmed/16301339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16301339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tait.2012.28">Tait C, Baglin T, Watson H, Laffan M, Makris M, Perry D, Keeling D, et al.  Guidelines on the investigation and management of venous thrombosis at unusual sites. <span><span class="ref-journal">Br J Haematol. </span>2012;<span class="ref-vol">159</span>:28–38.</span> [<a href="/pubmed/22881455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22881455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tirado.2001.1200">Tirado I, Mateo J, Soria JM, Oliver A, Borrell M, Coll I, Vallve C, Souto JC, Martinez-Sanchez E, Fontcuberta J. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. <span><span class="ref-journal">Haematologica. </span>2001;<span class="ref-vol">86</span>:1200–8.</span> [<a href="/pubmed/11694407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11694407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tormene.2002.2403">Tormene D, Simioni P, Prandoni P, Franz F, Zerbinati P, Tognin G, Girolami A. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">100</span>:2403–5.</span> [<a href="/pubmed/12239149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12239149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tosetto.1999.1395">Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. <span><span class="ref-journal">Thromb Haemost. </span>1999;<span class="ref-vol">82</span>:1395–8.</span> [<a href="/pubmed/10595625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10595625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.toth.2008.325">Toth B, Vocke F, Rogenhofer N, Friese K, Thaler CJ, Lohse P. Paternal thrombophilic gene mutations are not associated with recurrent miscarriage. <span><span class="ref-journal">Am J Reprod Immunol. </span>2008;<span class="ref-vol">60</span>:325–32.</span> [<a href="/pubmed/18754836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18754836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.tuckuviene.2011.663">Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen SR. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. <span><span class="ref-journal">J Pediatr. </span>2011;<span class="ref-vol">159</span>:663–9.</span> [<a href="/pubmed/21596390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21596390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.undas.2009.4272">Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopyd&#x00142;owska A, Skubiszak A, Ciep&#x00142;uch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>:4272–8.</span> [<a href="/pubmed/19690336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19690336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_hylckama_vlieg.2003.2186">van Hylckama Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:2186–90.</span> [<a href="/pubmed/14521603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14521603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_hylckama_vlieg.2000.3678">van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">95</span>:3678–82.</span> [<a href="/pubmed/10845896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10845896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_ommen.2003.2516">van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:2516–22.</span> [<a href="/pubmed/14675086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_rooden.2004.201">Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. <span><span class="ref-journal">Haematologica. </span>2004;<span class="ref-vol">89</span>:201–6.</span> [<a href="/pubmed/15003896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15003896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_stralen.2008.21">van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. <span><span class="ref-journal">Arch Intern Med. </span>2008;<span class="ref-vol">168</span>:21–6.</span> [<a href="/pubmed/18195191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18195191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.van_vlijmen.2011.2055">van Vlijmen EF, Veeger NJ, Middeldorp S, Hamuly&#x000e1;k K, Prins MH, B&#x000fc;ller HR, Meijer K. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:2055–61.</span> [<a href="/pubmed/21659542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21659542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.vay_.2003.452">Vay&#x000e1; A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Corella D, Fontcuberta J, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. <span><span class="ref-journal">Thromb Haemost. </span>2003;<span class="ref-vol">89</span>:452–7.</span> [<a href="/pubmed/12624627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12624627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.visser.2011.295">Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, Kaaja RJ. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. <span><span class="ref-journal">Thromb Haemost. </span>2011;<span class="ref-vol">105</span>:295–301.</span> [<a href="/pubmed/21103659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21103659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.w_hlander.2002.580">W&#x000e5;hlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, Bylock A, Eriksson BI. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. <span><span class="ref-journal">Thromb Haemost. </span>2002;<span class="ref-vol">87</span>:580–5.</span> [<a href="/pubmed/12008938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12008938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.warren.2009.281.e1">Warren JE, Simonsen SE, Branch DW, Porter TF, Silver RM. Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2009;<span class="ref-vol">200</span>:281.e1–5.</span> [<a href="/pubmed/19114274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19114274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.warshawsky.2002.152">Warshawsky I, Hren C, Sercia L, Shadrach B, Deitcher SR, Newton E, Kottke-Marchant K. Detection of a novel point mutation of the prothrombin gene at position 20209. <span><span class="ref-journal">Diagn Mol Pathol. </span>2002;<span class="ref-vol">11</span>:152–6.</span> [<a href="/pubmed/12218454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12218454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.warshawsky.2009.1585">Warshawsky I, Makkar V, Rimmerman C, Kottke-Marchant K. Prothrombin 20209C&#x0003e;T: 16 new cases, association with the 19911A&#x0003e;G polymorphism, and literature review. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span>:1585–7.</span> [<a href="/pubmed/19522744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19522744</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.weitz.2012">Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e120S-51S. [<a href="/pmc/articles/PMC3278067/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3278067</span></a>] [<a href="/pubmed/22315258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22315258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.wells.2006.101">Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. <span><span class="ref-journal">Am J Epidemiol. </span>2006;<span class="ref-vol">164</span>:101–9.</span> [<a href="/pubmed/16740590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16740590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.white.2008.246">White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. <span><span class="ref-journal">Thromb Haemost. </span>2008;<span class="ref-vol">100</span>:246–52.</span> [<a href="/pubmed/18690344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18690344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.wu.2005.17">Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Brenkel I, Regan L, Greer IA. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. <span><span class="ref-journal">Thromb Haemost. </span>2005;<span class="ref-vol">94</span>:17–25.</span> [<a href="/pubmed/16113779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16113779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.ye.2006.651">Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. <span><span class="ref-journal">Lancet. </span>2006;<span class="ref-vol">367</span>:651–8.</span> [<a href="/pubmed/16503463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16503463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.yenicesu.2010.126">Yenicesu GI, Cetin M, Ozdemir O, Cetin A, Ozen F, Yenicesu C, Yildiz C, Kocak N. A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. <span><span class="ref-journal">Am J Reprod Immunol. </span>2010;<span class="ref-vol">63</span>:126–36.</span> [<a href="/pubmed/19906129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19906129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.young.2008.1373">Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, Goldenberg NA, Grabowski E, Heller C, Journeycake J, Kenet G, Kr&#x000fc;mpel A, Kurnik K, Lubetsky A, Male C, Manco-Johnson M, Mathew P, Monagle P, van Ommen H, Simioni P, Svirin P, Tormene D, Nowak-G&#x000f6;ttl U. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. <span><span class="ref-journal">Circulation. </span>2008;<span class="ref-vol">118</span>:1373–82.</span> [<a href="/pubmed/18779442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18779442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.young.2009.72">Young G, Becker S, D&#x000fc;ring C, Friedrichs F, Goldenberg N, Kenet G, Manco-Johnson M, Scheffold C, Nowak-G&#x000f6;ttl U. Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism in children: an international multicenter cohort study. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span>:72–9.</span> [<a href="/pubmed/18983482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18983482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.young.2003.958">Young G, Manco-Johnson M, Gill JC, Dimichele DM, Tarantino MD, Abshire T, Nugent DJ. Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:958–62.</span> [<a href="/pubmed/12871361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.zenz.1998.763">Zenz W, Bodo Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Ploier R, Hofler G, Mannhalter C, Muntean W. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. <span><span class="ref-journal">Thromb Haemost. </span>1998;<span class="ref-vol">80</span>:763–6.</span> [<a href="/pubmed/9843168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9843168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.zivelin.2006.4666">Zivelin A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conard J, Peyvandi F, Kyrle PA, Bertina R, Peyvandi F, Emmerich J, Seligsohn U. Prothrombin 20210G&#x0003e;A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:4666–8.</span> [<a href="/pubmed/16493002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16493002</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ptt.REF.zivelin.1998.1119">Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. <span><span class="ref-journal">Blood. </span>1998;<span class="ref-vol">92</span>:1119–24.</span> [<a href="/pubmed/9694698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9694698</span></a>]</div></li></ul></div></div><div id="ptt.Chapter_Notes"><h2 id="_ptt_Chapter_Notes_">Chapter Notes</h2><div id="ptt.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 August 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 March 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 July 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>25 April 2005 (jk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1148</span><span class="label">PMID: <a href="/pubmed/20301327" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301327</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/proteus/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/psach/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1148&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1148/?report=reader">PubReader</a></li><li><a href="/books/NBK1148/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1148" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1148" style="display:none" title="Cite this Page"><div class="bk_tt">Kujovich JL. Prothrombin-Related Thrombophilia. 2006 Jul 25 [Updated 2014 Aug 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1148/pdf/Bookshelf_NBK1148.pdf">PDF version of this page</a> (727K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ptt.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ptt.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ptt.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ptt.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ptt.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ptt.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ptt.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ptt.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ptt.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ptt.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ptt.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2147[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">F2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4524[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MTHFR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3026[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HABP2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2162[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">F13A1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1476746" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1476746" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1476746" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1476746" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301542" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Factor V Leiden Thrombophilia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Factor V Leiden Thrombophilia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kujovich JL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16595080" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.</a><span class="source">[Health Technol Assess. 2006]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Health Technol Assess. 2006 Apr; 10(11):1-110. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20034330" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Thrombophilia, preeclampsia and other pregnancy complications].</a><span class="source">[Acta Med Croatica. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Thrombophilia, preeclampsia and other pregnancy complications].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vucić N, Frleta M, Petrović D, Ostojić V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Acta Med Croatica. 2009 Oct; 63(4):297-305. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21150787" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G&amp;gt;A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.</a><span class="source">[Genet Med. 2011]</span><div class="brieflinkpop offscreen_noflow">Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G&amp;gt;A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Genet Med. 2011 Jan; 13(1):67-76. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15199464" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oral anticoagulant therapy in venous thromboembolism.</a><span class="source">[Semin Vasc Med. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oral anticoagulant therapy in venous thromboembolism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cosmi B, Palareti G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Vasc Med. 2003 Aug; 3(3):303-14. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301327" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301327" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041a7adde089116963f247">Prothrombin-Related Thrombophilia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Prothrombin-Related Thrombophilia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:27:06-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BF05CE0418F210000000000AD0049&amp;ncbi_session=CE8BF05CE041A791_0173SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1148%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1148&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1148/&amp;ncbi_pagename=Prothrombin-Related Thrombophilia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BF05CE041A791_0173SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>